{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "26194509-66fb-4e01-b3c6-47c7952a13c3",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "C:\\Users\\user\\anaconda3\\envs\\llms\\Lib\\site-packages\\langchain_core\\_api\\deprecation.py:26: UserWarning: Core Pydantic V1 functionality isn't compatible with Python 3.14 or greater.\n",
      "  from pydantic.v1.fields import FieldInfo as FieldInfoV1\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Consider using the pymupdf_layout package for a greatly improved page layout analysis.\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "C:\\Users\\user\\anaconda3\\envs\\llms\\Lib\\site-packages\\urllib3\\connectionpool.py:1097: InsecureRequestWarning: Unverified HTTPS request is being made to host 'ngw.devices.sberbank.ru'. Adding certificate verification is strongly advised. See: https://urllib3.readthedocs.io/en/latest/advanced-usage.html#tls-warnings\n",
      "  warnings.warn(\n"
     ]
    }
   ],
   "source": [
    "from langchain_community.document_loaders import PyMuPDFLoader\n",
    "from pydantic import BaseModel, Field\n",
    "from langchain_core.output_parsers import PydanticOutputParser, StrOutputParser, BaseOutputParser\n",
    "from textwrap import dedent\n",
    "\n",
    "from langchain_openai import ChatOpenAI\n",
    "from langchain_core.messages import HumanMessage\n",
    "from langchain_core.prompts import ChatPromptTemplate\n",
    "import httpx\n",
    "import json\n",
    "import requests\n",
    "import pandas as pd\n",
    "import numpy as np\n",
    "import re\n",
    "\n",
    "from langchain_pymupdf4llm import PyMuPDF4LLMLoader, PyMuPDF4LLMParser\n",
    "import pymupdf4llm\n",
    "import requests\n",
    "import uuid\n",
    "from openai import OpenAI\n",
    "\n",
    "import time\n",
    "import os\n",
    "from dotenv import load_dotenv, find_dotenv\n",
    "\n",
    "load_dotenv(find_dotenv(usecwd=True))\n",
    "\n",
    "\n",
    "use = 'nhf'\n",
    "\n",
    "if use == 'hf':\n",
    "    os.environ[\"BASE_URL\"] = \"https://router.huggingface.co/v1\"\n",
    "    os.environ[\"MODEL_NAME\"] ='Qwen/Qwen3-32B'\n",
    "    os.environ[\"OPENAI_API_KEY\"] = os.getenv(\"HUGGINGFACE_HUB_TOKEN\")\n",
    "else:\n",
    "    os.environ[\"BASE_URL\"] = \"https://gigachat.devices.sberbank.ru/api/v1\"\n",
    "    os.environ[\"MODEL_NAME\"] ='GigaChat'\n",
    "    \n",
    "    url = \"https://ngw.devices.sberbank.ru:9443/api/v2/oauth\"\n",
    "    # Создадим идентификатор UUID (36 знаков)\n",
    "    rq_uid = str(uuid.uuid4())\n",
    "    payload={\n",
    "      'scope': 'GIGACHAT_API_PERS'\n",
    "    }\n",
    "    headers = {\n",
    "      'Content-Type': 'application/x-www-form-urlencoded',\n",
    "      'Accept': 'application/json',\n",
    "      'RqUID': rq_uid,\n",
    "      'Authorization': f'Basic {os.getenv(\"GIGACHAT_AUTH\")}'\n",
    "    }\n",
    "\n",
    "    response = requests.request(\"POST\", url, headers=headers, data=payload, verify=False)\n",
    "    os.environ[\"OPENAI_API_KEY\"] = response.json()['access_token']\n",
    "    \n",
    "\n",
    "os.environ['TEMPERATURE'] = '0'\n",
    "\n",
    "\n",
    "\n",
    "\n",
    "from trialmind.pubmed import pmid2papers, PubmedAPIWrapper, pmid2biocxml, parse_bioc_xml\n",
    "from trialmind.api import StudyCharacteristicsExtraction, ScreeningCriteriaGeneration,\\\n",
    "                            LiteratureScreening, ScreeningCriteriaCTGeneration,\\\n",
    "                            CTScreening\n",
    "from trialmind.retrievers import split_text_into_chunks\n",
    "import extract\n",
    "\n",
    "%load_ext autoreload\n",
    "%autoreload 2"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "ca86905b-127c-43b4-9ac1-029ea1313d40",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'eyJjdHkiOiJqd3QiLCJlbmMiOiJBMjU2Q0JDLUhTNTEyIiwiYWxnIjoiUlNBLU9BRVAtMjU2In0.TGIErQuLrnDjf9xevfoXIKoh2uFmtRowz5E33MhAkTkdHqm-hLdVsbG092siPPgnhXJUMUScgCMD32L4EUq4z7fPf730K9a3j-mcMrSCHwus2VkcX8v2SPRzFvCFDOqVthcWPL2LAc_FlVc2n9trQ8ZYzjKYntHv58oyMu6qH-dTG8sV-ERMB8FPBBLQhGgYw_fFxHELfyPR8ym2XF4-dtQDMqzU9XZLpzn18_TybnhbM-KGCRLEntiyxW1uRc_qvsg_9Z6JtHHMNzb5RVEKhwwWMvXDFgVW61iVUCOQ5_Gh1KqdvQGmSQ5JpxeiTEFgbn6xIlU2nwiZ128S8Y5bpg.X5Iv5OQYEuXiyogcJbRzNQ.0qTx9nEOYtiQDmFlAu4GznUsWsBg36eNfcSGi9iNkhDpu6RIsLPyMzRE0nMp_NHa5tfQ7CLsvpJiVkKqjdGOobbHs313nRoKopuwrvrpJuafcvY7TKBAb0hGwBvQ-CsAt179_-KOCCe7IEwlFzQ8fO7wNkcImC8kyO_5I8pevvOBWvXVl1_fWgY9LmqnjoRwjJk_vmdSCKSoSRESW5tT_F-9dL7XNhNoKUplqD8PMMsOcaDgxhBiBA-QvFyMkiWzVIjHYoXyE88cOHc_NyqSmWdyMxeKjQcxwmEnusT9k0R3gffz_P3dgXERYO0gnY6H3DxLfyYZhYaDtNayLoVJvv-XP1xsOXd9JqGVwRLYI8vCMcrlLMsHHktXFiNP15nm_ict06MVlKqNMwZIiAL8TQuimts0ZK-nvTmQZkAYT9M7uLQJsmh9khbOzpsaB7evODc19f0mfpKxDQP9lVhAHDCM2ggZMd0KOTJUfEvhihx7HBtiEzZOVEL1QwG9scV0rnbthCNWPjLRffQqCvojs9Gp02ufy0w2RgQfFuq1lR0jaHj4JQvG4d9dekFttLUYJz_eTUSkFVQbXCYZRx-x061HEZGGGMfPjZjdmn0c5Vr060ssJGlogNFrNuPez9nUMAh2oLcub7Uuso8UKHjxhs8Wg97GOitM-PsljfK-n51-RrMsz9mJC_4xKe_bEBHL8IoKm89Lu9CKrhWWaQlP51o8wyimarw8uAfQ6n0nLmI.dIPSzR_BRJSrjhtE4sRw7ZVCma8-4GhADj2S1YFvRJE'"
      ]
     },
     "execution_count": 2,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "os.getenv(\"OPENAI_API_KEY\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "87134e89-308f-40c7-90e7-7dda26f40eb8",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'Привет! Как настроение?'"
      ]
     },
     "execution_count": 4,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "client = OpenAI(\n",
    "        base_url=os.getenv(\"BASE_URL\"),\n",
    "        api_key=os.getenv(\"OPENAI_API_KEY\"),\n",
    "        http_client=httpx.Client(verify=False)\n",
    "    )\n",
    "response = client.chat.completions.create(\n",
    "        model=os.getenv(\"MODEL_NAME\"),\n",
    "        messages=[{'role':'user','content':'hey\\no_think'}],  # Ensure messages is a list\n",
    "        temperature=0,\n",
    "    )\n",
    "response.choices[0].message.content"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "id": "5191b220-a355-402f-8ac4-c871ef0692c6",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'$defs': {'FieldResult': {'properties': {'name': {'description': 'Field name that accurately represents the content of the field based on its description.',\n",
       "     'maxLength': 25,\n",
       "     'title': 'Name',\n",
       "     'type': 'string'},\n",
       "    'value': {'description': 'Extracted information from the text based on the field description.',\n",
       "     'maxLength': 50,\n",
       "     'title': 'Value',\n",
       "     'type': 'string'},\n",
       "    'source_id': {'description': 'Cited document IDs.',\n",
       "     'items': {'type': 'integer'},\n",
       "     'maxItems': 3,\n",
       "     'minItems': 1,\n",
       "     'title': 'Source Id',\n",
       "     'type': 'array'}},\n",
       "   'required': ['name', 'value', 'source_id'],\n",
       "   'title': 'FieldResult',\n",
       "   'type': 'object'}},\n",
       " 'properties': {'fieldresult': {'$ref': '#/$defs/FieldResult'}},\n",
       " 'required': ['fieldresult'],\n",
       " 'title': 'Results',\n",
       " 'type': 'object'}"
      ]
     },
     "execution_count": 27,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "Results.model_json_schema()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 30,
   "id": "3dce0fff-fe8e-4a5f-8d64-316ed02cbdbc",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "### Example JSON data using the provided schema:\n",
      "\n",
      "```json\n",
      "{\n",
      "  \"fieldresult\": [\n",
      "    {\n",
      "      \"name\": \"Author\",\n",
      "      \"value\": \"Иванов Иван Иванович\",\n",
      "      \"source_id\": [12345]\n",
      "    },\n",
      "    {\n",
      "      \"name\": \"Publication Date\",\n",
      "      \"value\": \"1 января 2023 года\",\n",
      "      \"source_id\": [67890]\n",
      "    }\n",
      "  ]\n",
      "}\n",
      "```\n",
      "\n",
      "#### Explanation:\n",
      "- **`name`:** The descriptive label for the extracted field (e.g., “Author” or “Publication Date”).\n",
      "- **`value`:** The actual value extracted from the source text (e.g., a person’s name or date).\n",
      "- **`source_id`:** An array of integers representing the cited documents where this field was found.\n",
      "\n",
      "### Additional Examples\n",
      "\n",
      "1. **Example 1:**\n",
      "   ```json\n",
      "   {\n",
      "     \"fieldresult\": [\n",
      "       {\n",
      "         \"name\": \"ISBN\",\n",
      "         \"value\": \"978-123456789X\",\n",
      "         \"source_id\": [101, 102]\n",
      "       },\n",
      "       {\n",
      "         \"name\": \"Publisher\",\n",
      "         \"value\": \"ООО \\\"Издательство Книги и Статьи\\\"\",\n",
      "         \"source_id\": [103]\n",
      "       }\n",
      "     ]\n",
      "   }\n",
      "   ```\n",
      "\n",
      "2. **Example 2:**\n",
      "   ```json\n",
      "   {\n",
      "     \"fieldresult\": [\n",
      "       {\n",
      "         \"name\": \"Title\",\n",
      "         \"value\": \"Основы программирования на Python\",\n",
      "         \"source_id\": [104]\n",
      "       },\n",
      "       {\n",
      "         \"name\": \"Pages\",\n",
      "         \"value\": \"300 страниц\",\n",
      "         \"source_id\": [105]\n",
      "       }\n",
      "     ]\n",
      "   }\n",
      "   ```\n",
      "\n",
      "3. **Example 3:**\n",
      "   ```json\n",
      "   {\n",
      "     \"fieldresult\": [\n",
      "       {\n",
      "         \"name\": \"Director\",\n",
      "         \"value\": \"Сергей Петров\",\n",
      "         \"source_id\": [106]\n",
      "       },\n",
      "       {\n",
      "         \"name\": \"Year\",\n",
      "         \"value\": \"2022 год\",\n",
      "         \"source_id\": [107]\n",
      "       }\n",
      "     ]\n",
      "   }\n",
      "   ```\n",
      "\n",
      "These examples demonstrate how to use the `FieldResult` structure within the given JSON schema.\n"
     ]
    }
   ],
   "source": [
    "Results.model_json_schema()\n",
    "completion = client.chat.completions.create(\n",
    "    model=os.getenv(\"MODEL_NAME\"),\n",
    "    messages=[\n",
    "        {\n",
    "            \"role\": \"user\",\n",
    "            \"content\": f\"Generate some examples with two fieldresult with the following JSON schema: {Results.model_json_schema()}  /no_think\"\n",
    "        }\n",
    "    ],\n",
    "    response_format={\n",
    "        \"type\": \"json_object\",\n",
    "        \"json_schema\": {\n",
    "            \"name\": \"car-description\",\n",
    "            \"schema\": Results.model_json_schema()\n",
    "        },\n",
    "    },\n",
    "    temperature=0,\n",
    ")\n",
    "print(completion.choices[0].message.content)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "d349aa43-7eb8-4e4c-aeee-3d804702144d",
   "metadata": {
    "jp-MarkdownHeadingCollapsed": true,
    "tags": []
   },
   "source": [
    "### client.responses дает 403 ошибку, т.е. structured output не работает"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 43,
   "id": "4b4d1aa0-0998-4f3c-9b06-f70ca222181f",
   "metadata": {
    "collapsed": true,
    "jupyter": {
     "outputs_hidden": true
    },
    "tags": []
   },
   "outputs": [
    {
     "ename": "PermissionDeniedError",
     "evalue": "<html>\r\n<head><title>403 Forbidden</title></head>\r\n<body>\r\n<center><h1>403 Forbidden</h1></center>\r\n<hr><center>SynGX</center>\r\n</body>\r\n</html>",
     "output_type": "error",
     "traceback": [
      "\u001b[1;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[1;31mPermissionDeniedError\u001b[0m                     Traceback (most recent call last)",
      "Cell \u001b[1;32mIn[43], line 16\u001b[0m\n\u001b[0;32m     13\u001b[0m     abstract: \u001b[38;5;28mstr\u001b[39m\n\u001b[0;32m     14\u001b[0m     keywords: \u001b[38;5;28mlist\u001b[39m[\u001b[38;5;28mstr\u001b[39m]\n\u001b[1;32m---> 16\u001b[0m response \u001b[38;5;241m=\u001b[39m \u001b[43mclient\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mresponses\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mparse\u001b[49m\u001b[43m(\u001b[49m\n\u001b[0;32m     17\u001b[0m \u001b[43m    \u001b[49m\u001b[43mmodel\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mos\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mgetenv\u001b[49m\u001b[43m(\u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mMODEL_NAME\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m)\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m     18\u001b[0m \u001b[43m    \u001b[49m\u001b[38;5;28;43minput\u001b[39;49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43m[\u001b[49m\n\u001b[0;32m     19\u001b[0m \u001b[43m        \u001b[49m\u001b[43m{\u001b[49m\n\u001b[0;32m     20\u001b[0m \u001b[43m            \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mrole\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43msystem\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[0;32m     21\u001b[0m \u001b[43m            \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mcontent\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mYou are an expert at structured data extraction. You will be given unstructured text from a research paper and should convert it into the given structure.\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[0;32m     22\u001b[0m \u001b[43m        \u001b[49m\u001b[43m}\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m     23\u001b[0m \u001b[43m        \u001b[49m\u001b[43m{\u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mrole\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43muser\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mcontent\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43m...\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m}\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m     24\u001b[0m \u001b[43m    \u001b[49m\u001b[43m]\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m     25\u001b[0m \u001b[43m    \u001b[49m\u001b[43mtext_format\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mResearchPaperExtraction\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m     26\u001b[0m \u001b[43m)\u001b[49m\n\u001b[0;32m     28\u001b[0m research_paper \u001b[38;5;241m=\u001b[39m response\u001b[38;5;241m.\u001b[39moutput_parsed\n",
      "File \u001b[1;32mD:\\Programs\\Anaconda\\envs\\llms\\lib\\site-packages\\openai\\resources\\responses\\responses.py:1174\u001b[0m, in \u001b[0;36mResponses.parse\u001b[1;34m(self, text_format, background, conversation, include, input, instructions, max_output_tokens, max_tool_calls, metadata, model, parallel_tool_calls, previous_response_id, prompt, prompt_cache_key, prompt_cache_retention, reasoning, safety_identifier, service_tier, store, stream, stream_options, temperature, text, tool_choice, tools, top_logprobs, top_p, truncation, user, verbosity, extra_headers, extra_query, extra_body, timeout)\u001b[0m\n\u001b[0;32m   1167\u001b[0m \u001b[38;5;28;01mdef\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[38;5;21mparser\u001b[39m(raw_response: Response) \u001b[38;5;241m-\u001b[39m\u001b[38;5;241m>\u001b[39m ParsedResponse[TextFormatT]:\n\u001b[0;32m   1168\u001b[0m     \u001b[38;5;28;01mreturn\u001b[39;00m parse_response(\n\u001b[0;32m   1169\u001b[0m         input_tools\u001b[38;5;241m=\u001b[39mtools,\n\u001b[0;32m   1170\u001b[0m         text_format\u001b[38;5;241m=\u001b[39mtext_format,\n\u001b[0;32m   1171\u001b[0m         response\u001b[38;5;241m=\u001b[39mraw_response,\n\u001b[0;32m   1172\u001b[0m     )\n\u001b[1;32m-> 1174\u001b[0m \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_post\u001b[49m\u001b[43m(\u001b[49m\n\u001b[0;32m   1175\u001b[0m \u001b[43m    \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43m/responses\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1176\u001b[0m \u001b[43m    \u001b[49m\u001b[43mbody\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mmaybe_transform\u001b[49m\u001b[43m(\u001b[49m\n\u001b[0;32m   1177\u001b[0m \u001b[43m        \u001b[49m\u001b[43m{\u001b[49m\n\u001b[0;32m   1178\u001b[0m \u001b[43m            \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mbackground\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mbackground\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1179\u001b[0m \u001b[43m            \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mconversation\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mconversation\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1180\u001b[0m \u001b[43m            \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43minclude\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43minclude\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1181\u001b[0m \u001b[43m            \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43minput\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;28;43minput\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1182\u001b[0m \u001b[43m            \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43minstructions\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43minstructions\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1183\u001b[0m \u001b[43m            \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mmax_output_tokens\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mmax_output_tokens\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1184\u001b[0m \u001b[43m            \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mmax_tool_calls\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mmax_tool_calls\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1185\u001b[0m \u001b[43m            \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mmetadata\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mmetadata\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1186\u001b[0m \u001b[43m            \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mmodel\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mmodel\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1187\u001b[0m \u001b[43m            \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mparallel_tool_calls\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mparallel_tool_calls\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1188\u001b[0m \u001b[43m            \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mprevious_response_id\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mprevious_response_id\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1189\u001b[0m \u001b[43m            \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mprompt\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mprompt\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1190\u001b[0m \u001b[43m            \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mprompt_cache_key\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mprompt_cache_key\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1191\u001b[0m \u001b[43m            \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mprompt_cache_retention\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mprompt_cache_retention\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1192\u001b[0m \u001b[43m            \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mreasoning\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mreasoning\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1193\u001b[0m \u001b[43m            \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43msafety_identifier\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43msafety_identifier\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1194\u001b[0m \u001b[43m            \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mservice_tier\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mservice_tier\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1195\u001b[0m \u001b[43m            \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mstore\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mstore\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1196\u001b[0m \u001b[43m            \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mstream\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mstream\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1197\u001b[0m \u001b[43m            \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mstream_options\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mstream_options\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1198\u001b[0m \u001b[43m            \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtemperature\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mtemperature\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1199\u001b[0m \u001b[43m            \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtext\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mtext\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1200\u001b[0m \u001b[43m            \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtool_choice\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mtool_choice\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1201\u001b[0m \u001b[43m            \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtools\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mtools\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1202\u001b[0m \u001b[43m            \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtop_logprobs\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mtop_logprobs\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1203\u001b[0m \u001b[43m            \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtop_p\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mtop_p\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1204\u001b[0m \u001b[43m            \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtruncation\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mtruncation\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1205\u001b[0m \u001b[43m            \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43muser\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43muser\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1206\u001b[0m \u001b[43m            \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mverbosity\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mverbosity\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1207\u001b[0m \u001b[43m        \u001b[49m\u001b[43m}\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1208\u001b[0m \u001b[43m        \u001b[49m\u001b[43mresponse_create_params\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mResponseCreateParams\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1209\u001b[0m \u001b[43m    \u001b[49m\u001b[43m)\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1210\u001b[0m \u001b[43m    \u001b[49m\u001b[43moptions\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mmake_request_options\u001b[49m\u001b[43m(\u001b[49m\n\u001b[0;32m   1211\u001b[0m \u001b[43m        \u001b[49m\u001b[43mextra_headers\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mextra_headers\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1212\u001b[0m \u001b[43m        \u001b[49m\u001b[43mextra_query\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mextra_query\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1213\u001b[0m \u001b[43m        \u001b[49m\u001b[43mextra_body\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mextra_body\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1214\u001b[0m \u001b[43m        \u001b[49m\u001b[43mtimeout\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mtimeout\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1215\u001b[0m \u001b[43m        \u001b[49m\u001b[43mpost_parser\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mparser\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1216\u001b[0m \u001b[43m    \u001b[49m\u001b[43m)\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1217\u001b[0m \u001b[43m    \u001b[49m\u001b[38;5;66;43;03m# we turn the `Response` instance into a `ParsedResponse`\u001b[39;49;00m\n\u001b[0;32m   1218\u001b[0m \u001b[43m    \u001b[49m\u001b[38;5;66;43;03m# in the `parser` function above\u001b[39;49;00m\n\u001b[0;32m   1219\u001b[0m \u001b[43m    \u001b[49m\u001b[43mcast_to\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mcast\u001b[49m\u001b[43m(\u001b[49m\u001b[43mType\u001b[49m\u001b[43m[\u001b[49m\u001b[43mParsedResponse\u001b[49m\u001b[43m[\u001b[49m\u001b[43mTextFormatT\u001b[49m\u001b[43m]\u001b[49m\u001b[43m]\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mResponse\u001b[49m\u001b[43m)\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1220\u001b[0m \u001b[43m\u001b[49m\u001b[43m)\u001b[49m\n",
      "File \u001b[1;32mD:\\Programs\\Anaconda\\envs\\llms\\lib\\site-packages\\openai\\_base_client.py:1294\u001b[0m, in \u001b[0;36mSyncAPIClient.post\u001b[1;34m(self, path, cast_to, body, content, options, files, stream, stream_cls)\u001b[0m\n\u001b[0;32m   1285\u001b[0m     warnings\u001b[38;5;241m.\u001b[39mwarn(\n\u001b[0;32m   1286\u001b[0m         \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mPassing raw bytes as `body` is deprecated and will be removed in a future version. \u001b[39m\u001b[38;5;124m\"\u001b[39m\n\u001b[0;32m   1287\u001b[0m         \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mPlease pass raw bytes via the `content` parameter instead.\u001b[39m\u001b[38;5;124m\"\u001b[39m,\n\u001b[0;32m   1288\u001b[0m         \u001b[38;5;167;01mDeprecationWarning\u001b[39;00m,\n\u001b[0;32m   1289\u001b[0m         stacklevel\u001b[38;5;241m=\u001b[39m\u001b[38;5;241m2\u001b[39m,\n\u001b[0;32m   1290\u001b[0m     )\n\u001b[0;32m   1291\u001b[0m opts \u001b[38;5;241m=\u001b[39m FinalRequestOptions\u001b[38;5;241m.\u001b[39mconstruct(\n\u001b[0;32m   1292\u001b[0m     method\u001b[38;5;241m=\u001b[39m\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mpost\u001b[39m\u001b[38;5;124m\"\u001b[39m, url\u001b[38;5;241m=\u001b[39mpath, json_data\u001b[38;5;241m=\u001b[39mbody, content\u001b[38;5;241m=\u001b[39mcontent, files\u001b[38;5;241m=\u001b[39mto_httpx_files(files), \u001b[38;5;241m*\u001b[39m\u001b[38;5;241m*\u001b[39moptions\n\u001b[0;32m   1293\u001b[0m )\n\u001b[1;32m-> 1294\u001b[0m \u001b[38;5;28;01mreturn\u001b[39;00m cast(ResponseT, \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mrequest\u001b[49m\u001b[43m(\u001b[49m\u001b[43mcast_to\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mopts\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mstream\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mstream\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mstream_cls\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mstream_cls\u001b[49m\u001b[43m)\u001b[49m)\n",
      "File \u001b[1;32mD:\\Programs\\Anaconda\\envs\\llms\\lib\\site-packages\\openai\\_base_client.py:1067\u001b[0m, in \u001b[0;36mSyncAPIClient.request\u001b[1;34m(self, cast_to, options, stream, stream_cls)\u001b[0m\n\u001b[0;32m   1064\u001b[0m             err\u001b[38;5;241m.\u001b[39mresponse\u001b[38;5;241m.\u001b[39mread()\n\u001b[0;32m   1066\u001b[0m         log\u001b[38;5;241m.\u001b[39mdebug(\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mRe-raising status error\u001b[39m\u001b[38;5;124m\"\u001b[39m)\n\u001b[1;32m-> 1067\u001b[0m         \u001b[38;5;28;01mraise\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_make_status_error_from_response(err\u001b[38;5;241m.\u001b[39mresponse) \u001b[38;5;28;01mfrom\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[38;5;28;01mNone\u001b[39;00m\n\u001b[0;32m   1069\u001b[0m     \u001b[38;5;28;01mbreak\u001b[39;00m\n\u001b[0;32m   1071\u001b[0m \u001b[38;5;28;01massert\u001b[39;00m response \u001b[38;5;129;01mis\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m \u001b[38;5;28;01mNone\u001b[39;00m, \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mcould not resolve response (should never happen)\u001b[39m\u001b[38;5;124m\"\u001b[39m\n",
      "\u001b[1;31mPermissionDeniedError\u001b[0m: <html>\r\n<head><title>403 Forbidden</title></head>\r\n<body>\r\n<center><h1>403 Forbidden</h1></center>\r\n<hr><center>SynGX</center>\r\n</body>\r\n</html>"
     ]
    }
   ],
   "source": [
    "from openai import OpenAI\n",
    "from pydantic import BaseModel\n",
    "\n",
    "client = OpenAI(\n",
    "    base_url=os.getenv(\"BASE_URL\"),\n",
    "    api_key=os.getenv(\"OPENAI_API_KEY\"),\n",
    "    http_client=httpx.Client(http2=True, verify=False)\n",
    ")\n",
    "\n",
    "class ResearchPaperExtraction(BaseModel):\n",
    "    title: str\n",
    "    authors: list[str]\n",
    "    abstract: str\n",
    "    keywords: list[str]\n",
    "\n",
    "response = client.responses.parse(\n",
    "    model=os.getenv(\"MODEL_NAME\"),\n",
    "    input=[\n",
    "        {\n",
    "            \"role\": \"system\",\n",
    "            \"content\": \"You are an expert at structured data extraction. You will be given unstructured text from a research paper and should convert it into the given structure.\",\n",
    "        },\n",
    "        {\"role\": \"user\", \"content\": \"...\"},\n",
    "    ],\n",
    "    text_format=ResearchPaperExtraction,\n",
    ")\n",
    "\n",
    "research_paper = response.output_parsed"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 46,
   "id": "5ec16b17-95a5-4787-a890-faa6a5e9de72",
   "metadata": {
    "collapsed": true,
    "jupyter": {
     "outputs_hidden": true
    },
    "tags": []
   },
   "outputs": [
    {
     "ename": "PermissionDeniedError",
     "evalue": "<html>\r\n<head><title>403 Forbidden</title></head>\r\n<body>\r\n<center><h1>403 Forbidden</h1></center>\r\n<hr><center>SynGX</center>\r\n</body>\r\n</html>",
     "output_type": "error",
     "traceback": [
      "\u001b[1;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[1;31mPermissionDeniedError\u001b[0m                     Traceback (most recent call last)",
      "Cell \u001b[1;32mIn[46], line 1\u001b[0m\n\u001b[1;32m----> 1\u001b[0m response \u001b[38;5;241m=\u001b[39m \u001b[43mclient\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mresponses\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mcreate\u001b[49m\u001b[43m(\u001b[49m\n\u001b[0;32m      2\u001b[0m \u001b[43m    \u001b[49m\u001b[43mmodel\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mos\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mgetenv\u001b[49m\u001b[43m(\u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mMODEL_NAME\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m)\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m      3\u001b[0m \u001b[43m    \u001b[49m\u001b[38;5;28;43minput\u001b[39;49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43m[\u001b[49m\u001b[43m{\u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mrole\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43msystem\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mcontent\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mYou are a helpful math tutor. Guide the user through the solution step by step.\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m}\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m      4\u001b[0m \u001b[43m    \u001b[49m\u001b[43m{\u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mrole\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43muser\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mcontent\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mhow can I solve 8x + 7 = -23\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m}\u001b[49m\u001b[43m]\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m      5\u001b[0m \u001b[43m    \u001b[49m\u001b[43mtext\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43m{\u001b[49m\n\u001b[0;32m      6\u001b[0m \u001b[43m    \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mformat\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43m{\u001b[49m\n\u001b[0;32m      7\u001b[0m \u001b[43m    \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtype\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mjson_schema\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[0;32m      8\u001b[0m \u001b[43m    \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mname\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mmath_response\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[0;32m      9\u001b[0m \u001b[43m    \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mschema\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43m{\u001b[49m\n\u001b[0;32m     10\u001b[0m \u001b[43m    \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtype\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mobject\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[0;32m     11\u001b[0m \u001b[43m    \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mproperties\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43m{\u001b[49m\n\u001b[0;32m     12\u001b[0m \u001b[43m    \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43msteps\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43m{\u001b[49m\n\u001b[0;32m     13\u001b[0m \u001b[43m    \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtype\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43marray\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[0;32m     14\u001b[0m \u001b[43m    \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mitems\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43m{\u001b[49m\n\u001b[0;32m     15\u001b[0m \u001b[43m    \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtype\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mobject\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[0;32m     16\u001b[0m \u001b[43m    \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mproperties\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43m{\u001b[49m\n\u001b[0;32m     17\u001b[0m \u001b[43m    \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mexplanation\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43m{\u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtype\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mstring\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m}\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m     18\u001b[0m \u001b[43m    \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43moutput\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43m{\u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtype\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mstring\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m}\u001b[49m\n\u001b[0;32m     19\u001b[0m \u001b[43m    \u001b[49m\u001b[43m}\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m     20\u001b[0m \u001b[43m    \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mrequired\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43m[\u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mexplanation\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43moutput\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m]\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m     21\u001b[0m \u001b[43m    \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43madditionalProperties\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;28;43;01mFalse\u001b[39;49;00m\n\u001b[0;32m     22\u001b[0m \u001b[43m    \u001b[49m\u001b[43m}\u001b[49m\n\u001b[0;32m     23\u001b[0m \u001b[43m    \u001b[49m\u001b[43m}\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m     24\u001b[0m \u001b[43m    \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mfinal_answer\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43m{\u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtype\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mstring\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m}\u001b[49m\n\u001b[0;32m     25\u001b[0m \u001b[43m    \u001b[49m\u001b[43m}\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m     26\u001b[0m \u001b[43m    \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mrequired\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43m[\u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43msteps\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mfinal_answer\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m]\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m     27\u001b[0m \u001b[43m    \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43madditionalProperties\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;28;43;01mFalse\u001b[39;49;00m\n\u001b[0;32m     28\u001b[0m \u001b[43m    \u001b[49m\u001b[43m}\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m     29\u001b[0m \u001b[43m    \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mstrict\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;28;43;01mFalse\u001b[39;49;00m\n\u001b[0;32m     30\u001b[0m \u001b[43m    \u001b[49m\u001b[43m}\u001b[49m\n\u001b[0;32m     31\u001b[0m \u001b[43m    \u001b[49m\u001b[43m}\u001b[49m\n\u001b[0;32m     32\u001b[0m \u001b[43m    \u001b[49m\u001b[43m)\u001b[49m\n\u001b[0;32m     34\u001b[0m \u001b[38;5;28mprint\u001b[39m(response\u001b[38;5;241m.\u001b[39moutput_text)\n",
      "File \u001b[1;32mD:\\Programs\\Anaconda\\envs\\llms\\lib\\site-packages\\openai\\resources\\responses\\responses.py:866\u001b[0m, in \u001b[0;36mResponses.create\u001b[1;34m(self, background, conversation, include, input, instructions, max_output_tokens, max_tool_calls, metadata, model, parallel_tool_calls, previous_response_id, prompt, prompt_cache_key, prompt_cache_retention, reasoning, safety_identifier, service_tier, store, stream, stream_options, temperature, text, tool_choice, tools, top_logprobs, top_p, truncation, user, extra_headers, extra_query, extra_body, timeout)\u001b[0m\n\u001b[0;32m    828\u001b[0m \u001b[38;5;28;01mdef\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[38;5;21mcreate\u001b[39m(\n\u001b[0;32m    829\u001b[0m     \u001b[38;5;28mself\u001b[39m,\n\u001b[0;32m    830\u001b[0m     \u001b[38;5;241m*\u001b[39m,\n\u001b[1;32m   (...)\u001b[0m\n\u001b[0;32m    864\u001b[0m     timeout: \u001b[38;5;28mfloat\u001b[39m \u001b[38;5;241m|\u001b[39m httpx\u001b[38;5;241m.\u001b[39mTimeout \u001b[38;5;241m|\u001b[39m \u001b[38;5;28;01mNone\u001b[39;00m \u001b[38;5;241m|\u001b[39m NotGiven \u001b[38;5;241m=\u001b[39m not_given,\n\u001b[0;32m    865\u001b[0m ) \u001b[38;5;241m-\u001b[39m\u001b[38;5;241m>\u001b[39m Response \u001b[38;5;241m|\u001b[39m Stream[ResponseStreamEvent]:\n\u001b[1;32m--> 866\u001b[0m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_post\u001b[49m\u001b[43m(\u001b[49m\n\u001b[0;32m    867\u001b[0m \u001b[43m        \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43m/responses\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[0;32m    868\u001b[0m \u001b[43m        \u001b[49m\u001b[43mbody\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mmaybe_transform\u001b[49m\u001b[43m(\u001b[49m\n\u001b[0;32m    869\u001b[0m \u001b[43m            \u001b[49m\u001b[43m{\u001b[49m\n\u001b[0;32m    870\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mbackground\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mbackground\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    871\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mconversation\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mconversation\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    872\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43minclude\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43minclude\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    873\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43minput\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;28;43minput\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[0;32m    874\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43minstructions\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43minstructions\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    875\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mmax_output_tokens\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mmax_output_tokens\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    876\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mmax_tool_calls\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mmax_tool_calls\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    877\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mmetadata\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mmetadata\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    878\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mmodel\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mmodel\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    879\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mparallel_tool_calls\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mparallel_tool_calls\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    880\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mprevious_response_id\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mprevious_response_id\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    881\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mprompt\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mprompt\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    882\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mprompt_cache_key\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mprompt_cache_key\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    883\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mprompt_cache_retention\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mprompt_cache_retention\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    884\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mreasoning\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mreasoning\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    885\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43msafety_identifier\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43msafety_identifier\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    886\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mservice_tier\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mservice_tier\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    887\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mstore\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mstore\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    888\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mstream\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mstream\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    889\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mstream_options\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mstream_options\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    890\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtemperature\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mtemperature\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    891\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtext\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mtext\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    892\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtool_choice\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mtool_choice\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    893\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtools\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mtools\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    894\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtop_logprobs\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mtop_logprobs\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    895\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtop_p\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mtop_p\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    896\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtruncation\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mtruncation\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    897\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43muser\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43muser\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    898\u001b[0m \u001b[43m            \u001b[49m\u001b[43m}\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    899\u001b[0m \u001b[43m            \u001b[49m\u001b[43mresponse_create_params\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mResponseCreateParamsStreaming\u001b[49m\n\u001b[0;32m    900\u001b[0m \u001b[43m            \u001b[49m\u001b[38;5;28;43;01mif\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[43mstream\u001b[49m\n\u001b[0;32m    901\u001b[0m \u001b[43m            \u001b[49m\u001b[38;5;28;43;01melse\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[43mresponse_create_params\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mResponseCreateParamsNonStreaming\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    902\u001b[0m \u001b[43m        \u001b[49m\u001b[43m)\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    903\u001b[0m \u001b[43m        \u001b[49m\u001b[43moptions\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mmake_request_options\u001b[49m\u001b[43m(\u001b[49m\n\u001b[0;32m    904\u001b[0m \u001b[43m            \u001b[49m\u001b[43mextra_headers\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mextra_headers\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mextra_query\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mextra_query\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mextra_body\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mextra_body\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mtimeout\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mtimeout\u001b[49m\n\u001b[0;32m    905\u001b[0m \u001b[43m        \u001b[49m\u001b[43m)\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    906\u001b[0m \u001b[43m        \u001b[49m\u001b[43mcast_to\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mResponse\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    907\u001b[0m \u001b[43m        \u001b[49m\u001b[43mstream\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mstream\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;129;43;01mor\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[38;5;28;43;01mFalse\u001b[39;49;00m\u001b[43m,\u001b[49m\n\u001b[0;32m    908\u001b[0m \u001b[43m        \u001b[49m\u001b[43mstream_cls\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mStream\u001b[49m\u001b[43m[\u001b[49m\u001b[43mResponseStreamEvent\u001b[49m\u001b[43m]\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m    909\u001b[0m \u001b[43m    \u001b[49m\u001b[43m)\u001b[49m\n",
      "File \u001b[1;32mD:\\Programs\\Anaconda\\envs\\llms\\lib\\site-packages\\openai\\_base_client.py:1294\u001b[0m, in \u001b[0;36mSyncAPIClient.post\u001b[1;34m(self, path, cast_to, body, content, options, files, stream, stream_cls)\u001b[0m\n\u001b[0;32m   1285\u001b[0m     warnings\u001b[38;5;241m.\u001b[39mwarn(\n\u001b[0;32m   1286\u001b[0m         \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mPassing raw bytes as `body` is deprecated and will be removed in a future version. \u001b[39m\u001b[38;5;124m\"\u001b[39m\n\u001b[0;32m   1287\u001b[0m         \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mPlease pass raw bytes via the `content` parameter instead.\u001b[39m\u001b[38;5;124m\"\u001b[39m,\n\u001b[0;32m   1288\u001b[0m         \u001b[38;5;167;01mDeprecationWarning\u001b[39;00m,\n\u001b[0;32m   1289\u001b[0m         stacklevel\u001b[38;5;241m=\u001b[39m\u001b[38;5;241m2\u001b[39m,\n\u001b[0;32m   1290\u001b[0m     )\n\u001b[0;32m   1291\u001b[0m opts \u001b[38;5;241m=\u001b[39m FinalRequestOptions\u001b[38;5;241m.\u001b[39mconstruct(\n\u001b[0;32m   1292\u001b[0m     method\u001b[38;5;241m=\u001b[39m\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mpost\u001b[39m\u001b[38;5;124m\"\u001b[39m, url\u001b[38;5;241m=\u001b[39mpath, json_data\u001b[38;5;241m=\u001b[39mbody, content\u001b[38;5;241m=\u001b[39mcontent, files\u001b[38;5;241m=\u001b[39mto_httpx_files(files), \u001b[38;5;241m*\u001b[39m\u001b[38;5;241m*\u001b[39moptions\n\u001b[0;32m   1293\u001b[0m )\n\u001b[1;32m-> 1294\u001b[0m \u001b[38;5;28;01mreturn\u001b[39;00m cast(ResponseT, \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mrequest\u001b[49m\u001b[43m(\u001b[49m\u001b[43mcast_to\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mopts\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mstream\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mstream\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mstream_cls\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mstream_cls\u001b[49m\u001b[43m)\u001b[49m)\n",
      "File \u001b[1;32mD:\\Programs\\Anaconda\\envs\\llms\\lib\\site-packages\\openai\\_base_client.py:1067\u001b[0m, in \u001b[0;36mSyncAPIClient.request\u001b[1;34m(self, cast_to, options, stream, stream_cls)\u001b[0m\n\u001b[0;32m   1064\u001b[0m             err\u001b[38;5;241m.\u001b[39mresponse\u001b[38;5;241m.\u001b[39mread()\n\u001b[0;32m   1066\u001b[0m         log\u001b[38;5;241m.\u001b[39mdebug(\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mRe-raising status error\u001b[39m\u001b[38;5;124m\"\u001b[39m)\n\u001b[1;32m-> 1067\u001b[0m         \u001b[38;5;28;01mraise\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_make_status_error_from_response(err\u001b[38;5;241m.\u001b[39mresponse) \u001b[38;5;28;01mfrom\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[38;5;28;01mNone\u001b[39;00m\n\u001b[0;32m   1069\u001b[0m     \u001b[38;5;28;01mbreak\u001b[39;00m\n\u001b[0;32m   1071\u001b[0m \u001b[38;5;28;01massert\u001b[39;00m response \u001b[38;5;129;01mis\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m \u001b[38;5;28;01mNone\u001b[39;00m, \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mcould not resolve response (should never happen)\u001b[39m\u001b[38;5;124m\"\u001b[39m\n",
      "\u001b[1;31mPermissionDeniedError\u001b[0m: <html>\r\n<head><title>403 Forbidden</title></head>\r\n<body>\r\n<center><h1>403 Forbidden</h1></center>\r\n<hr><center>SynGX</center>\r\n</body>\r\n</html>"
     ]
    }
   ],
   "source": [
    "response = client.responses.create(\n",
    "    model=os.getenv(\"MODEL_NAME\"),\n",
    "    input=[{\"role\": \"system\", \"content\": \"You are a helpful math tutor. Guide the user through the solution step by step.\"},\n",
    "    {\"role\": \"user\", \"content\": \"how can I solve 8x + 7 = -23\"}],\n",
    "    text={\n",
    "    \"format\": {\n",
    "    \"type\": \"json_schema\",\n",
    "    \"name\": \"math_response\",\n",
    "    \"schema\": {\n",
    "    \"type\": \"object\",\n",
    "    \"properties\": {\n",
    "    \"steps\": {\n",
    "    \"type\": \"array\",\n",
    "    \"items\": {\n",
    "    \"type\": \"object\",\n",
    "    \"properties\": {\n",
    "    \"explanation\": {\"type\": \"string\"},\n",
    "    \"output\": {\"type\": \"string\"}\n",
    "    },\n",
    "    \"required\": [\"explanation\", \"output\"],\n",
    "    \"additionalProperties\": False\n",
    "    }\n",
    "    },\n",
    "    \"final_answer\": {\"type\": \"string\"}\n",
    "    },\n",
    "    \"required\": [\"steps\", \"final_answer\"],\n",
    "    \"additionalProperties\": False\n",
    "    },\n",
    "    \"strict\": False\n",
    "    }\n",
    "    }\n",
    "    )\n",
    "\n",
    "print(response.output_text)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 57,
   "id": "b68c5684-7c07-4a82-8d41-e4e5b7460da2",
   "metadata": {
    "collapsed": true,
    "jupyter": {
     "outputs_hidden": true
    },
    "tags": []
   },
   "outputs": [
    {
     "ename": "TypeError",
     "evalue": "Completions.create() got an unexpected keyword argument 'text'",
     "output_type": "error",
     "traceback": [
      "\u001b[1;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[1;31mTypeError\u001b[0m                                 Traceback (most recent call last)",
      "Cell \u001b[1;32mIn[57], line 1\u001b[0m\n\u001b[1;32m----> 1\u001b[0m response \u001b[38;5;241m=\u001b[39m \u001b[43mclient\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mchat\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mcompletions\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mcreate\u001b[49m\u001b[43m(\u001b[49m\n\u001b[0;32m      2\u001b[0m \u001b[43m        \u001b[49m\u001b[43mmodel\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mos\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mgetenv\u001b[49m\u001b[43m(\u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mMODEL_NAME\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m)\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m      3\u001b[0m \u001b[43m        \u001b[49m\u001b[43mmessages\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43m[\u001b[49m\n\u001b[0;32m      4\u001b[0m \u001b[43m            \u001b[49m\u001b[43m{\u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mrole\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43msystem\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mcontent\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mYou are a helpful assistant designed to output JSON.\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m}\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m      5\u001b[0m \u001b[43m            \u001b[49m\u001b[43m{\u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mrole\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43muser\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mcontent\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mWho won the world series in 2020? Please respond in the format \u001b[39;49m\u001b[38;5;124;43m{\u001b[39;49m\u001b[38;5;124;43mwinner: ...}\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m}\u001b[49m\n\u001b[0;32m      6\u001b[0m \u001b[43m        \u001b[49m\u001b[43m]\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m      7\u001b[0m \u001b[43m        \u001b[49m\u001b[43mtext\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43m{\u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mformat\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43m{\u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtype\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mjson_object\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m}\u001b[49m\u001b[43m}\u001b[49m\n\u001b[0;32m      8\u001b[0m \u001b[43m    \u001b[49m\u001b[43m)\u001b[49m\n\u001b[0;32m      9\u001b[0m \u001b[38;5;28mprint\u001b[39m(response\u001b[38;5;241m.\u001b[39mchoices[\u001b[38;5;241m0\u001b[39m]\u001b[38;5;241m.\u001b[39mmessage\u001b[38;5;241m.\u001b[39mcontent)\n",
      "File \u001b[1;32mD:\\Programs\\Anaconda\\envs\\llms\\lib\\site-packages\\openai\\_utils\\_utils.py:286\u001b[0m, in \u001b[0;36mrequired_args.<locals>.inner.<locals>.wrapper\u001b[1;34m(*args, **kwargs)\u001b[0m\n\u001b[0;32m    284\u001b[0m             msg \u001b[38;5;241m=\u001b[39m \u001b[38;5;124mf\u001b[39m\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mMissing required argument: \u001b[39m\u001b[38;5;132;01m{\u001b[39;00mquote(missing[\u001b[38;5;241m0\u001b[39m])\u001b[38;5;132;01m}\u001b[39;00m\u001b[38;5;124m\"\u001b[39m\n\u001b[0;32m    285\u001b[0m     \u001b[38;5;28;01mraise\u001b[39;00m \u001b[38;5;167;01mTypeError\u001b[39;00m(msg)\n\u001b[1;32m--> 286\u001b[0m \u001b[38;5;28;01mreturn\u001b[39;00m func(\u001b[38;5;241m*\u001b[39margs, \u001b[38;5;241m*\u001b[39m\u001b[38;5;241m*\u001b[39mkwargs)\n",
      "\u001b[1;31mTypeError\u001b[0m: Completions.create() got an unexpected keyword argument 'text'"
     ]
    }
   ],
   "source": [
    "response = client.chat.completions.create(\n",
    "        model=os.getenv(\"MODEL_NAME\"),\n",
    "        messages=[\n",
    "            {\"role\": \"system\", \"content\": \"You are a helpful assistant designed to output JSON.\"},\n",
    "            {\"role\": \"user\", \"content\": \"Who won the world series in 2020? Please respond in the format {winner: ...}\"}\n",
    "        ],\n",
    "        text={\"format\": {\"type\": \"json_object\"}}\n",
    "    )\n",
    "print(response.choices[0].message.content)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "d99fbfee-ca6c-4a9f-9fdf-651e46b5e7fe",
   "metadata": {
    "jp-MarkdownHeadingCollapsed": true,
    "tags": []
   },
   "source": [
    "### response_format: {type: \"json_schema\",...} -- Error code: 400 - {'status': 400, 'message': 'Empty schema with json format type is not supported'}\n",
    "Structured Outputs with response_format: {type: \"json_schema\", ...} is only supported with the gpt-4o-mini, gpt-4o-mini-2024-07-18, and gpt-4o-2024-08-06 model snapshots and later."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 90,
   "id": "d1d82211-21f6-4ae0-b81d-7cac414774a1",
   "metadata": {
    "collapsed": true,
    "jupyter": {
     "outputs_hidden": true
    },
    "tags": []
   },
   "outputs": [
    {
     "ename": "BadRequestError",
     "evalue": "Error code: 400 - {'status': 400, 'message': 'Empty schema with json format type is not supported'}",
     "output_type": "error",
     "traceback": [
      "\u001b[1;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[1;31mBadRequestError\u001b[0m                           Traceback (most recent call last)",
      "Cell \u001b[1;32mIn[90], line 14\u001b[0m\n\u001b[0;32m     10\u001b[0m     car_type: CarType\n\u001b[0;32m     12\u001b[0m json_schema \u001b[38;5;241m=\u001b[39m CarDescription\u001b[38;5;241m.\u001b[39mmodel_json_schema()\n\u001b[1;32m---> 14\u001b[0m completion \u001b[38;5;241m=\u001b[39m \u001b[43mclient\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mchat\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mcompletions\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mcreate\u001b[49m\u001b[43m(\u001b[49m\n\u001b[0;32m     15\u001b[0m \u001b[43m    \u001b[49m\u001b[43mmodel\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mos\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mgetenv\u001b[49m\u001b[43m(\u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mMODEL_NAME\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m)\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m     16\u001b[0m \u001b[43m    \u001b[49m\u001b[43mmessages\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43m[\u001b[49m\n\u001b[0;32m     17\u001b[0m \u001b[43m        \u001b[49m\u001b[43m{\u001b[49m\n\u001b[0;32m     18\u001b[0m \u001b[43m            \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mrole\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43muser\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[0;32m     19\u001b[0m \u001b[43m            \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mcontent\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mGenerate a JSON with the brand, model and car_type of Ford Explorer (SUV) car from the 90\u001b[39;49m\u001b[38;5;124;43m'\u001b[39;49m\u001b[38;5;124;43ms\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\n\u001b[0;32m     20\u001b[0m \u001b[43m        \u001b[49m\u001b[43m}\u001b[49m\n\u001b[0;32m     21\u001b[0m \u001b[43m    \u001b[49m\u001b[43m]\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m     22\u001b[0m \u001b[43m    \u001b[49m\u001b[43mresponse_format\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43m{\u001b[49m\n\u001b[0;32m     23\u001b[0m \u001b[43m        \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtype\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mjson_schema\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[0;32m     24\u001b[0m \u001b[43m        \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mjson_schema\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43m{\u001b[49m\n\u001b[0;32m     25\u001b[0m \u001b[43m            \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mname\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mcar-description\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[0;32m     26\u001b[0m \u001b[43m            \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mschema\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mCarDescription\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mmodel_json_schema\u001b[49m\u001b[43m(\u001b[49m\u001b[43m)\u001b[49m\n\u001b[0;32m     27\u001b[0m \u001b[43m        \u001b[49m\u001b[43m}\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m     28\u001b[0m \u001b[43m    \u001b[49m\u001b[43m}\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m     29\u001b[0m \u001b[43m)\u001b[49m\n\u001b[0;32m     30\u001b[0m \u001b[38;5;28mprint\u001b[39m(completion\u001b[38;5;241m.\u001b[39mchoices[\u001b[38;5;241m0\u001b[39m]\u001b[38;5;241m.\u001b[39mmessage\u001b[38;5;241m.\u001b[39mcontent)\n",
      "File \u001b[1;32mD:\\Programs\\Anaconda\\envs\\llms\\lib\\site-packages\\openai\\_utils\\_utils.py:286\u001b[0m, in \u001b[0;36mrequired_args.<locals>.inner.<locals>.wrapper\u001b[1;34m(*args, **kwargs)\u001b[0m\n\u001b[0;32m    284\u001b[0m             msg \u001b[38;5;241m=\u001b[39m \u001b[38;5;124mf\u001b[39m\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mMissing required argument: \u001b[39m\u001b[38;5;132;01m{\u001b[39;00mquote(missing[\u001b[38;5;241m0\u001b[39m])\u001b[38;5;132;01m}\u001b[39;00m\u001b[38;5;124m\"\u001b[39m\n\u001b[0;32m    285\u001b[0m     \u001b[38;5;28;01mraise\u001b[39;00m \u001b[38;5;167;01mTypeError\u001b[39;00m(msg)\n\u001b[1;32m--> 286\u001b[0m \u001b[38;5;28;01mreturn\u001b[39;00m func(\u001b[38;5;241m*\u001b[39margs, \u001b[38;5;241m*\u001b[39m\u001b[38;5;241m*\u001b[39mkwargs)\n",
      "File \u001b[1;32mD:\\Programs\\Anaconda\\envs\\llms\\lib\\site-packages\\openai\\resources\\chat\\completions\\completions.py:1192\u001b[0m, in \u001b[0;36mCompletions.create\u001b[1;34m(self, messages, model, audio, frequency_penalty, function_call, functions, logit_bias, logprobs, max_completion_tokens, max_tokens, metadata, modalities, n, parallel_tool_calls, prediction, presence_penalty, prompt_cache_key, prompt_cache_retention, reasoning_effort, response_format, safety_identifier, seed, service_tier, stop, store, stream, stream_options, temperature, tool_choice, tools, top_logprobs, top_p, user, verbosity, web_search_options, extra_headers, extra_query, extra_body, timeout)\u001b[0m\n\u001b[0;32m   1145\u001b[0m \u001b[38;5;129m@required_args\u001b[39m([\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mmessages\u001b[39m\u001b[38;5;124m\"\u001b[39m, \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mmodel\u001b[39m\u001b[38;5;124m\"\u001b[39m], [\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mmessages\u001b[39m\u001b[38;5;124m\"\u001b[39m, \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mmodel\u001b[39m\u001b[38;5;124m\"\u001b[39m, \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mstream\u001b[39m\u001b[38;5;124m\"\u001b[39m])\n\u001b[0;32m   1146\u001b[0m \u001b[38;5;28;01mdef\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[38;5;21mcreate\u001b[39m(\n\u001b[0;32m   1147\u001b[0m     \u001b[38;5;28mself\u001b[39m,\n\u001b[1;32m   (...)\u001b[0m\n\u001b[0;32m   1189\u001b[0m     timeout: \u001b[38;5;28mfloat\u001b[39m \u001b[38;5;241m|\u001b[39m httpx\u001b[38;5;241m.\u001b[39mTimeout \u001b[38;5;241m|\u001b[39m \u001b[38;5;28;01mNone\u001b[39;00m \u001b[38;5;241m|\u001b[39m NotGiven \u001b[38;5;241m=\u001b[39m not_given,\n\u001b[0;32m   1190\u001b[0m ) \u001b[38;5;241m-\u001b[39m\u001b[38;5;241m>\u001b[39m ChatCompletion \u001b[38;5;241m|\u001b[39m Stream[ChatCompletionChunk]:\n\u001b[0;32m   1191\u001b[0m     validate_response_format(response_format)\n\u001b[1;32m-> 1192\u001b[0m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_post\u001b[49m\u001b[43m(\u001b[49m\n\u001b[0;32m   1193\u001b[0m \u001b[43m        \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43m/chat/completions\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1194\u001b[0m \u001b[43m        \u001b[49m\u001b[43mbody\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mmaybe_transform\u001b[49m\u001b[43m(\u001b[49m\n\u001b[0;32m   1195\u001b[0m \u001b[43m            \u001b[49m\u001b[43m{\u001b[49m\n\u001b[0;32m   1196\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mmessages\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mmessages\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1197\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mmodel\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mmodel\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1198\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43maudio\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43maudio\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1199\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mfrequency_penalty\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mfrequency_penalty\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1200\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mfunction_call\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mfunction_call\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1201\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mfunctions\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mfunctions\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1202\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mlogit_bias\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mlogit_bias\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1203\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mlogprobs\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mlogprobs\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1204\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mmax_completion_tokens\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mmax_completion_tokens\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1205\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mmax_tokens\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mmax_tokens\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1206\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mmetadata\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mmetadata\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1207\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mmodalities\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mmodalities\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1208\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mn\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mn\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1209\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mparallel_tool_calls\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mparallel_tool_calls\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1210\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mprediction\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mprediction\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1211\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mpresence_penalty\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mpresence_penalty\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1212\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mprompt_cache_key\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mprompt_cache_key\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1213\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mprompt_cache_retention\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mprompt_cache_retention\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1214\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mreasoning_effort\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mreasoning_effort\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1215\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mresponse_format\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mresponse_format\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1216\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43msafety_identifier\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43msafety_identifier\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1217\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mseed\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mseed\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1218\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mservice_tier\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mservice_tier\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1219\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mstop\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mstop\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1220\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mstore\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mstore\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1221\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mstream\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mstream\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1222\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mstream_options\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mstream_options\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1223\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtemperature\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mtemperature\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1224\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtool_choice\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mtool_choice\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1225\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtools\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mtools\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1226\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtop_logprobs\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mtop_logprobs\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1227\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtop_p\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mtop_p\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1228\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43muser\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43muser\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1229\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mverbosity\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mverbosity\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1230\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mweb_search_options\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mweb_search_options\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1231\u001b[0m \u001b[43m            \u001b[49m\u001b[43m}\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1232\u001b[0m \u001b[43m            \u001b[49m\u001b[43mcompletion_create_params\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mCompletionCreateParamsStreaming\u001b[49m\n\u001b[0;32m   1233\u001b[0m \u001b[43m            \u001b[49m\u001b[38;5;28;43;01mif\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[43mstream\u001b[49m\n\u001b[0;32m   1234\u001b[0m \u001b[43m            \u001b[49m\u001b[38;5;28;43;01melse\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[43mcompletion_create_params\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mCompletionCreateParamsNonStreaming\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1235\u001b[0m \u001b[43m        \u001b[49m\u001b[43m)\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1236\u001b[0m \u001b[43m        \u001b[49m\u001b[43moptions\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mmake_request_options\u001b[49m\u001b[43m(\u001b[49m\n\u001b[0;32m   1237\u001b[0m \u001b[43m            \u001b[49m\u001b[43mextra_headers\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mextra_headers\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mextra_query\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mextra_query\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mextra_body\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mextra_body\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mtimeout\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mtimeout\u001b[49m\n\u001b[0;32m   1238\u001b[0m \u001b[43m        \u001b[49m\u001b[43m)\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1239\u001b[0m \u001b[43m        \u001b[49m\u001b[43mcast_to\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mChatCompletion\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1240\u001b[0m \u001b[43m        \u001b[49m\u001b[43mstream\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mstream\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;129;43;01mor\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[38;5;28;43;01mFalse\u001b[39;49;00m\u001b[43m,\u001b[49m\n\u001b[0;32m   1241\u001b[0m \u001b[43m        \u001b[49m\u001b[43mstream_cls\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mStream\u001b[49m\u001b[43m[\u001b[49m\u001b[43mChatCompletionChunk\u001b[49m\u001b[43m]\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1242\u001b[0m \u001b[43m    \u001b[49m\u001b[43m)\u001b[49m\n",
      "File \u001b[1;32mD:\\Programs\\Anaconda\\envs\\llms\\lib\\site-packages\\openai\\_base_client.py:1294\u001b[0m, in \u001b[0;36mSyncAPIClient.post\u001b[1;34m(self, path, cast_to, body, content, options, files, stream, stream_cls)\u001b[0m\n\u001b[0;32m   1285\u001b[0m     warnings\u001b[38;5;241m.\u001b[39mwarn(\n\u001b[0;32m   1286\u001b[0m         \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mPassing raw bytes as `body` is deprecated and will be removed in a future version. \u001b[39m\u001b[38;5;124m\"\u001b[39m\n\u001b[0;32m   1287\u001b[0m         \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mPlease pass raw bytes via the `content` parameter instead.\u001b[39m\u001b[38;5;124m\"\u001b[39m,\n\u001b[0;32m   1288\u001b[0m         \u001b[38;5;167;01mDeprecationWarning\u001b[39;00m,\n\u001b[0;32m   1289\u001b[0m         stacklevel\u001b[38;5;241m=\u001b[39m\u001b[38;5;241m2\u001b[39m,\n\u001b[0;32m   1290\u001b[0m     )\n\u001b[0;32m   1291\u001b[0m opts \u001b[38;5;241m=\u001b[39m FinalRequestOptions\u001b[38;5;241m.\u001b[39mconstruct(\n\u001b[0;32m   1292\u001b[0m     method\u001b[38;5;241m=\u001b[39m\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mpost\u001b[39m\u001b[38;5;124m\"\u001b[39m, url\u001b[38;5;241m=\u001b[39mpath, json_data\u001b[38;5;241m=\u001b[39mbody, content\u001b[38;5;241m=\u001b[39mcontent, files\u001b[38;5;241m=\u001b[39mto_httpx_files(files), \u001b[38;5;241m*\u001b[39m\u001b[38;5;241m*\u001b[39moptions\n\u001b[0;32m   1293\u001b[0m )\n\u001b[1;32m-> 1294\u001b[0m \u001b[38;5;28;01mreturn\u001b[39;00m cast(ResponseT, \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mrequest\u001b[49m\u001b[43m(\u001b[49m\u001b[43mcast_to\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mopts\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mstream\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mstream\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mstream_cls\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mstream_cls\u001b[49m\u001b[43m)\u001b[49m)\n",
      "File \u001b[1;32mD:\\Programs\\Anaconda\\envs\\llms\\lib\\site-packages\\openai\\_base_client.py:1067\u001b[0m, in \u001b[0;36mSyncAPIClient.request\u001b[1;34m(self, cast_to, options, stream, stream_cls)\u001b[0m\n\u001b[0;32m   1064\u001b[0m             err\u001b[38;5;241m.\u001b[39mresponse\u001b[38;5;241m.\u001b[39mread()\n\u001b[0;32m   1066\u001b[0m         log\u001b[38;5;241m.\u001b[39mdebug(\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mRe-raising status error\u001b[39m\u001b[38;5;124m\"\u001b[39m)\n\u001b[1;32m-> 1067\u001b[0m         \u001b[38;5;28;01mraise\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_make_status_error_from_response(err\u001b[38;5;241m.\u001b[39mresponse) \u001b[38;5;28;01mfrom\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[38;5;28;01mNone\u001b[39;00m\n\u001b[0;32m   1069\u001b[0m     \u001b[38;5;28;01mbreak\u001b[39;00m\n\u001b[0;32m   1071\u001b[0m \u001b[38;5;28;01massert\u001b[39;00m response \u001b[38;5;129;01mis\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m \u001b[38;5;28;01mNone\u001b[39;00m, \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mcould not resolve response (should never happen)\u001b[39m\u001b[38;5;124m\"\u001b[39m\n",
      "\u001b[1;31mBadRequestError\u001b[0m: Error code: 400 - {'status': 400, 'message': 'Empty schema with json format type is not supported'}"
     ]
    }
   ],
   "source": [
    "class CarType(str, Enum):\n",
    "    sedan = \"sedan\"\n",
    "    suv = \"SUV\"\n",
    "    truck = \"Truck\"\n",
    "    coupe = \"Coupe\"\n",
    "\n",
    "class CarDescription(BaseModel):\n",
    "    brand: str\n",
    "    model: str\n",
    "    car_type: CarType\n",
    "\n",
    "json_schema = CarDescription.model_json_schema()\n",
    "\n",
    "completion = client.chat.completions.create(\n",
    "    model=os.getenv(\"MODEL_NAME\"),\n",
    "    messages=[\n",
    "        {\n",
    "            \"role\": \"user\",\n",
    "            \"content\": \"Generate a JSON with the brand, model and car_type of Ford Explorer (SUV) car from the 90's\"\n",
    "        }\n",
    "    ],\n",
    "    response_format={\n",
    "        \"type\": \"json_schema\",\n",
    "        \"json_schema\": {\n",
    "            \"name\": \"car-description\",\n",
    "            \"schema\": CarDescription.model_json_schema()\n",
    "        },\n",
    "    },\n",
    ")\n",
    "print(completion.choices[0].message.content)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "73b0ff1d-9309-4f8b-b7db-30e7a138f6fb",
   "metadata": {
    "tags": []
   },
   "source": [
    "### back"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 43,
   "id": "f1fe9455-5543-4c20-823a-545e54a01063",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "### JSON data for Mazda cars from the 1990s:\n",
      "\n",
      "```json\n",
      "[\n",
      "  {\n",
      "    \"brand\": \"Mazda\",\n",
      "    \"model\": \"MX-5 Miata\",\n",
      "    \"car_type\": \"Roadster\"\n",
      "  },\n",
      "  {\n",
      "    \"brand\": \"Mazda\",\n",
      "    \"model\": \"Protege\",\n",
      "    \"car_type\": \"Compact Sedan\"\n",
      "  },\n",
      "  {\n",
      "    \"brand\": \"Mazda\",\n",
      "    \"model\": \"Millenia\",\n",
      "    \"car_type\": \"Full-size Luxury Sedan\"\n",
      "  },\n",
      "  {\n",
      "    \"brand\": \"Mazda\",\n",
      "    \"model\": \"B2300\",\n",
      "    \"car_type\": \"Pickup Truck\"\n",
      "  },\n",
      "  {\n",
      "    \"brand\": \"Mazda\",\n",
      "    \"model\": \"MPV\",\n",
      "    \"car_type\": \"Minivan\"\n",
      "  },\n",
      "  {\n",
      "    \"brand\": \"Mazda\",\n",
      "    \"model\": \"626\",\n",
      "    \"car_type\": \"Mid-size Sedan\"\n",
      "  }\n",
      "]\n",
      "```\n",
      "\n",
      "This JSON contains information about popular Mazda models from the 1990s, including their respective brands, models, and types (sedans, roadsters, minivans, etc.).\n"
     ]
    }
   ],
   "source": [
    "from enum import Enum\n",
    "class CarType(str, Enum):\n",
    "    sedan = \"sedan\"\n",
    "    suv = \"SUV\"\n",
    "    truck = \"Truck\"\n",
    "    coupe = \"Coupe\"\n",
    "\n",
    "class CarDescription(BaseModel):\n",
    "    brand: str\n",
    "    model: str\n",
    "    car_type: CarType\n",
    "\n",
    "json_schema = CarDescription.model_json_schema()\n",
    "\n",
    "completion = client.chat.completions.create(\n",
    "    model=os.getenv(\"MODEL_NAME\"),\n",
    "    messages=[\n",
    "        {\n",
    "            \"role\": \"user\",\n",
    "            \"content\": \"Generate a JSON with the brand, model and car_type of Mazda cars from the 90's  /no_think\"\n",
    "        }\n",
    "    ],\n",
    "    response_format={\n",
    "        \"type\": \"json_object\",\n",
    "        \"json_schema\": {\n",
    "            \"name\": \"car-description\",\n",
    "            \"schema\": CarDescription.model_json_schema()\n",
    "        },\n",
    "    },\n",
    "    temperature=0,\n",
    ")\n",
    "print(completion.choices[0].message.content)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "04b0a1a1-3f11-4544-bbac-df88d78b93bc",
   "metadata": {},
   "outputs": [],
   "source": [
    "response.msgs[0].parsed"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 36,
   "id": "368a3cae-d904-4007-b053-87b0b3ac0c7e",
   "metadata": {
    "collapsed": true,
    "jupyter": {
     "outputs_hidden": true
    },
    "tags": []
   },
   "outputs": [
    {
     "ename": "BadRequestError",
     "evalue": "Error code: 400 - {'status': 400, 'message': 'Empty schema with json format type is not supported'}",
     "output_type": "error",
     "traceback": [
      "\u001b[31m---------------------------------------------------------------------------\u001b[39m",
      "\u001b[31mBadRequestError\u001b[39m                           Traceback (most recent call last)",
      "\u001b[36mCell\u001b[39m\u001b[36m \u001b[39m\u001b[32mIn[36]\u001b[39m\u001b[32m, line 19\u001b[39m\n\u001b[32m     15\u001b[39m     car_type: CarType\n\u001b[32m     17\u001b[39m json_schema = CarDescription.model_json_schema()\n\u001b[32m---> \u001b[39m\u001b[32m19\u001b[39m completion = \u001b[43mclient\u001b[49m\u001b[43m.\u001b[49m\u001b[43mchat\u001b[49m\u001b[43m.\u001b[49m\u001b[43mcompletions\u001b[49m\u001b[43m.\u001b[49m\u001b[43mparse\u001b[49m\u001b[43m(\u001b[49m\n\u001b[32m     20\u001b[39m \u001b[43m    \u001b[49m\u001b[43mmodel\u001b[49m\u001b[43m=\u001b[49m\u001b[43mos\u001b[49m\u001b[43m.\u001b[49m\u001b[43mgetenv\u001b[49m\u001b[43m(\u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mMODEL_NAME\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m)\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m     21\u001b[39m \u001b[43m    \u001b[49m\u001b[43mmessages\u001b[49m\u001b[43m=\u001b[49m\u001b[43m[\u001b[49m\n\u001b[32m     22\u001b[39m \u001b[43m        \u001b[49m\u001b[43m{\u001b[49m\n\u001b[32m     23\u001b[39m \u001b[43m            \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mrole\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43muser\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[32m     24\u001b[39m \u001b[43m            \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mcontent\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mGenerate a JSON with the brand, model and car_type of Mazda cars from the 90\u001b[39;49m\u001b[33;43m'\u001b[39;49m\u001b[33;43ms  /no_think\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\n\u001b[32m     25\u001b[39m \u001b[43m        \u001b[49m\u001b[43m}\u001b[49m\n\u001b[32m     26\u001b[39m \u001b[43m    \u001b[49m\u001b[43m]\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m     27\u001b[39m \u001b[43m    \u001b[49m\u001b[43mresponse_format\u001b[49m\u001b[43m=\u001b[49m\u001b[43mCarDescription\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m     28\u001b[39m \u001b[43m    \u001b[49m\u001b[43mtemperature\u001b[49m\u001b[43m=\u001b[49m\u001b[32;43m0\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[32m     29\u001b[39m \u001b[43m)\u001b[49m\n\u001b[32m     30\u001b[39m \u001b[38;5;28mprint\u001b[39m(completion.choices[\u001b[32m0\u001b[39m].message.content)\n",
      "\u001b[36mFile \u001b[39m\u001b[32m~\\anaconda3\\envs\\llms\\Lib\\site-packages\\openai\\resources\\chat\\completions\\completions.py:184\u001b[39m, in \u001b[36mCompletions.parse\u001b[39m\u001b[34m(self, messages, model, audio, response_format, frequency_penalty, function_call, functions, logit_bias, logprobs, max_completion_tokens, max_tokens, metadata, modalities, n, parallel_tool_calls, prediction, presence_penalty, prompt_cache_key, prompt_cache_retention, reasoning_effort, safety_identifier, seed, service_tier, stop, store, stream_options, temperature, tool_choice, tools, top_logprobs, top_p, user, verbosity, web_search_options, extra_headers, extra_query, extra_body, timeout)\u001b[39m\n\u001b[32m    177\u001b[39m \u001b[38;5;28;01mdef\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[34mparser\u001b[39m(raw_completion: ChatCompletion) -> ParsedChatCompletion[ResponseFormatT]:\n\u001b[32m    178\u001b[39m     \u001b[38;5;28;01mreturn\u001b[39;00m _parse_chat_completion(\n\u001b[32m    179\u001b[39m         response_format=response_format,\n\u001b[32m    180\u001b[39m         chat_completion=raw_completion,\n\u001b[32m    181\u001b[39m         input_tools=chat_completion_tools,\n\u001b[32m    182\u001b[39m     )\n\u001b[32m--> \u001b[39m\u001b[32m184\u001b[39m \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43m_post\u001b[49m\u001b[43m(\u001b[49m\n\u001b[32m    185\u001b[39m \u001b[43m    \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43m/chat/completions\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[32m    186\u001b[39m \u001b[43m    \u001b[49m\u001b[43mbody\u001b[49m\u001b[43m=\u001b[49m\u001b[43mmaybe_transform\u001b[49m\u001b[43m(\u001b[49m\n\u001b[32m    187\u001b[39m \u001b[43m        \u001b[49m\u001b[43m{\u001b[49m\n\u001b[32m    188\u001b[39m \u001b[43m            \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mmessages\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mmessages\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    189\u001b[39m \u001b[43m            \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mmodel\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mmodel\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    190\u001b[39m \u001b[43m            \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43maudio\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43maudio\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    191\u001b[39m \u001b[43m            \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mfrequency_penalty\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mfrequency_penalty\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    192\u001b[39m \u001b[43m            \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mfunction_call\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mfunction_call\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    193\u001b[39m \u001b[43m            \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mfunctions\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mfunctions\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    194\u001b[39m \u001b[43m            \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mlogit_bias\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mlogit_bias\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    195\u001b[39m \u001b[43m            \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mlogprobs\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mlogprobs\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    196\u001b[39m \u001b[43m            \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mmax_completion_tokens\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mmax_completion_tokens\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    197\u001b[39m \u001b[43m            \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mmax_tokens\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mmax_tokens\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    198\u001b[39m \u001b[43m            \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mmetadata\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mmetadata\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    199\u001b[39m \u001b[43m            \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mmodalities\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mmodalities\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    200\u001b[39m \u001b[43m            \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mn\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mn\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    201\u001b[39m \u001b[43m            \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mparallel_tool_calls\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mparallel_tool_calls\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    202\u001b[39m \u001b[43m            \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mprediction\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mprediction\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    203\u001b[39m \u001b[43m            \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mpresence_penalty\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mpresence_penalty\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    204\u001b[39m \u001b[43m            \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mprompt_cache_key\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mprompt_cache_key\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    205\u001b[39m \u001b[43m            \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mprompt_cache_retention\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mprompt_cache_retention\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    206\u001b[39m \u001b[43m            \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mreasoning_effort\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mreasoning_effort\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    207\u001b[39m \u001b[43m            \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mresponse_format\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43m_type_to_response_format\u001b[49m\u001b[43m(\u001b[49m\u001b[43mresponse_format\u001b[49m\u001b[43m)\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    208\u001b[39m \u001b[43m            \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43msafety_identifier\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43msafety_identifier\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    209\u001b[39m \u001b[43m            \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mseed\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mseed\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    210\u001b[39m \u001b[43m            \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mservice_tier\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mservice_tier\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    211\u001b[39m \u001b[43m            \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mstop\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mstop\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    212\u001b[39m \u001b[43m            \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mstore\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mstore\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    213\u001b[39m \u001b[43m            \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mstream\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;28;43;01mFalse\u001b[39;49;00m\u001b[43m,\u001b[49m\n\u001b[32m    214\u001b[39m \u001b[43m            \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mstream_options\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mstream_options\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    215\u001b[39m \u001b[43m            \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mtemperature\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mtemperature\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    216\u001b[39m \u001b[43m            \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mtool_choice\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mtool_choice\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    217\u001b[39m \u001b[43m            \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mtools\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mtools\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    218\u001b[39m \u001b[43m            \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mtop_logprobs\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mtop_logprobs\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    219\u001b[39m \u001b[43m            \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mtop_p\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mtop_p\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    220\u001b[39m \u001b[43m            \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43muser\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43muser\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    221\u001b[39m \u001b[43m            \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mverbosity\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mverbosity\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    222\u001b[39m \u001b[43m            \u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mweb_search_options\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mweb_search_options\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    223\u001b[39m \u001b[43m        \u001b[49m\u001b[43m}\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    224\u001b[39m \u001b[43m        \u001b[49m\u001b[43mcompletion_create_params\u001b[49m\u001b[43m.\u001b[49m\u001b[43mCompletionCreateParams\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    225\u001b[39m \u001b[43m    \u001b[49m\u001b[43m)\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    226\u001b[39m \u001b[43m    \u001b[49m\u001b[43moptions\u001b[49m\u001b[43m=\u001b[49m\u001b[43mmake_request_options\u001b[49m\u001b[43m(\u001b[49m\n\u001b[32m    227\u001b[39m \u001b[43m        \u001b[49m\u001b[43mextra_headers\u001b[49m\u001b[43m=\u001b[49m\u001b[43mextra_headers\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    228\u001b[39m \u001b[43m        \u001b[49m\u001b[43mextra_query\u001b[49m\u001b[43m=\u001b[49m\u001b[43mextra_query\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    229\u001b[39m \u001b[43m        \u001b[49m\u001b[43mextra_body\u001b[49m\u001b[43m=\u001b[49m\u001b[43mextra_body\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    230\u001b[39m \u001b[43m        \u001b[49m\u001b[43mtimeout\u001b[49m\u001b[43m=\u001b[49m\u001b[43mtimeout\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    231\u001b[39m \u001b[43m        \u001b[49m\u001b[43mpost_parser\u001b[49m\u001b[43m=\u001b[49m\u001b[43mparser\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    232\u001b[39m \u001b[43m    \u001b[49m\u001b[43m)\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    233\u001b[39m \u001b[43m    \u001b[49m\u001b[38;5;66;43;03m# we turn the `ChatCompletion` instance into a `ParsedChatCompletion`\u001b[39;49;00m\n\u001b[32m    234\u001b[39m \u001b[43m    \u001b[49m\u001b[38;5;66;43;03m# in the `parser` function above\u001b[39;49;00m\n\u001b[32m    235\u001b[39m \u001b[43m    \u001b[49m\u001b[43mcast_to\u001b[49m\u001b[43m=\u001b[49m\u001b[43mcast\u001b[49m\u001b[43m(\u001b[49m\u001b[43mType\u001b[49m\u001b[43m[\u001b[49m\u001b[43mParsedChatCompletion\u001b[49m\u001b[43m[\u001b[49m\u001b[43mResponseFormatT\u001b[49m\u001b[43m]\u001b[49m\u001b[43m]\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mChatCompletion\u001b[49m\u001b[43m)\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    236\u001b[39m \u001b[43m    \u001b[49m\u001b[43mstream\u001b[49m\u001b[43m=\u001b[49m\u001b[38;5;28;43;01mFalse\u001b[39;49;00m\u001b[43m,\u001b[49m\n\u001b[32m    237\u001b[39m \u001b[43m\u001b[49m\u001b[43m)\u001b[49m\n",
      "\u001b[36mFile \u001b[39m\u001b[32m~\\anaconda3\\envs\\llms\\Lib\\site-packages\\openai\\_base_client.py:1259\u001b[39m, in \u001b[36mSyncAPIClient.post\u001b[39m\u001b[34m(self, path, cast_to, body, options, files, stream, stream_cls)\u001b[39m\n\u001b[32m   1245\u001b[39m \u001b[38;5;28;01mdef\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[34mpost\u001b[39m(\n\u001b[32m   1246\u001b[39m     \u001b[38;5;28mself\u001b[39m,\n\u001b[32m   1247\u001b[39m     path: \u001b[38;5;28mstr\u001b[39m,\n\u001b[32m   (...)\u001b[39m\u001b[32m   1254\u001b[39m     stream_cls: \u001b[38;5;28mtype\u001b[39m[_StreamT] | \u001b[38;5;28;01mNone\u001b[39;00m = \u001b[38;5;28;01mNone\u001b[39;00m,\n\u001b[32m   1255\u001b[39m ) -> ResponseT | _StreamT:\n\u001b[32m   1256\u001b[39m     opts = FinalRequestOptions.construct(\n\u001b[32m   1257\u001b[39m         method=\u001b[33m\"\u001b[39m\u001b[33mpost\u001b[39m\u001b[33m\"\u001b[39m, url=path, json_data=body, files=to_httpx_files(files), **options\n\u001b[32m   1258\u001b[39m     )\n\u001b[32m-> \u001b[39m\u001b[32m1259\u001b[39m     \u001b[38;5;28;01mreturn\u001b[39;00m cast(ResponseT, \u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43mrequest\u001b[49m\u001b[43m(\u001b[49m\u001b[43mcast_to\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mopts\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mstream\u001b[49m\u001b[43m=\u001b[49m\u001b[43mstream\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mstream_cls\u001b[49m\u001b[43m=\u001b[49m\u001b[43mstream_cls\u001b[49m\u001b[43m)\u001b[49m)\n",
      "\u001b[36mFile \u001b[39m\u001b[32m~\\anaconda3\\envs\\llms\\Lib\\site-packages\\openai\\_base_client.py:1047\u001b[39m, in \u001b[36mSyncAPIClient.request\u001b[39m\u001b[34m(self, cast_to, options, stream, stream_cls)\u001b[39m\n\u001b[32m   1044\u001b[39m             err.response.read()\n\u001b[32m   1046\u001b[39m         log.debug(\u001b[33m\"\u001b[39m\u001b[33mRe-raising status error\u001b[39m\u001b[33m\"\u001b[39m)\n\u001b[32m-> \u001b[39m\u001b[32m1047\u001b[39m         \u001b[38;5;28;01mraise\u001b[39;00m \u001b[38;5;28mself\u001b[39m._make_status_error_from_response(err.response) \u001b[38;5;28;01mfrom\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[38;5;28;01mNone\u001b[39;00m\n\u001b[32m   1049\u001b[39m     \u001b[38;5;28;01mbreak\u001b[39;00m\n\u001b[32m   1051\u001b[39m \u001b[38;5;28;01massert\u001b[39;00m response \u001b[38;5;129;01mis\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m \u001b[38;5;28;01mNone\u001b[39;00m, \u001b[33m\"\u001b[39m\u001b[33mcould not resolve response (should never happen)\u001b[39m\u001b[33m\"\u001b[39m\n",
      "\u001b[31mBadRequestError\u001b[39m: Error code: 400 - {'status': 400, 'message': 'Empty schema with json format type is not supported'}"
     ]
    }
   ],
   "source": [
    "'''\n",
    "Gigachat --  Error code: 400 - {'status': 400, 'message': 'Empty schema with json format type is not supported'}\n",
    "works for qwen! \n",
    "'''\n",
    "from enum import Enum\n",
    "class CarType(str, Enum):\n",
    "    sedan = \"sedan\"\n",
    "    suv = \"SUV\"\n",
    "    truck = \"Truck\"\n",
    "    coupe = \"Coupe\"\n",
    "\n",
    "class CarDescription(BaseModel):\n",
    "    brand: str\n",
    "    model: str\n",
    "    car_type: CarType\n",
    "\n",
    "json_schema = CarDescription.model_json_schema()\n",
    "\n",
    "completion = client.chat.completions.parse(\n",
    "    model=os.getenv(\"MODEL_NAME\"),\n",
    "    messages=[\n",
    "        {\n",
    "            \"role\": \"user\",\n",
    "            \"content\": \"Generate a JSON with the brand, model and car_type of Mazda cars from the 90's  /no_think\"\n",
    "        }\n",
    "    ],\n",
    "    response_format=CarDescription,\n",
    "    temperature=0,\n",
    ")\n",
    "print(completion.choices[0].message.content)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 37,
   "id": "37646cf9-44d7-44f1-be8a-021ea4489b09",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'$defs': {'CarType': {'enum': ['sedan', 'SUV', 'Truck', 'Coupe'],\n",
       "   'title': 'CarType',\n",
       "   'type': 'string'}},\n",
       " 'properties': {'brand': {'title': 'Brand', 'type': 'string'},\n",
       "  'model': {'title': 'Model', 'type': 'string'},\n",
       "  'car_type': {'$ref': '#/$defs/CarType'}},\n",
       " 'required': ['brand', 'model', 'car_type'],\n",
       " 'title': 'CarDescription',\n",
       " 'type': 'object'}"
      ]
     },
     "execution_count": 37,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "json_schema"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 40,
   "id": "4beaba66-e561-4c2f-bb2a-0d41c7d760ad",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "### JSON data for Mazda cars from the 1990s\n",
      "\n",
      "```json\n",
      "[\n",
      "  {\n",
      "    \"brand\": \"Mazda\",\n",
      "    \"model\": \"626\",\n",
      "    \"car_type\": \"sedan\"\n",
      "  },\n",
      "  {\n",
      "    \"brand\": \"Mazda\",\n",
      "    \"model\": \"MX-5\",\n",
      "    \"car_type\": \"Coupe\"\n",
      "  },\n",
      "  {\n",
      "    \"brand\": \"Mazda\",\n",
      "    \"model\": \"Bongo\",\n",
      "    \"car_type\": \"Van\"\n",
      "  },\n",
      "  {\n",
      "    \"brand\": \"Mazda\",\n",
      "    \"model\": \"MPV\",\n",
      "    \"car_type\": \"Minivan\"\n",
      "  },\n",
      "  {\n",
      "    \"brand\": \"Mazda\",\n",
      "    \"model\": \"Navajo\",\n",
      "    \"car_type\": \"Pickup Truck\"\n",
      "  },\n",
      "  {\n",
      "    \"brand\": \"Mazda\",\n",
      "    \"model\": \"Protege\",\n",
      "    \"car_type\": \"Hatchback\"\n",
      "  },\n",
      "  {\n",
      "    \"brand\": \"Mazda\",\n",
      "    \"model\": \"Millenia\",\n",
      "    \"car_type\": \"Sedan\"\n",
      "  },\n",
      "  {\n",
      "    \"brand\": \"Mazda\",\n",
      "    \"model\": \"Tribute\",\n",
      "    \"car_type\": \"SUV\"\n",
      "  }\n",
      "]\n",
      "```\n",
      "\n",
      "### Explanation:\n",
      "- The `'$defs'` section defines the allowed values for the `car_type`.\n",
      "- Each entry in the array represents a different Mazda car from the 1990s.\n",
      "- The required fields (`brand`, `model`, and `car_type`) are specified as per the given JSON schema.\n",
      "- The `'$ref'` is used to reference the predefined `CarType` enum within the schema.\n"
     ]
    }
   ],
   "source": [
    "from enum import Enum\n",
    "class CarType(str, Enum):\n",
    "    sedan = \"sedan\"\n",
    "    suv = \"SUV\"\n",
    "    truck = \"Truck\"\n",
    "    coupe = \"Coupe\"\n",
    "\n",
    "class CarDescription(BaseModel):\n",
    "    brand: str\n",
    "    model: str\n",
    "    car_type: CarType\n",
    "\n",
    "json_schema = CarDescription.model_json_schema()\n",
    "\n",
    "completion = client.chat.completions.create(\n",
    "    model=os.getenv(\"MODEL_NAME\"),\n",
    "    messages=[\n",
    "        {\n",
    "            \"role\": \"user\",\n",
    "            \"content\": \"Generate a JSON with the brand, model and car_type of Mazda cars from the 90's\"+\\\n",
    "        f\" and follow the JSON format defined by the following JSON schema: {json_schema} /no_think\"\n",
    "        }\n",
    "    ],\n",
    "    #tools=[json_schema],\n",
    "    temperature=0,\n",
    ")\n",
    "print(completion.choices[0].message.content)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 39,
   "id": "58b1c4e5-c0a2-4bfa-846d-29e6ebff7c1f",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "### Example JSON structure for Mazda cars from the 1990s:\n",
      "\n",
      "```json\n",
      "[\n",
      "  {\n",
      "    \"brand\": \"Mazda\",\n",
      "    \"model\": \"MX-5 Miata\",\n",
      "    \"car_type\": \"Convertible\"\n",
      "  },\n",
      "  {\n",
      "    \"brand\": \"Mazda\",\n",
      "    \"model\": \"626\",\n",
      "    \"car_type\": \"Sedan/SUV\"\n",
      "  },\n",
      "  {\n",
      "    \"brand\": \"Mazda\",\n",
      "    \"model\": \"Capella\",\n",
      "    \"car_type\": \"Compact Car\"\n",
      "  },\n",
      "  {\n",
      "    \"brand\": \"Mazda\",\n",
      "    \"model\": \"Bongo Freestyle\",\n",
      "    \"car_type\": \"Minivan/MPV\"\n",
      "  },\n",
      "  {\n",
      "    \"brand\": \"Mazda\",\n",
      "    \"model\": \"Millenia\",\n",
      "    \"car_type\": \"Mid-size Luxury Sedan\"\n",
      "  },\n",
      "  {\n",
      "    \"brand\": \"Mazda\",\n",
      "    \"model\": \"Protégé\",\n",
      "    \"car_type\": \"Compact Car\"\n",
      "  }\n",
      "]\n",
      "```\n",
      "\n",
      "#### Explanation:\n",
      "- The `brand` field contains the manufacturer name (`Mazda`).\n",
      "- The `model` field specifies the individual car models that were popular in the 1990s.\n",
      "- The `car_type` indicates the type (sedan, convertible, minivan, etc.) to provide more context about each vehicle.\n",
      "\n",
      "You can modify or extend this list based on specific Mazda models you want to include from the 1990s.\n"
     ]
    }
   ],
   "source": [
    "'''\n",
    "qwen doesnt support \"structured_outputs\" in body\n",
    "'''\n",
    "class CarType(str, Enum):\n",
    "    sedan = \"sedan\"\n",
    "    suv = \"SUV\"\n",
    "    truck = \"Truck\"\n",
    "    coupe = \"Coupe\"\n",
    "\n",
    "class CarDescription(BaseModel):\n",
    "    brand: str\n",
    "    model: str\n",
    "    car_type: CarType\n",
    "\n",
    "json_schema = CarDescription.model_json_schema()\n",
    "\n",
    "completion = client.chat.completions.create(\n",
    "    model=os.getenv(\"MODEL_NAME\"),\n",
    "    messages=[\n",
    "        {\n",
    "            \"role\": \"user\",\n",
    "            \"content\": \"Generate a JSON with the brand, model and car_type of Mazda cars from the 90's\"\n",
    "        }\n",
    "    ],\n",
    "    extra_body={\"structured_outputs\": {\"json\": json_schema}}\n",
    ")\n",
    "print(completion.choices[0].message.content)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 42,
   "id": "5367e36b-e29f-4c02-a6b7-33a012c5b182",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "### JSON format for Mazda Cars from the 1990s\n",
      "\n",
      "```json\n",
      "[\n",
      "  {\n",
      "    \"brand\": \"Mazda\",\n",
      "    \"model\": \"MX-5 (Miata)\",\n",
      "    \"car_type\": \"Convertible sports car\"\n",
      "  },\n",
      "  {\n",
      "    \"brand\": \"Mazda\",\n",
      "    \"model\": \"Protégé\",\n",
      "    \"car_type\": \"Compact sedan/coupe\"\n",
      "  },\n",
      "  {\n",
      "    \"brand\": \"Mazda\",\n",
      "    \"model\": \"B-series pickup truck\",\n",
      "    \"car_type\": \"Pickup truck\"\n",
      "  },\n",
      "  {\n",
      "    \"brand\": \"Mazda\",\n",
      "    \"model\": \"Millenia\",\n",
      "    \"car_type\": \"Full-size luxury sedan\"\n",
      "  },\n",
      "  {\n",
      "    \"brand\": \"Mazda\",\n",
      "    \"model\": \"MPV\",\n",
      "    \"car_type\": \"Minivan\"\n",
      "  },\n",
      "  {\n",
      "    \"brand\": \"Mazda\",\n",
      "    \"model\": \"Navajo\",\n",
      "    \"car_type\": \"Sport utility vehicle (SUV)\"\n",
      "  }\n",
      "]\n",
      "```\n",
      "\n",
      "This JSON contains information about popular Mazda models from the 1990s, including their brand, model name, and car type.\n"
     ]
    }
   ],
   "source": [
    "'''\n",
    "qwen doesnt support \"structured_outputs\" in body\n",
    "'''\n",
    "class CarType(str, Enum):\n",
    "    sedan = \"sedan\"\n",
    "    suv = \"SUV\"\n",
    "    truck = \"Truck\"\n",
    "    coupe = \"Coupe\"\n",
    "\n",
    "class CarDescription(BaseModel):\n",
    "    brand: str\n",
    "    model: str\n",
    "    car_type: CarType\n",
    "\n",
    "json_schema = CarDescription.model_json_schema()\n",
    "\n",
    "completion = client.chat.completions.create(\n",
    "    model=os.getenv(\"MODEL_NAME\"),\n",
    "    messages=[\n",
    "        {\n",
    "            \"role\": \"user\",\n",
    "            \"content\": \"Generate a JSON with the brand, model and car_type of Mazda cars from the 90's\"\n",
    "        }\n",
    "    ],\n",
    "    tools = [json_schema]\n",
    ")\n",
    "print(completion.choices[0].message.content)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "5301994a-a15c-47ce-b6b8-ce0ceae9e67b",
   "metadata": {
    "tags": []
   },
   "source": [
    "## 1. clinical trials"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "7eb1ed4e-88ad-454d-a841-868d8d03925b",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "('Colorectal cancer',\n",
       " ['Crizotinib',\n",
       "  'Lorlatinib',\n",
       "  'Necitumumab',\n",
       "  'Nimotuzumab',\n",
       "  'Panitumumab',\n",
       "  'Cetuximab',\n",
       "  'Brigatinib',\n",
       "  'Ramucirumab',\n",
       "  'Pomalidomide',\n",
       "  'Tamoxifen',\n",
       "  'Denosumab',\n",
       "  'Duvelisib',\n",
       "  'Inavilisib',\n",
       "  'Bevacizumab',\n",
       "  'Anastrozole',\n",
       "  'Exemestane'])"
      ]
     },
     "execution_count": 4,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "file_path = \"docs/CC_215_L00_DL_fusion_fixed_oncobox_ru.pdf\"\n",
    "fin_condition, treatements_eng = extract.info_from_doc(file_path)\n",
    "fin_condition, treatements_eng"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "b2be323d-2d66-4dd7-beec-1828340f37b8",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "markdown",
   "id": "e3c68437-54be-4611-9aa0-d7f6a379a924",
   "metadata": {},
   "source": [
    "1. загрузить док\n",
    "2. взять 1-ую страницу; рег.выражениями взять диагноз\n",
    "-- с ЛЛМ перевести на англ.\n",
    "3. найти страницу с таблицей; или взять таблицы с PyMuPDFLoader\n",
    "4. извлечь таблицу"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "0b55cf5c-e883-4a42-ad8f-08633873be8f",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>hasResults</th>\n",
       "      <th>nctId</th>\n",
       "      <th>briefTitle</th>\n",
       "      <th>overallStatus</th>\n",
       "      <th>briefSummary</th>\n",
       "      <th>conditions</th>\n",
       "      <th>studyType</th>\n",
       "      <th>phases</th>\n",
       "      <th>interventions</th>\n",
       "      <th>outcomeMeasures</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>True</td>\n",
       "      <td>NCT02510001</td>\n",
       "      <td>MEK and MET Inhibition in Colorectal Cancer</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>This trial is designed to try two new cancer d...</td>\n",
       "      <td>[Solid Tumor, Colorectal Cancer]</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>[PHASE1]</td>\n",
       "      <td>[pf-02341066, pd-0325901, binimetinib]</td>\n",
       "      <td>[{'type': 'PRIMARY', 'title': 'Maximal Tolerat...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>False</td>\n",
       "      <td>NCT03792568</td>\n",
       "      <td>ALK Inhibitor in Metastatic Colorectal Cancer ...</td>\n",
       "      <td>UNKNOWN</td>\n",
       "      <td>This clinical trial aims to evaluate the effic...</td>\n",
       "      <td>[Colorectal Cancer]</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>[NA]</td>\n",
       "      <td>[]</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>False</td>\n",
       "      <td>NCT02465060</td>\n",
       "      <td>Targeted Therapy Directed by Genetic Testing i...</td>\n",
       "      <td>ACTIVE_NOT_RECRUITING</td>\n",
       "      <td>This phase II MATCH screening and multi-sub-tr...</td>\n",
       "      <td>[Advanced Lymphoma, Advanced Malignant Solid N...</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>[PHASE2]</td>\n",
       "      <td>[adavosertib, afatinib, afatinib dimaleate, bi...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>False</td>\n",
       "      <td>NCT03947385</td>\n",
       "      <td>Study of IDE196 in Patients With Solid Tumors ...</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>This is a Phase 1/2, multi-center, open-label ...</td>\n",
       "      <td>[Metastatic Uveal Melanoma, Cutaneous Melanoma...</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>[PHASE1, PHASE2]</td>\n",
       "      <td>[ide196, binimetinib, crizotinib]</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>False</td>\n",
       "      <td>NCT06214793</td>\n",
       "      <td>Taletrectinib in Previously Treated Metastatic...</td>\n",
       "      <td>SUSPENDED</td>\n",
       "      <td>The purpose of this study is to evaluate the s...</td>\n",
       "      <td>[Breast Cancer, Metastatic Breast Cancer]</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>[PHASE2]</td>\n",
       "      <td>[taletrectinib]</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>False</td>\n",
       "      <td>NCT02568267</td>\n",
       "      <td>Basket Study of Entrectinib (RXDX-101) for the...</td>\n",
       "      <td>ACTIVE_NOT_RECRUITING</td>\n",
       "      <td>This is an open-label, multicenter, global Pha...</td>\n",
       "      <td>[Breast Cancer, Cholangiocarcinoma, Colorectal...</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>[PHASE2]</td>\n",
       "      <td>[entrectinib]</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>False</td>\n",
       "      <td>NCT05725200</td>\n",
       "      <td>Study to Investigate Outcome of Individualized...</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>The purpose of the study is to investigate the...</td>\n",
       "      <td>[Metastatic Colorectal Cancer]</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>[PHASE2]</td>\n",
       "      <td>[alectinib, cetuximab, crizotinib, dasatinib, ...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   hasResults        nctId                                         briefTitle  \\\n",
       "0        True  NCT02510001        MEK and MET Inhibition in Colorectal Cancer   \n",
       "1       False  NCT03792568  ALK Inhibitor in Metastatic Colorectal Cancer ...   \n",
       "2       False  NCT02465060  Targeted Therapy Directed by Genetic Testing i...   \n",
       "3       False  NCT03947385  Study of IDE196 in Patients With Solid Tumors ...   \n",
       "4       False  NCT06214793  Taletrectinib in Previously Treated Metastatic...   \n",
       "5       False  NCT02568267  Basket Study of Entrectinib (RXDX-101) for the...   \n",
       "6       False  NCT05725200  Study to Investigate Outcome of Individualized...   \n",
       "\n",
       "           overallStatus                                       briefSummary  \\\n",
       "0              COMPLETED  This trial is designed to try two new cancer d...   \n",
       "1                UNKNOWN  This clinical trial aims to evaluate the effic...   \n",
       "2  ACTIVE_NOT_RECRUITING  This phase II MATCH screening and multi-sub-tr...   \n",
       "3             RECRUITING  This is a Phase 1/2, multi-center, open-label ...   \n",
       "4              SUSPENDED  The purpose of this study is to evaluate the s...   \n",
       "5  ACTIVE_NOT_RECRUITING  This is an open-label, multicenter, global Pha...   \n",
       "6             RECRUITING  The purpose of the study is to investigate the...   \n",
       "\n",
       "                                          conditions       studyType  \\\n",
       "0                   [Solid Tumor, Colorectal Cancer]  INTERVENTIONAL   \n",
       "1                                [Colorectal Cancer]  INTERVENTIONAL   \n",
       "2  [Advanced Lymphoma, Advanced Malignant Solid N...  INTERVENTIONAL   \n",
       "3  [Metastatic Uveal Melanoma, Cutaneous Melanoma...  INTERVENTIONAL   \n",
       "4          [Breast Cancer, Metastatic Breast Cancer]  INTERVENTIONAL   \n",
       "5  [Breast Cancer, Cholangiocarcinoma, Colorectal...  INTERVENTIONAL   \n",
       "6                     [Metastatic Colorectal Cancer]  INTERVENTIONAL   \n",
       "\n",
       "             phases                                      interventions  \\\n",
       "0          [PHASE1]             [pf-02341066, pd-0325901, binimetinib]   \n",
       "1              [NA]                                                 []   \n",
       "2          [PHASE2]  [adavosertib, afatinib, afatinib dimaleate, bi...   \n",
       "3  [PHASE1, PHASE2]                  [ide196, binimetinib, crizotinib]   \n",
       "4          [PHASE2]                                    [taletrectinib]   \n",
       "5          [PHASE2]                                      [entrectinib]   \n",
       "6          [PHASE2]  [alectinib, cetuximab, crizotinib, dasatinib, ...   \n",
       "\n",
       "                                     outcomeMeasures  \n",
       "0  [{'type': 'PRIMARY', 'title': 'Maximal Tolerat...  \n",
       "1                                                NaN  \n",
       "2                                                NaN  \n",
       "3                                                NaN  \n",
       "4                                                NaN  \n",
       "5                                                NaN  \n",
       "6                                                NaN  "
      ]
     },
     "execution_count": 5,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "all_studies = extract.get_clinicaltrials(f'''\"{fin_condition}\"''', \n",
    "                                      #' OR '.join(treatements_eng), \n",
    "                                       treatements_eng[0],  \n",
    "                                      max_studies=10)\n",
    "all_studies"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "8216cd98-24dc-4eb9-896f-16d7662879d3",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "call_openai https://gigachat.devices.sberbank.ru/api/v1\n",
      "api_call_single https://gigachat.devices.sberbank.ru/api/v1/\n",
      "```json\n",
      "{\n",
      "    \"ELIGIBILITY_ANALYSIS\": [\n",
      "        \"Patients must have colorectal cancer confirmed by histopathology or imaging studies\",\n",
      "        \"Treatment with Crizotinib as part of standard therapy or experimental protocol\",\n",
      "        \"Comparative intervention against placebo or other treatments\",\n",
      "        \"Clearly reported outcomes related to efficacy or safety endpoints\",\n",
      "        \"Published in peer-reviewed journals\"\n",
      "    ],\n",
      "    \"TITLE_CRITERIA\": [\n",
      "        \"Does the title mention 'colorectal cancer'?\",\n",
      "        \"Does the title mention 'Crizotinib'?\"\n",
      "    ],\n",
      "    \"CONTENT_CRITERIA\": [\n",
      "        \"Is there a description of patient population matching the inclusion criteria?\",\n",
      "        \"Are the outcomes specified in the abstract relevant to the study objectives?\"\n",
      "    ]\n",
      "}\n",
      "```\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "{'title_criteria': [\"Does the title mention 'colorectal cancer'?\",\n",
       "  \"Does the title mention 'Crizotinib'?\"],\n",
       " 'content_criteria': ['Is there a description of patient population matching the inclusion criteria?',\n",
       "  'Are the outcomes specified in the abstract relevant to the study objectives?'],\n",
       " 'eligibility_analysis': ['Patients must have colorectal cancer confirmed by histopathology or imaging studies',\n",
       "  'Treatment with Crizotinib as part of standard therapy or experimental protocol',\n",
       "  'Comparative intervention against placebo or other treatments',\n",
       "  'Clearly reported outcomes related to efficacy or safety endpoints',\n",
       "  'Published in peer-reviewed journals']}"
      ]
     },
     "execution_count": 6,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# test the apis\n",
    "\n",
    "api = ScreeningCriteriaCTGeneration()\n",
    "ecs = api.run(\n",
    "    population = f\"Patients with {fin_condition} undergoing treatment with {treatements_eng[0]}\",\n",
    "    intervention = f\"{treatements_eng[0]}\",\n",
    "    comparator = \"\",\n",
    "    outcome = \"\",\n",
    "    llm = os.getenv(\"MODEL_NAME\"),\n",
    "    num_title_criteria=2,\n",
    "    num_abstract_criteria=2,\n",
    "    thinking=False,\n",
    ")\n",
    "ecs"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "e33c1fe2-f484-4c6a-80c0-396413ad3bb1",
   "metadata": {
    "jp-MarkdownHeadingCollapsed": true,
    "tags": []
   },
   "source": [
    "### __check"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "d352bb46-d626-4b92-a6ea-ec0a7a964422",
   "metadata": {
    "tags": []
   },
   "outputs": [],
   "source": [
    "from trialmind.api import parse_json_outputs"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "id": "0f4abfe0-939d-4687-a181-4ea02aa36d73",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[{}]"
      ]
     },
     "execution_count": 29,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "parse_json_outputs(['''```json\n",
    "{\n",
    "    \"ELIGIBILITY_ANALYSIS\": [\n",
    "        \"Patients must have colorectal cancer confirmed by histopathology or imaging studies\",\n",
    "        \"Treatment with crizotinib as part of standard therapy or experimental protocol\",\n",
    "        \"Comparative intervention against placebo or other treatments\",\n",
    "        \"Clearly reported outcomes related to efficacy or safety endpoints\",\n",
    "        \"Published in peer-reviewed journals\"\n",
    "    ],\n",
    "    \"TITLE_CRITERIA\": [\n",
    "        \"Does the title mention 'colorectal cancer'?\",\n",
    "        \"Does the title mention 'crizotinib'?\"\n",
    "    ],\n",
    "    \"CONTENT_CRITERIA\": [\n",
    "        \"Is there a description of patient population including diagnosis and stage of disease?\",\n",
    "        \"Are details provided about the intervention and comparison groups?\"\n",
    "]\n",
    "} ```\n",
    "'''])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "id": "4172c789-e604-42b5-82f0-106c320ba8a6",
   "metadata": {
    "tags": []
   },
   "outputs": [],
   "source": [
    "json_pattern = r\"\\`\\`\\`json([\\s\\S]*?)\\`\\`\\`\"\n",
    "if re.search(r\"\\`\\`\\`json([\\s\\S]*?)\", '''```json\n",
    "{{\n",
    "    \"ELIGIBILITY_ANALYSIS\": [\n",
    "        \"Patients must have colorectal cancer confirmed by histopathology or imaging studies\",\n",
    "        \"Treatment with crizotinib as part of standard therapy or experimental protocol\",\n",
    "        \"Comparative intervention against placebo or other treatments\",\n",
    "        \"Clearly reported outcomes related to efficacy or safety endpoints\",\n",
    "        \"Published in peer-reviewed journals\"\n",
    "    ],\n",
    "    \"TITLE_CRITERIA\": [\n",
    "        \"Does the title mention 'colorectal cancer'?\",\n",
    "        \"Does the title mention 'crizotinib'?\"\n",
    "    ],\n",
    "    \"CONTENT_CRITERIA\": [\n",
    "        \"Is there a description of patient population including diagnosis and stage of disease?\",\n",
    "        \"Are details provided about the intervention and comparison groups?\"\n",
    "]'''):\n",
    "    print(1)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 128,
   "id": "024db3d5-8f06-4f52-8fd3-666303a1e30e",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'$defs': {'ScreeningResult': {'enum': [\"annotation=NoneType required=True description='Evaluation for a criteria'\",\n",
       "    \"annotation=NoneType required=True description='A rationale for a criteria evaluation'\"],\n",
       "   'title': 'ScreeningResult',\n",
       "   'type': 'string'}},\n",
       " 'properties': {'one_result': {'$ref': '#/$defs/ScreeningResult'}},\n",
       " 'required': ['one_result'],\n",
       " 'title': 'ScreeningResults',\n",
       " 'type': 'object'}"
      ]
     },
     "execution_count": 128,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "from typing import Literal\n",
    "class ScreeningResult(str, Enum):\n",
    "    evaluations: Literal['YES', 'NO', 'UNCERTAIN'] = Field(description=f\"Evaluation for a criteria\")\n",
    "    rationale: str = Field(description=\"A rationale for a criteria evaluation\")\n",
    "\n",
    "class ScreeningResults(BaseModel):\n",
    "    one_result: ScreeningResult\n",
    "\n",
    "json_schema = ScreeningResults.model_json_schema()\n",
    "json_schema"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "95d99dc1-7182-49b3-9204-45fbb3ac6f17",
   "metadata": {},
   "source": [
    "### 2. CT screen"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "7e3f42bf-60e8-403b-a791-b99131a5d2ca",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[\"MEK and MET Inhibition in Colorectal Cancer: This trial is designed to try two new cancer drugs together for the first time. The investigators think that they might be effective in some types of bowel cancer. The first part of the trial will see what doses of the two drugs can safely be given together. Once the investigators have identified a suitable dose combination they will look at how effective treatment is in bowel cancers where either the RAS gene is mutated, or MET is over-active. In the trial the investigators will look at samples of blood, skin and tumour to check the drugs are working in the way expected. The trial will take place in three sites in the UK and 5 sites in Europe. The trial is funded as part of the European commission's FP7 program.\"]"
      ]
     },
     "execution_count": 7,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "all_text = all_studies.briefTitle.fillna(\"\") + \": \" + all_studies.briefSummary.fillna(\"\")\n",
    "all_text.values.tolist()[:1]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "6ff25002-4ddb-4ace-ab4f-fe5534509b87",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "# CONTEXT #\n",
      "You are a clinical specialist tasked with assessing clinical trials for inclusion in a meta-analysis based on specific eligibility criteria.\n",
      "\n",
      "# OBJECTIVE #\n",
      "Evaluate each criterion of a given clinical trial to determine its eligibility for inclusion in the meta-analysis. Provide a list of decisions (\"YES\", \"NO\", or \"UNCERTAIN\") for each eligibility criterion. You must deliver exactly {num_criteria} responses.\n",
      "\n",
      "# IMPORTANT NOTE #\n",
      "If the information within the provided clinical trial content is insufficient to conclusively evaluate a criterion, you must opt for \"UNCERTAIN\" as your response. Avoid making assumptions or extrapolating beyond the provided data, as accurate and reliable responses are crucial, and fabricating information (hallucinations) could lead to serious errors in the meta-analysis.\n",
      "\n",
      "# PICO FRAMEWORK #\n",
      "- P (Patient, Problem or Population): {P}\n",
      "- I (Intervention): {I}\n",
      "- C (Comparison): {C}\n",
      "- O (Outcome): {O}\n",
      "\n",
      "# PAPER DETAILS #\n",
      "- Provided clinical trial: {paper_content}\n",
      "\n",
      "# EVALUATION CRITERIA #\n",
      "- Number of Criteria: {num_criteria}\n",
      "- Criteria for Inclusion: {criteria_text}\n",
      "\n",
      "# RESPONSE FORMAT #\n",
      "Return the information in the following JSON-format.\n",
      "\n",
      "```json\n",
      "{{\n",
      "    \"evaluations\": [\"YES\", \"NO\", \"UNCERTAIN\", ...],\n",
      "    \"rationale\": [\"rationale1\",\"rationale2\",\"rationale3\",...]\n",
      "}}\n",
      "```\n",
      "\n",
      "You MUST return ONLY valid JSON, Do NOT include any explanations, comments, or extra text.\n",
      "\n",
      "1\n",
      "\n",
      "parsed_results in asynch ['```json\\n{\\n    \"evaluations\": [\"YES\", \"YES\", \"YES\", \"UNCERTAIN\"],\\n    \"rationale\": [\\n        \"The title mentions \\'Colorectal cancer\\'\",\\n        \"The title mentions \\'Crizotinib\\'\",\\n        \"There is a description mentioning patients with colorectal cancer\",\\n        \"The outcomes mentioned in the abstract do not explicitly state relevance to Crizotinib use\"\\n    ]\\n}']\n",
      "\n",
      "parsed_results in asynch ['```json\\n{\\n    \"evaluations\": [\"YES\", \"YES\", \"YES\", \"YES\"],\\n    \"rationale\": [\\n        \"Title mentions \\'Colorectal cancer\\'\",\\n        \"Title mentions \\'Crizotinib\\'\",\\n        \"Patient population described as having colorectal cancer with ALK mutation\",\\n        \"Abstract specifies outcomes related to efficacy and safety\"\\n    ]\\n}']\n",
      "\n",
      "parsed_results in asynch ['```json\\n{\\n    \"evaluations\": [\"NO\", \"NO\", \"UNCERTAIN\", \"UNCERTAIN\"],\\n    \"rationale\": [\\n        \"Title does not mention colorectal cancer\",\\n        \"Title does not mention Crizotinib\",\\n        \"Patient population described but not specifically colorectal cancer\",\\n        \"Outcomes unspecified in provided abstract\"\\n    ]\\n}']\n",
      "\n",
      "parsed_results in asynch ['```json\\n{\\n    \"evaluations\": [\"YES\", \"YES\", \"YES\", \"UNCERTAIN\"],\\n    \"rationale\": [\\n        \"Title mentions \\'Colorectal cancer\\'\",\\n        \"Title mentions \\'Crizotinib\\'\",\\n        \"There is a description of patient population matching the inclusion criteria\",\\n        \"Outcomes not explicitly mentioned in the abstract\"\\n    ]\\n}']\n",
      "\n",
      "parsed_results in asynch ['```json\\n{\\n    \"evaluations\": [\"NO\", \"NO\", \"UNCERTAIN\", \"UNCERTAIN\"],\\n    \"rationale\": [\"Title does not mention colorectal cancer\", \"Title does not mention Crizotinib\", \"Patient population details are absent from provided content\", \"Outcomes unspecified in provided abstract\"]\\n}\\n```']\n",
      "\n",
      "parsed_results in asynch ['```json\\n{\\n    \"evaluations\": [\"NO\", \"NO\", \"UNCERTAIN\", \"UNCERTAIN\"],\\n    \"rationale\": [\"Title does not mention colorectal cancer\", \"Title does not mention Crizotinib\", \"Insufficient information about patient population\", \"Insufficient information about outcomes\"]\\n}']\n",
      "\n",
      "parsed_results in asynch ['```json\\n{\\n    \"evaluations\": [\"YES\", \"YES\", \"YES\", \"YES\"],\\n    \"rationale\": [\\n        \"The title mentions \\'Colorectal cancer\\'\",\\n        \"The title mentions \\'Crizotinib\\'\",\\n        \"The patient population includes patients with metastatic colorectal cancer\",\\n        \"The study aims to investigate the effect and side effects of personalized cancer treatment\"\\n    ]\\n}']\n",
      "\n",
      "OUTPUTS after json extr:  [{'evaluations': ['YES', 'YES', 'YES', 'UNCERTAIN'], 'rationale': [\"The title mentions 'Colorectal cancer'\", \"The title mentions 'Crizotinib'\", 'There is a description mentioning patients with colorectal cancer', 'The outcomes mentioned in the abstract do not explicitly state relevance to Crizotinib use']}, {'evaluations': ['YES', 'YES', 'YES', 'YES'], 'rationale': [\"Title mentions 'Colorectal cancer'\", \"Title mentions 'Crizotinib'\", 'Patient population described as having colorectal cancer with ALK mutation', 'Abstract specifies outcomes related to efficacy and safety']}, {'evaluations': ['NO', 'NO', 'UNCERTAIN', 'UNCERTAIN'], 'rationale': ['Title does not mention colorectal cancer', 'Title does not mention Crizotinib', 'Patient population described but not specifically colorectal cancer', 'Outcomes unspecified in provided abstract']}, {'evaluations': ['YES', 'YES', 'YES', 'UNCERTAIN'], 'rationale': [\"Title mentions 'Colorectal cancer'\", \"Title mentions 'Crizotinib'\", 'There is a description of patient population matching the inclusion criteria', 'Outcomes not explicitly mentioned in the abstract']}, {'evaluations': ['NO', 'NO', 'UNCERTAIN', 'UNCERTAIN'], 'rationale': ['Title does not mention colorectal cancer', 'Title does not mention Crizotinib', 'Patient population details are absent from provided content', 'Outcomes unspecified in provided abstract']}, {'evaluations': ['NO', 'NO', 'UNCERTAIN', 'UNCERTAIN'], 'rationale': ['Title does not mention colorectal cancer', 'Title does not mention Crizotinib', 'Insufficient information about patient population', 'Insufficient information about outcomes']}, {'evaluations': ['YES', 'YES', 'YES', 'YES'], 'rationale': [\"The title mentions 'Colorectal cancer'\", \"The title mentions 'Crizotinib'\", 'The patient population includes patients with metastatic colorectal cancer', 'The study aims to investigate the effect and side effects of personalized cancer treatment']}]\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "[{'evaluations': ['YES', 'YES', 'YES', 'UNCERTAIN'],\n",
       "  'rationale': [\"The title mentions 'Colorectal cancer'\",\n",
       "   \"The title mentions 'Crizotinib'\",\n",
       "   'There is a description mentioning patients with colorectal cancer',\n",
       "   'The outcomes mentioned in the abstract do not explicitly state relevance to Crizotinib use']},\n",
       " {'evaluations': ['YES', 'YES', 'YES', 'YES'],\n",
       "  'rationale': [\"Title mentions 'Colorectal cancer'\",\n",
       "   \"Title mentions 'Crizotinib'\",\n",
       "   'Patient population described as having colorectal cancer with ALK mutation',\n",
       "   'Abstract specifies outcomes related to efficacy and safety']},\n",
       " {'evaluations': ['NO', 'NO', 'UNCERTAIN', 'UNCERTAIN'],\n",
       "  'rationale': ['Title does not mention colorectal cancer',\n",
       "   'Title does not mention Crizotinib',\n",
       "   'Patient population described but not specifically colorectal cancer',\n",
       "   'Outcomes unspecified in provided abstract']},\n",
       " {'evaluations': ['YES', 'YES', 'YES', 'UNCERTAIN'],\n",
       "  'rationale': [\"Title mentions 'Colorectal cancer'\",\n",
       "   \"Title mentions 'Crizotinib'\",\n",
       "   'There is a description of patient population matching the inclusion criteria',\n",
       "   'Outcomes not explicitly mentioned in the abstract']},\n",
       " {'evaluations': ['NO', 'NO', 'UNCERTAIN', 'UNCERTAIN'],\n",
       "  'rationale': ['Title does not mention colorectal cancer',\n",
       "   'Title does not mention Crizotinib',\n",
       "   'Patient population details are absent from provided content',\n",
       "   'Outcomes unspecified in provided abstract']},\n",
       " {'evaluations': ['NO', 'NO', 'UNCERTAIN', 'UNCERTAIN'],\n",
       "  'rationale': ['Title does not mention colorectal cancer',\n",
       "   'Title does not mention Crizotinib',\n",
       "   'Insufficient information about patient population',\n",
       "   'Insufficient information about outcomes']},\n",
       " {'evaluations': ['YES', 'YES', 'YES', 'YES'],\n",
       "  'rationale': [\"The title mentions 'Colorectal cancer'\",\n",
       "   \"The title mentions 'Crizotinib'\",\n",
       "   'The patient population includes patients with metastatic colorectal cancer',\n",
       "   'The study aims to investigate the effect and side effects of personalized cancer treatment']}]"
      ]
     },
     "execution_count": 8,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "\n",
    "api = CTScreening()\n",
    "ec_pred = api.run(\n",
    "    population = f\"Patients with {fin_condition} undergoing treatment with {treatements_eng[0]}\",\n",
    "    intervention = f\"{treatements_eng[0]}\",\n",
    "    comparator = \"\",\n",
    "    outcome = \"\",\n",
    "    llm = os.getenv(\"MODEL_NAME\"),\n",
    "    criteria = ecs['title_criteria'] + ecs['content_criteria'],\n",
    "    papers = all_text.values.tolist(), # make for the top-100 for demo\n",
    ")\n",
    "ec_pred"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "id": "c0c04eee-151d-43c2-a50f-dc106bada7ae",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[[ 1  1  1  0]\n",
      " [ 1  1  1  1]\n",
      " [-1 -1  0  0]\n",
      " [ 1  1  1  0]\n",
      " [-1 -1  0  0]\n",
      " [-1 -1  0  0]\n",
      " [ 1  1  1  1]]\n",
      "[ 3  4 -2  3 -2 -2  4]\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>hasResults</th>\n",
       "      <th>nctId</th>\n",
       "      <th>briefTitle</th>\n",
       "      <th>overallStatus</th>\n",
       "      <th>briefSummary</th>\n",
       "      <th>conditions</th>\n",
       "      <th>studyType</th>\n",
       "      <th>phases</th>\n",
       "      <th>interventions</th>\n",
       "      <th>outcomeMeasures</th>\n",
       "      <th>screen_eval</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>True</td>\n",
       "      <td>NCT02510001</td>\n",
       "      <td>MEK and MET Inhibition in Colorectal Cancer</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>This trial is designed to try two new cancer d...</td>\n",
       "      <td>[Solid Tumor, Colorectal Cancer]</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>[PHASE1]</td>\n",
       "      <td>[pf-02341066, pd-0325901, binimetinib]</td>\n",
       "      <td>[{'type': 'PRIMARY', 'title': 'Maximal Tolerat...</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>False</td>\n",
       "      <td>NCT03792568</td>\n",
       "      <td>ALK Inhibitor in Metastatic Colorectal Cancer ...</td>\n",
       "      <td>UNKNOWN</td>\n",
       "      <td>This clinical trial aims to evaluate the effic...</td>\n",
       "      <td>[Colorectal Cancer]</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>[NA]</td>\n",
       "      <td>[]</td>\n",
       "      <td>NaN</td>\n",
       "      <td>4</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>False</td>\n",
       "      <td>NCT02465060</td>\n",
       "      <td>Targeted Therapy Directed by Genetic Testing i...</td>\n",
       "      <td>ACTIVE_NOT_RECRUITING</td>\n",
       "      <td>This phase II MATCH screening and multi-sub-tr...</td>\n",
       "      <td>[Advanced Lymphoma, Advanced Malignant Solid N...</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>[PHASE2]</td>\n",
       "      <td>[adavosertib, afatinib, afatinib dimaleate, bi...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>-2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>False</td>\n",
       "      <td>NCT03947385</td>\n",
       "      <td>Study of IDE196 in Patients With Solid Tumors ...</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>This is a Phase 1/2, multi-center, open-label ...</td>\n",
       "      <td>[Metastatic Uveal Melanoma, Cutaneous Melanoma...</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>[PHASE1, PHASE2]</td>\n",
       "      <td>[ide196, binimetinib, crizotinib]</td>\n",
       "      <td>NaN</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>False</td>\n",
       "      <td>NCT06214793</td>\n",
       "      <td>Taletrectinib in Previously Treated Metastatic...</td>\n",
       "      <td>SUSPENDED</td>\n",
       "      <td>The purpose of this study is to evaluate the s...</td>\n",
       "      <td>[Breast Cancer, Metastatic Breast Cancer]</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>[PHASE2]</td>\n",
       "      <td>[taletrectinib]</td>\n",
       "      <td>NaN</td>\n",
       "      <td>-2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>False</td>\n",
       "      <td>NCT02568267</td>\n",
       "      <td>Basket Study of Entrectinib (RXDX-101) for the...</td>\n",
       "      <td>ACTIVE_NOT_RECRUITING</td>\n",
       "      <td>This is an open-label, multicenter, global Pha...</td>\n",
       "      <td>[Breast Cancer, Cholangiocarcinoma, Colorectal...</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>[PHASE2]</td>\n",
       "      <td>[entrectinib]</td>\n",
       "      <td>NaN</td>\n",
       "      <td>-2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>False</td>\n",
       "      <td>NCT05725200</td>\n",
       "      <td>Study to Investigate Outcome of Individualized...</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>The purpose of the study is to investigate the...</td>\n",
       "      <td>[Metastatic Colorectal Cancer]</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>[PHASE2]</td>\n",
       "      <td>[alectinib, cetuximab, crizotinib, dasatinib, ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>4</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   hasResults        nctId                                         briefTitle  \\\n",
       "0        True  NCT02510001        MEK and MET Inhibition in Colorectal Cancer   \n",
       "1       False  NCT03792568  ALK Inhibitor in Metastatic Colorectal Cancer ...   \n",
       "2       False  NCT02465060  Targeted Therapy Directed by Genetic Testing i...   \n",
       "3       False  NCT03947385  Study of IDE196 in Patients With Solid Tumors ...   \n",
       "4       False  NCT06214793  Taletrectinib in Previously Treated Metastatic...   \n",
       "5       False  NCT02568267  Basket Study of Entrectinib (RXDX-101) for the...   \n",
       "6       False  NCT05725200  Study to Investigate Outcome of Individualized...   \n",
       "\n",
       "           overallStatus                                       briefSummary  \\\n",
       "0              COMPLETED  This trial is designed to try two new cancer d...   \n",
       "1                UNKNOWN  This clinical trial aims to evaluate the effic...   \n",
       "2  ACTIVE_NOT_RECRUITING  This phase II MATCH screening and multi-sub-tr...   \n",
       "3             RECRUITING  This is a Phase 1/2, multi-center, open-label ...   \n",
       "4              SUSPENDED  The purpose of this study is to evaluate the s...   \n",
       "5  ACTIVE_NOT_RECRUITING  This is an open-label, multicenter, global Pha...   \n",
       "6             RECRUITING  The purpose of the study is to investigate the...   \n",
       "\n",
       "                                          conditions       studyType  \\\n",
       "0                   [Solid Tumor, Colorectal Cancer]  INTERVENTIONAL   \n",
       "1                                [Colorectal Cancer]  INTERVENTIONAL   \n",
       "2  [Advanced Lymphoma, Advanced Malignant Solid N...  INTERVENTIONAL   \n",
       "3  [Metastatic Uveal Melanoma, Cutaneous Melanoma...  INTERVENTIONAL   \n",
       "4          [Breast Cancer, Metastatic Breast Cancer]  INTERVENTIONAL   \n",
       "5  [Breast Cancer, Cholangiocarcinoma, Colorectal...  INTERVENTIONAL   \n",
       "6                     [Metastatic Colorectal Cancer]  INTERVENTIONAL   \n",
       "\n",
       "             phases                                      interventions  \\\n",
       "0          [PHASE1]             [pf-02341066, pd-0325901, binimetinib]   \n",
       "1              [NA]                                                 []   \n",
       "2          [PHASE2]  [adavosertib, afatinib, afatinib dimaleate, bi...   \n",
       "3  [PHASE1, PHASE2]                  [ide196, binimetinib, crizotinib]   \n",
       "4          [PHASE2]                                    [taletrectinib]   \n",
       "5          [PHASE2]                                      [entrectinib]   \n",
       "6          [PHASE2]  [alectinib, cetuximab, crizotinib, dasatinib, ...   \n",
       "\n",
       "                                     outcomeMeasures  screen_eval  \n",
       "0  [{'type': 'PRIMARY', 'title': 'Maximal Tolerat...            3  \n",
       "1                                                NaN            4  \n",
       "2                                                NaN           -2  \n",
       "3                                                NaN            3  \n",
       "4                                                NaN           -2  \n",
       "5                                                NaN           -2  \n",
       "6                                                NaN            4  "
      ]
     },
     "execution_count": 9,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "evals = [i['evaluations'] for i in ec_pred]\n",
    "\n",
    "word2int = {\"YES\": 1, \n",
    "            \"UNCERTAIN\": 0,\n",
    "            \"NO\": -1\n",
    "           }\n",
    "#rev_subs = { v:k for k, v in word2int.items()} # subs.iteritems() In Python 3\n",
    "new_evals = []\n",
    "for one_e in evals:\n",
    "    new_evals.append([word2int.get(item, 0) for item in one_e ])\n",
    "new_evals = np.array(new_evals)    \n",
    "print(new_evals)\n",
    "print(new_evals.sum(axis=1))\n",
    "all_studies['screen_eval'] = new_evals.sum(axis=1)\n",
    "all_studies"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "id": "311045ba-470d-4ef5-92e4-615ad05e5911",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>hasResults</th>\n",
       "      <th>nctId</th>\n",
       "      <th>briefTitle</th>\n",
       "      <th>overallStatus</th>\n",
       "      <th>briefSummary</th>\n",
       "      <th>conditions</th>\n",
       "      <th>studyType</th>\n",
       "      <th>phases</th>\n",
       "      <th>interventions</th>\n",
       "      <th>outcomeMeasures</th>\n",
       "      <th>screen_eval</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>True</td>\n",
       "      <td>NCT02510001</td>\n",
       "      <td>MEK and MET Inhibition in Colorectal Cancer</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>This trial is designed to try two new cancer d...</td>\n",
       "      <td>[Solid Tumor, Colorectal Cancer]</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>[PHASE1]</td>\n",
       "      <td>[pf-02341066, pd-0325901, binimetinib]</td>\n",
       "      <td>[{'type': 'PRIMARY', 'title': 'Maximal Tolerat...</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>False</td>\n",
       "      <td>NCT03792568</td>\n",
       "      <td>ALK Inhibitor in Metastatic Colorectal Cancer ...</td>\n",
       "      <td>UNKNOWN</td>\n",
       "      <td>This clinical trial aims to evaluate the effic...</td>\n",
       "      <td>[Colorectal Cancer]</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>[NA]</td>\n",
       "      <td>[]</td>\n",
       "      <td>NaN</td>\n",
       "      <td>4</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>False</td>\n",
       "      <td>NCT03947385</td>\n",
       "      <td>Study of IDE196 in Patients With Solid Tumors ...</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>This is a Phase 1/2, multi-center, open-label ...</td>\n",
       "      <td>[Metastatic Uveal Melanoma, Cutaneous Melanoma...</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>[PHASE1, PHASE2]</td>\n",
       "      <td>[ide196, binimetinib, crizotinib]</td>\n",
       "      <td>NaN</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>False</td>\n",
       "      <td>NCT05725200</td>\n",
       "      <td>Study to Investigate Outcome of Individualized...</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>The purpose of the study is to investigate the...</td>\n",
       "      <td>[Metastatic Colorectal Cancer]</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>[PHASE2]</td>\n",
       "      <td>[alectinib, cetuximab, crizotinib, dasatinib, ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>4</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   hasResults        nctId                                         briefTitle  \\\n",
       "0        True  NCT02510001        MEK and MET Inhibition in Colorectal Cancer   \n",
       "1       False  NCT03792568  ALK Inhibitor in Metastatic Colorectal Cancer ...   \n",
       "3       False  NCT03947385  Study of IDE196 in Patients With Solid Tumors ...   \n",
       "6       False  NCT05725200  Study to Investigate Outcome of Individualized...   \n",
       "\n",
       "  overallStatus                                       briefSummary  \\\n",
       "0     COMPLETED  This trial is designed to try two new cancer d...   \n",
       "1       UNKNOWN  This clinical trial aims to evaluate the effic...   \n",
       "3    RECRUITING  This is a Phase 1/2, multi-center, open-label ...   \n",
       "6    RECRUITING  The purpose of the study is to investigate the...   \n",
       "\n",
       "                                          conditions       studyType  \\\n",
       "0                   [Solid Tumor, Colorectal Cancer]  INTERVENTIONAL   \n",
       "1                                [Colorectal Cancer]  INTERVENTIONAL   \n",
       "3  [Metastatic Uveal Melanoma, Cutaneous Melanoma...  INTERVENTIONAL   \n",
       "6                     [Metastatic Colorectal Cancer]  INTERVENTIONAL   \n",
       "\n",
       "             phases                                      interventions  \\\n",
       "0          [PHASE1]             [pf-02341066, pd-0325901, binimetinib]   \n",
       "1              [NA]                                                 []   \n",
       "3  [PHASE1, PHASE2]                  [ide196, binimetinib, crizotinib]   \n",
       "6          [PHASE2]  [alectinib, cetuximab, crizotinib, dasatinib, ...   \n",
       "\n",
       "                                     outcomeMeasures  screen_eval  \n",
       "0  [{'type': 'PRIMARY', 'title': 'Maximal Tolerat...            3  \n",
       "1                                                NaN            4  \n",
       "3                                                NaN            3  \n",
       "6                                                NaN            4  "
      ]
     },
     "execution_count": 10,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "all_studies[all_studies.screen_eval>=0]"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "7a7a20de-f7d2-4970-b101-656a671b3a80",
   "metadata": {
    "tags": []
   },
   "source": [
    "### 3. CT outcome results\n",
    "Взяли все результаты, отдельно сохранили испытания с результатами, и з них отбираем рез-ты только с unit==participants\n",
    "\n",
    "filter by interventional study type?"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 55,
   "id": "4483a6d0-1c86-4027-b557-575b85502863",
   "metadata": {
    "tags": []
   },
   "outputs": [],
   "source": [
    "from trialmind.llm import batch_call_llm"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "id": "d49df219-e6db-4e19-bad8-064aec8aba27",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "C:\\Users\\user\\AppData\\Local\\Temp\\ipykernel_9776\\3128703095.py:4: SettingWithCopyWarning: \n",
      "A value is trying to be set on a copy of a slice from a DataFrame.\n",
      "Try using .loc[row_indexer,col_indexer] = value instead\n",
      "\n",
      "See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
      "  chosen['res_with_part'] = chosen['outcomeMeasures'].apply(lambda x: [obj for obj in x \\\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1\n",
      "**Outcome Measure Efficiency Statistics:**\n",
      "\n",
      "1. **Complete Response (CR):** Not reported.\n",
      "2. **Partial Response (PR):** Not reported.\n",
      "3. **Stable Disease (SD):** 7 participants out of 30 (23.3%).\n",
      "4. **Progressive Disease:** 22 participants out of 30 (73.3%).\n",
      "5. **Early Death from Malignant Disease:** 1 participant out of 30 (3.3%).\n",
      "-----\n"
     ]
    }
   ],
   "source": [
    "at_once = False\n",
    "\n",
    "chosen = all_studies[(all_studies.screen_eval>=0)&(all_studies.hasResults==True)]\n",
    "chosen['res_with_part'] = chosen['outcomeMeasures'].apply(lambda x: [obj for obj in x \\\n",
    "                                                          if(obj.get('unitOfMeasure','').lower() in ['percentage of participants','participants'])])\n",
    "\n",
    "to_work = chosen[chosen.res_with_part.str.len()>0]\n",
    "if to_work.shape[0]:\n",
    "    messages = []\n",
    "    for i in to_work.res_with_part.values[:2]:\n",
    "        n_outcomes = len(i)\n",
    "        print(n_outcomes)\n",
    "        messages.append([{'role':'system', 'content':f'You are a helpful medical assistant. Answer with a concise description of the efficiency statistics for EACH of {n_outcomes} provided outcome measures /no_think'},\n",
    "                {'role':'user', 'content':f\"{i}\"}])\n",
    "    if at_once:\n",
    "        results = batch_call_openai(messages, os.getenv('MODEL_NAME'), \n",
    "                                    int(os.getenv('TEMPERATURE')), thinking=False)\n",
    "    else:\n",
    "        results = []\n",
    "        for i in messages:\n",
    "            answer = extract.use_llm(os.getenv('MODEL_NAME'),i)\n",
    "            results.append(answer)\n",
    "    for i in results:\n",
    "        print(i)\n",
    "        print('-----')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 59,
   "id": "e0034192-ab00-4acf-ab8b-09830756d13c",
   "metadata": {
    "collapsed": true,
    "jupyter": {
     "outputs_hidden": true
    },
    "tags": []
   },
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "C:\\Users\\user\\AppData\\Local\\Temp\\ipykernel_17840\\480369459.py:4: SettingWithCopyWarning: \n",
      "A value is trying to be set on a copy of a slice from a DataFrame.\n",
      "Try using .loc[row_indexer,col_indexer] = value instead\n",
      "\n",
      "See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
      "  chosen['res_with_part'] = chosen.outcomes.apply(lambda x: [obj for obj in x if(obj.get('unitOfMeasure','') == 'Participants')])\n"
     ]
    },
    {
     "ename": "ValueError",
     "evalue": "The truth value of a DataFrame is ambiguous. Use a.empty, a.bool(), a.item(), a.any() or a.all().",
     "output_type": "error",
     "traceback": [
      "\u001b[31m---------------------------------------------------------------------------\u001b[39m",
      "\u001b[31mValueError\u001b[39m                                Traceback (most recent call last)",
      "\u001b[32m~\\AppData\\Local\\Temp\\ipykernel_17840\\480369459.py\u001b[39m in \u001b[36m?\u001b[39m\u001b[34m()\u001b[39m\n\u001b[32m     16\u001b[39m         \u001b[38;5;28;01mreturn\u001b[39;00m results\n\u001b[32m     17\u001b[39m     \u001b[38;5;28;01melse\u001b[39;00m:\n\u001b[32m     18\u001b[39m         \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;01mNone\u001b[39;00m\n\u001b[32m     19\u001b[39m \n\u001b[32m---> \u001b[39m\u001b[32m20\u001b[39m res = results_ct(all_studies)\n\u001b[32m     21\u001b[39m \u001b[38;5;28;01mfor\u001b[39;00m i \u001b[38;5;28;01min\u001b[39;00m res:\n\u001b[32m     22\u001b[39m     print(i)\n\u001b[32m     23\u001b[39m     print(\u001b[33m'-----'\u001b[39m)\n",
      "\u001b[32m~\\AppData\\Local\\Temp\\ipykernel_17840\\480369459.py\u001b[39m in \u001b[36m?\u001b[39m\u001b[34m(all_studies)\u001b[39m\n\u001b[32m      3\u001b[39m     chosen = all_studies[all_studies.results==\u001b[38;5;28;01mTrue\u001b[39;00m]\n\u001b[32m      4\u001b[39m     chosen[\u001b[33m'res_with_part'\u001b[39m] = chosen.outcomes.apply(\u001b[38;5;28;01mlambda\u001b[39;00m x: [obj \u001b[38;5;28;01mfor\u001b[39;00m obj \u001b[38;5;28;01min\u001b[39;00m x \u001b[38;5;28;01mif\u001b[39;00m(obj.get(\u001b[33m'unitOfMeasure'\u001b[39m,\u001b[33m''\u001b[39m) == \u001b[33m'Participants'\u001b[39m)])\n\u001b[32m      5\u001b[39m \n\u001b[32m      6\u001b[39m     to_work = chosen[chosen.res_with_part.str.len()>\u001b[32m0\u001b[39m].iloc[:\u001b[32m2\u001b[39m]\n\u001b[32m----> \u001b[39m\u001b[32m7\u001b[39m     \u001b[38;5;28;01mif\u001b[39;00m to_work:\n\u001b[32m      8\u001b[39m         outcome_participants = [obj for item_main in chosen.outcomes.values for obj in item_main \n\u001b[32m      9\u001b[39m                             \u001b[38;5;28;01mif\u001b[39;00m(obj.get(\u001b[33m'unitOfMeasure'\u001b[39m,\u001b[33m''\u001b[39m) == \u001b[33m'Participants'\u001b[39m)]\n\u001b[32m     10\u001b[39m         messages = []\n",
      "\u001b[32m~\\anaconda3\\envs\\llms\\Lib\\site-packages\\pandas\\core\\generic.py\u001b[39m in \u001b[36m?\u001b[39m\u001b[34m(self)\u001b[39m\n\u001b[32m   1578\u001b[39m     @final\n\u001b[32m   1579\u001b[39m     \u001b[38;5;28;01mdef\u001b[39;00m __nonzero__(self) -> NoReturn:\n\u001b[32m-> \u001b[39m\u001b[32m1580\u001b[39m         raise ValueError(\n\u001b[32m   1581\u001b[39m             f\"The truth value of a {type(self).__name__} is ambiguous. \"\n\u001b[32m   1582\u001b[39m             \u001b[33m\"Use a.empty, a.bool(), a.item(), a.any() or a.all().\"\u001b[39m\n\u001b[32m   1583\u001b[39m         )\n",
      "\u001b[31mValueError\u001b[39m: The truth value of a DataFrame is ambiguous. Use a.empty, a.bool(), a.item(), a.any() or a.all()."
     ]
    }
   ],
   "source": [
    "temperature=0\n",
    "def results_ct(all_studies):\n",
    "    chosen = all_studies[all_studies.results==True]\n",
    "    chosen['res_with_part'] = chosen.outcomes.apply(lambda x: [obj for obj in x if(obj.get('unitOfMeasure','') == 'Participants')])\n",
    "    \n",
    "    to_work = chosen[chosen.res_with_part.str.len()>0].iloc[:2]\n",
    "    if to_work:\n",
    "        outcome_participants = [obj for item_main in chosen.outcomes.values for obj in item_main \n",
    "                            if(obj.get('unitOfMeasure','') == 'Participants')] \n",
    "        messages = []\n",
    "        for i in to_work.res_with_part.values:\n",
    "            messages.append([{'role':'system', 'content':'You are a helpful medical assistant. Extract information about the efficiency statistics from each outcome measure. Give: 1) a concise description of results with percentages and 2) a short description of study objectives /no_think'},\n",
    "                    {'role':'user', 'content':f\"{i}\"}])\n",
    "\n",
    "        results = batch_call_openai(messages, os.getenv('MODEL_NAME'), int(os.getenv('TEMPERATURE')), thinking=False)\n",
    "        return results\n",
    "    else:\n",
    "        return None\n",
    "\n",
    "res = results_ct(all_studies)\n",
    "for i in res:\n",
    "    print(i)\n",
    "    print('-----')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "id": "db6360d3-76fa-4607-8764-0a705af4464c",
   "metadata": {
    "collapsed": true,
    "jupyter": {
     "outputs_hidden": true,
     "source_hidden": true
    },
    "tags": []
   },
   "outputs": [
    {
     "ename": "NameError",
     "evalue": "name 'llm_reasoning' is not defined",
     "output_type": "error",
     "traceback": [
      "\u001b[31m---------------------------------------------------------------------------\u001b[39m",
      "\u001b[31mNameError\u001b[39m                                 Traceback (most recent call last)",
      "\u001b[36mCell\u001b[39m\u001b[36m \u001b[39m\u001b[32mIn[19]\u001b[39m\u001b[32m, line 7\u001b[39m\n\u001b[32m      1\u001b[39m prompt2 = ChatPromptTemplate.from_messages([\n\u001b[32m      2\u001b[39m     (\u001b[33m\"\u001b[39m\u001b[33msystem\u001b[39m\u001b[33m\"\u001b[39m, \u001b[33m\"\u001b[39m\u001b[33mYou are a helpful medical assistant. Extract information about the efficiency statistics from each outcome measure. Give a concise description with percentages /no_think\u001b[39m\u001b[33m\"\u001b[39m),\n\u001b[32m      3\u001b[39m     (\u001b[33m\"\u001b[39m\u001b[33mhuman\u001b[39m\u001b[33m\"\u001b[39m, \u001b[33m\"\u001b[39m\u001b[38;5;132;01m{text}\u001b[39;00m\u001b[33m\"\u001b[39m),\n\u001b[32m      4\u001b[39m     \u001b[38;5;66;03m# (\"ai\", \"Good.\")\u001b[39;00m\n\u001b[32m      5\u001b[39m ])\n\u001b[32m----> \u001b[39m\u001b[32m7\u001b[39m chain2 = prompt2 | \u001b[43mllm_reasoning\u001b[49m\n\u001b[32m      8\u001b[39m response_res = \u001b[38;5;28;01mawait\u001b[39;00m chain2.ainvoke({\u001b[33m\"\u001b[39m\u001b[33mtext\u001b[39m\u001b[33m\"\u001b[39m: outcome_participants[\u001b[32m0\u001b[39m]})\n\u001b[32m      9\u001b[39m \u001b[38;5;28mprint\u001b[39m(response_res.content)\n",
      "\u001b[31mNameError\u001b[39m: name 'llm_reasoning' is not defined"
     ]
    }
   ],
   "source": [
    "prompt2 = ChatPromptTemplate.from_messages([\n",
    "    (\"system\", \"You are a helpful medical assistant. Extract information about the efficiency statistics from each outcome measure. Give a concise description with percentages /no_think\"),\n",
    "    (\"human\", \"{text}\"),\n",
    "    # (\"ai\", \"Good.\")\n",
    "])\n",
    "\n",
    "chain2 = prompt2 | llm_reasoning\n",
    "response_res = await chain2.ainvoke({\"text\": outcome_participants[0]})\n",
    "print(response_res.content)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "84f5d879-2920-4ec3-bac4-5ae64fb55099",
   "metadata": {
    "tags": []
   },
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "markdown",
   "id": "e706ee64-c65f-40a9-8606-8e71c97fa5d6",
   "metadata": {
    "jp-MarkdownHeadingCollapsed": true,
    "tags": []
   },
   "source": [
    "### results in a given format?"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "8f1d0545-8778-43fb-9af8-da1730e79453",
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "class Info(BaseModel):\n",
    "    diagnose: str = Field(..., description=\"База клинических испытаний\")\n",
    "    treatments: str = Field(..., description=\"Высшие позиции рейтинга таргетных препаратов\")\n",
    "\n",
    "parser = PydanticOutputParser(pydantic_object=Info)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "1d5b0edc-bb8f-4fcd-b443-36745ad7eaf7",
   "metadata": {
    "tags": []
   },
   "outputs": [],
   "source": [
    "prompt = ChatPromptTemplate.from_messages([\n",
    "    (\n",
    "        \"system\", \n",
    "        dedent(\n",
    "            \"\"\"\n",
    "            You are a helpful assistant. \n",
    "            Your goal is to extract related information from the text provided by the user.\n",
    "            Return the information in the following JSON-format.\n",
    "            {fmt}\n",
    "            \"\"\"\n",
    "        )\n",
    "    ),\n",
    "    (\n",
    "        \"human\", \n",
    "        dedent(\n",
    "            \"\"\"\n",
    "            Text: {text}\"\n",
    "            \"\"\"\n",
    "        )\n",
    "    ),\n",
    "])\n",
    "chain = (\n",
    "    prompt \n",
    "    | llm_reasoning \n",
    "    | parser\n",
    ")\n",
    "\n",
    "\n",
    "response = await chain.ainvoke({\"text\": text, \"fmt\": parser.get_format_instructions()})\n",
    "print(response)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "d963b7db-0c01-4b5f-af74-d7d566ae8a54",
   "metadata": {
    "tags": []
   },
   "source": [
    "## 4. papers"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "f1e430e6-c0a6-4a2f-9e92-2b0ca80bdd6e",
   "metadata": {
    "tags": []
   },
   "outputs": [],
   "source": [
    "fin_condition = 'Colorectal cancer'\n",
    "treatements_eng =  ['Crizotinib','Lorlatinib',]\n",
    "pubmed_api_key= '6892c4129cef143ff92d11533848d2e0d908'#os.getenv(\"PUBMED_API_KEY\", '')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "ceab5c26-765a-420c-82a6-8bfbacdb36f6",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(['38711893',\n",
       "  '40369167',\n",
       "  '41213063',\n",
       "  '40211189',\n",
       "  '40526090',\n",
       "  '40140597',\n",
       "  '41268440'],\n",
       " 'https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi?db=pubmed&term=(Colorectal cancer)+AND+(Crizotinib)&retmax=7&retmode=json&api_key=6892c4129cef143ff92d11533848d2e0d908',\n",
       " '67')"
      ]
     },
     "execution_count": 6,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "search_api = PubmedAPIWrapper()\n",
    "# page_size is the max number of records to return!!!! not pages!\n",
    "tmp_inputs = {\n",
    "        \"page_size\": 7,\n",
    "        \"keyword_map\": {'conditions':[fin_condition], \n",
    "                        'treatments':[treatements_eng[0]]\n",
    "                       },\n",
    "        \"keywords\": {\n",
    "            \"OPERATOR\": 'AND'\n",
    "        }\n",
    "}\n",
    "\n",
    "time.sleep(.5)\n",
    "response = search_api.build_search_query_and_get_pmid(tmp_inputs, \n",
    "                                                      api_key=pubmed_api_key)\n",
    "response"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "a54a4f2c-d723-4a4a-a1b1-77eb50eeaea8",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>PMID</th>\n",
       "      <th>Journal</th>\n",
       "      <th>Year</th>\n",
       "      <th>Month</th>\n",
       "      <th>Day</th>\n",
       "      <th>Title</th>\n",
       "      <th>Publication Type</th>\n",
       "      <th>Authors</th>\n",
       "      <th>Abstract</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>38711893</td>\n",
       "      <td>AME case reports</td>\n",
       "      <td>2024</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Partial response to crizotinib + regorafenib +...</td>\n",
       "      <td>Case Reports, Journal Article</td>\n",
       "      <td>Yingying Huang, Shuai Zhang, Xueqing Hu, Xiang...</td>\n",
       "      <td>Colorectal cancer (CRC) with the Raf murine sa...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>40369167</td>\n",
       "      <td>Cell death and differentiation</td>\n",
       "      <td>2025</td>\n",
       "      <td>Nov</td>\n",
       "      <td></td>\n",
       "      <td>ARID1A loss enhances sensitivity to c-MET inhi...</td>\n",
       "      <td>Journal Article</td>\n",
       "      <td>Xu Zhang, Zihuan Wang, Yilin He, Kejin Wang, C...</td>\n",
       "      <td>ARID1A, a subunit of the SWI/SNF chromatin-rem...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>41213063</td>\n",
       "      <td>Journal of environmental pathology, toxicology...</td>\n",
       "      <td>2025</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Radiotherapy-Related Autophagy Genes Predict P...</td>\n",
       "      <td>Journal Article</td>\n",
       "      <td>Mao Mao, Yichao Zhuang, Yan Chen</td>\n",
       "      <td>Numerous genes have been associated with color...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>40211189</td>\n",
       "      <td>BMC cancer</td>\n",
       "      <td>2025</td>\n",
       "      <td>Apr</td>\n",
       "      <td>10</td>\n",
       "      <td>A Phase Ia/b study of MEK1/2 inhibitor binimet...</td>\n",
       "      <td>Journal Article, Clinical Trial, Phase I</td>\n",
       "      <td>Francesca Aroldi, Elena Elez, Thierry André, G...</td>\n",
       "      <td>Targeting RAS mutant (MT) colorectal cancer (C...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>40526090</td>\n",
       "      <td>Oncotarget</td>\n",
       "      <td>2025</td>\n",
       "      <td>Jun</td>\n",
       "      <td>17</td>\n",
       "      <td>Case Report WIN-MTB-2023001 WIN International ...</td>\n",
       "      <td>Journal Article, Case Reports</td>\n",
       "      <td>Alberto Hernando-Calvo, Razelle Kurzrock, Nadi...</td>\n",
       "      <td>Heavily pretreated metastatic colorectal cance...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>40140597</td>\n",
       "      <td>BJC reports</td>\n",
       "      <td>2025</td>\n",
       "      <td>Mar</td>\n",
       "      <td>26</td>\n",
       "      <td>A phase Ia study of the MEK1/2 inhibitor PD-03...</td>\n",
       "      <td>Journal Article</td>\n",
       "      <td>Peter Gallagher, Christian Rolfo, Elena Elez, ...</td>\n",
       "      <td>Single-agent MEK1/2 inhibition has been disapp...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>41268440</td>\n",
       "      <td>Frontiers in pharmacology</td>\n",
       "      <td>2025</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Case Report: HGF and NF1 mutations as putative...</td>\n",
       "      <td>Case Reports, Journal Article</td>\n",
       "      <td>Zhitao Chen, Shan Luo, Yangjun Gu, Qiyong Li</td>\n",
       "      <td>Hepatocellular carcinoma (HCC) is a highly agg...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "       PMID                                            Journal  Year Month  \\\n",
       "0  38711893                                   AME case reports  2024         \n",
       "1  40369167                     Cell death and differentiation  2025   Nov   \n",
       "2  41213063  Journal of environmental pathology, toxicology...  2025         \n",
       "3  40211189                                         BMC cancer  2025   Apr   \n",
       "4  40526090                                         Oncotarget  2025   Jun   \n",
       "5  40140597                                        BJC reports  2025   Mar   \n",
       "6  41268440                          Frontiers in pharmacology  2025         \n",
       "\n",
       "  Day                                              Title  \\\n",
       "0      Partial response to crizotinib + regorafenib +...   \n",
       "1      ARID1A loss enhances sensitivity to c-MET inhi...   \n",
       "2      Radiotherapy-Related Autophagy Genes Predict P...   \n",
       "3  10  A Phase Ia/b study of MEK1/2 inhibitor binimet...   \n",
       "4  17  Case Report WIN-MTB-2023001 WIN International ...   \n",
       "5  26  A phase Ia study of the MEK1/2 inhibitor PD-03...   \n",
       "6      Case Report: HGF and NF1 mutations as putative...   \n",
       "\n",
       "                           Publication Type  \\\n",
       "0             Case Reports, Journal Article   \n",
       "1                           Journal Article   \n",
       "2                           Journal Article   \n",
       "3  Journal Article, Clinical Trial, Phase I   \n",
       "4             Journal Article, Case Reports   \n",
       "5                           Journal Article   \n",
       "6             Case Reports, Journal Article   \n",
       "\n",
       "                                             Authors  \\\n",
       "0  Yingying Huang, Shuai Zhang, Xueqing Hu, Xiang...   \n",
       "1  Xu Zhang, Zihuan Wang, Yilin He, Kejin Wang, C...   \n",
       "2                   Mao Mao, Yichao Zhuang, Yan Chen   \n",
       "3  Francesca Aroldi, Elena Elez, Thierry André, G...   \n",
       "4  Alberto Hernando-Calvo, Razelle Kurzrock, Nadi...   \n",
       "5  Peter Gallagher, Christian Rolfo, Elena Elez, ...   \n",
       "6       Zhitao Chen, Shan Luo, Yangjun Gu, Qiyong Li   \n",
       "\n",
       "                                            Abstract  \n",
       "0  Colorectal cancer (CRC) with the Raf murine sa...  \n",
       "1  ARID1A, a subunit of the SWI/SNF chromatin-rem...  \n",
       "2  Numerous genes have been associated with color...  \n",
       "3  Targeting RAS mutant (MT) colorectal cancer (C...  \n",
       "4  Heavily pretreated metastatic colorectal cance...  \n",
       "5  Single-agent MEK1/2 inhibition has been disapp...  \n",
       "6  Hepatocellular carcinoma (HCC) is a highly agg...  "
      ]
     },
     "execution_count": 7,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_papers = pmid2papers(#pmid_list=['40526090', '41213063', '41268440'],\n",
    "                        pmid_list=response[0], \n",
    "                        api_key=pubmed_api_key)\n",
    "df_papers[0]"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "f15bedd0-7b97-4696-ac71-2b9ddc4ef0d6",
   "metadata": {},
   "source": [
    "### papers screen criterias"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "02abfa1e-39b7-4f19-b669-16f0cc72cad5",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "call_openai https://gigachat.devices.sberbank.ru/api/v1\n",
      "api_call_single https://gigachat.devices.sberbank.ru/api/v1/\n",
      "```json\n",
      "{\n",
      "    \"ELIGIBILITY_ANALYSIS\": [\n",
      "        \"Patients must have colorectal cancer diagnosis confirmed by histopathology or imaging\",\n",
      "        \"Studies must report Crizotinib as an intervention used in treatment\",\n",
      "        \"Comparative studies involving Crizotinib versus other treatments or placebo are eligible\",\n",
      "        \"Outcomes related to efficacy, toxicity, survival rates, or quality of life are relevant\",\n",
      "        \"Study designs including randomized controlled trials, cohort studies, or case-control studies are acceptable\"\n",
      "    ],\n",
      "    \"TITLE_CRITERIA\": [\n",
      "        \"Does the title mention 'colorectal cancer'?\",\n",
      "        \"Does the title mention 'Crizotinib'?\"\n",
      "    ],\n",
      "    \"CONTENT_CRITERIA\": [\n",
      "        \"Is there evidence of Crizotinib administration in the study population?\",\n",
      "        \"Are outcomes such as response rate, progression-free survival, overall survival, or adverse events reported?\"\n",
      "    ]\n",
      "}\n",
      "```\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "{'title_criteria': [\"Does the title mention 'colorectal cancer'?\",\n",
       "  \"Does the title mention 'Crizotinib'?\"],\n",
       " 'content_criteria': ['Is there evidence of Crizotinib administration in the study population?',\n",
       "  'Are outcomes such as response rate, progression-free survival, overall survival, or adverse events reported?'],\n",
       " 'eligibility_analysis': ['Patients must have colorectal cancer diagnosis confirmed by histopathology or imaging',\n",
       "  'Studies must report Crizotinib as an intervention used in treatment',\n",
       "  'Comparative studies involving Crizotinib versus other treatments or placebo are eligible',\n",
       "  'Outcomes related to efficacy, toxicity, survival rates, or quality of life are relevant',\n",
       "  'Study designs including randomized controlled trials, cohort studies, or case-control studies are acceptable']}"
      ]
     },
     "execution_count": 8,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# test the apis\n",
    "\n",
    "api = ScreeningCriteriaGeneration()\n",
    "ecs_p = api.run(\n",
    "    population = f\"Patients with {fin_condition} undergoing treatment with {treatements_eng[0]}\",\n",
    "    intervention = f\"{treatements_eng[0]}\",\n",
    "    comparator = \"\",\n",
    "    outcome = \"\",\n",
    "    llm = os.getenv(\"MODEL_NAME\"),\n",
    "    num_title_criteria=2,\n",
    "    num_abstract_criteria=2,\n",
    "    thinking=False,\n",
    ")\n",
    "ecs_p"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "id": "f2858acb-a1e3-4d89-b8af-f1b7ce0cf1d4",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['Partial response to crizotinib + regorafenib + PD-1 inhibitor in a metastatic: Colorectal cancer (CRC) with the Raf murine sarcoma viral oncogene homolog B (\\nA 49-year-old Chinese male was diagnosed with ascending colon adenocarcinoma (cT3N+?M1) with liver metastases. The patient performed next-generation sequencing (NGS) using tissue and circulating tumor DNA (ctDNA), and the results showed a\\nThis study reported a co-existence of a']"
      ]
     },
     "execution_count": 9,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "papers = df_papers[0][\"Title\"] + \": \" + df_papers[0][\"Abstract\"].fillna(\"\") # important to fillna\n",
    "papers = papers.tolist()\n",
    "papers[:1]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "id": "e604d682-87c0-4bcb-97c0-0c4109f1bdd3",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[\"Does the title mention 'colorectal cancer'?\",\n",
       " \"Does the title mention 'Crizotinib'?\",\n",
       " 'Is there evidence of Crizotinib administration in the study population?',\n",
       " 'Are outcomes such as response rate, progression-free survival, overall survival, or adverse events reported?']"
      ]
     },
     "execution_count": 10,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "'''\n",
    "'title_criteria': [\"Does the title mention 'colorectal cancer'?\",\n",
    "  \"Does the title mention 'Crizotinib'?\"],\n",
    "'content_criteria': ['Is there evidence of Crizotinib administration in the study methods section?',\n",
    "  'Are outcomes related to patient response, adverse events, or survival discussed in the results section?'],\n",
    "'''\n",
    "title_criteria = ecs_p['title_criteria']\n",
    "content_criteria = ecs_p['content_criteria']\n",
    "title_criteria+content_criteria"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "98cbb36e-3268-45c7-83d1-c7e29254a270",
   "metadata": {
    "jp-MarkdownHeadingCollapsed": true,
    "tags": []
   },
   "source": [
    "### __check"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "id": "01b591d1-9455-484c-84d8-5257ddb17838",
   "metadata": {
    "tags": []
   },
   "outputs": [],
   "source": [
    "from trialmind.llm import _batch_inputs_to_messages"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "id": "1952514e-39be-48fd-a185-1840dfaf2ddc",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'\\n# CONTEXT #\\nYou are a clinical specialist tasked with assessing research papers for inclusion in a meta-analysis based on specific eligibility criteria.\\n\\n# OBJECTIVE #\\nEvaluate each criterion of a given paper to determine its eligibility for inclusion in the meta-analysis. Provide a list of decisions (\"YES\", \"NO\", or \"UNCERTAIN\") for each eligibility criterion. You must deliver exactly {num_criteria} responses.\\n\\n# IMPORTANT NOTE #\\nIf the information within the provided paper content is insufficient to conclusively evaluate a criterion, you must opt for \"UNCERTAIN\" as your response. Avoid making assumptions or extrapolating beyond the provided data, as accurate and reliable responses are crucial, and fabricating information (hallucinations) could lead to serious errors in the meta-analysis.\\n\\n# PICO FRAMEWORK #\\n- P (Patient, Problem or Population): {P}\\n- I (Intervention): {I}\\n- C (Comparison): {C}\\n- O (Outcome): {O}\\n\\n# PAPER DETAILS #\\n- Provided Paper: {paper_content}\\n\\n# EVALUATION CRITERIA #\\n- Number of Criteria: {num_criteria}\\n- Criteria for Inclusion: {criteria_text}\\n\\n# RESPONSE FORMAT #\\nReturn the information in a JSON object containing a list of decisions for each of the {num_criteria} eligibility criteria. Each decision should directly correspond to one of the criteria and be listed in the order they are presented. Ensure to use \"UNCERTAIN\" wherever the paper does not explicitly support a \"YES\" or \"NO\" decision.\\n\\nFor example:\\n```json\\n{{\\n    \"evaluations\": [\"YES\", \"NO\", \"UNCERTAIN\", \"YES\", \"YES\", ...],\\n    \"rationale\": [\"The title includes...\",\"...\",\"...\",\"...\",\"...\",...]\\n}}\\n```\\n\\nMANDATORY: Every single response then continues with valid JSON output complying to the included JSON schema, and will be validated, allowing no deviation.\\n'"
      ]
     },
     "execution_count": 22,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "from trialmind.prompts.screening import LITERATURE_SCREENING_FC\n",
    "population = f\"Patients with {fin_condition} undergoing treatment with {treatements_eng[0]}\",\n",
    "intervention = f\"{treatements_eng[0]}\",\n",
    "comparator = \"\",\n",
    "outcome = \"\",\n",
    "criteria = title_criteria + content_criteria\n",
    "criteria_text = [f\"{idx+1}. {c}\" for idx, c in enumerate(criteria)]\n",
    "n_criteria = len(criteria_text)\n",
    "    \n",
    "batch_inputs = []\n",
    "for paper in papers[:1]:\n",
    "    batch_inputs.append({\n",
    "        \"P\": population,\n",
    "        \"I\": intervention,\n",
    "        \"C\": comparator,\n",
    "        \"O\": outcome,\n",
    "        \"paper_content\": paper,\n",
    "        \"criteria_text\": criteria_text,\n",
    "        \"num_criteria\": n_criteria\n",
    "    })\n",
    "            \n",
    "LITERATURE_SCREENING_FC"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 37,
   "id": "ea150416-221c-4862-b25e-4d59707e2088",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[{'type': 'function',\n",
       "  'function': {'name': 'PaperEvaluation',\n",
       "   'description': '',\n",
       "   'parameters': {'properties': {'evaluations': {'description': 'Evaluations for 4 criteria, must be of length 4',\n",
       "      'items': {'enum': ['YES', 'NO', 'UNCERTAIN'], 'type': 'string'},\n",
       "      'maxItems': 4,\n",
       "      'minItems': 4,\n",
       "      'type': 'array'},\n",
       "     'rationale': {'description': 'A rationale for each criteria evaluation',\n",
       "      'items': {'type': 'string'},\n",
       "      'maxItems': 4,\n",
       "      'minItems': 4,\n",
       "      'type': 'array'}},\n",
       "    'required': ['evaluations', 'rationale'],\n",
       "    'type': 'object'}}}]"
      ]
     },
     "execution_count": 37,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "tools"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 45,
   "id": "c1677a10-4eb7-4811-89db-e49e4f46aa4a",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "ChatCompletionMessage(content='```json\\n{\\n  \"evaluations\": [\\n    \"YES\",\\n    \"YES\",\\n    \"UNCERTAIN\",\\n    \"YES\",\\n    \"YES\",\\n    \"UNCERTAIN\"\\n  ],\\n  \"rationale\": [\\n    \"The title mentions \\'metastatic colorectal cancer\\'\",\\n    \"The title mentions \\'Crizotinib\\'\",\\n    \"There is no comparison mentioned in the title\",\\n    \"Methods and results sections are briefly described but not detailed enough to confirm clarity\",\\n    \"The text indicates adenocarcinoma as the type of colorectal cancer\",\\n    \"No explicit statement about outcome duration is made\"\\n  ]\\n}\\n```  \\n\\n### Explanation of Decisions:\\n1. **Does the title mention \\'colorectal cancer\\'?**  \\n   *YES* — The title states “metastatic colorectal cancer.”\\n   \\n2. **Does the title mention \\'crizotinib\\'?**  \\n   *YES* — The term “Crizotinib” appears in the title.\\n\\n3. **Is there any indication in the title that the study compares crizotinib to another treatment?**  \\n   *UNCERTAIN* — There’s no direct comparison indicated in the title.\\n\\n4. **Are the methods section and results clearly described in the paper?**  \\n   *YES* — Methods and results are mentioned, though details are sparse.\\n\\n5. **Does the study specify the type of colorectal cancer (e.g., adenocarcinoma)?**  \\n   *YES* — The text specifies it as adenocarcinoma.\\n\\n6. **Were the outcomes measured over a sufficient duration to assess long-term effects?**  \\n   *UNCERTAIN* — No clear evidence of long-term follow-up is stated.', refusal=None, role='assistant', annotations=None, audio=None, function_call=None, tool_calls=None)"
      ]
     },
     "execution_count": 45,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "messages = _batch_inputs_to_messages(prompt_template=LITERATURE_SCREENING_FC, batch_inputs=batch_inputs)\n",
    "\n",
    "from openai import AsyncOpenAI\n",
    "tools = [{'type': 'function', 'function': {'name': 'PaperEvaluation', 'description': '', 'parameters': {'properties': {'evaluations': {'description': 'Evaluations for 4 criteria, must be of length 4', 'items': {'enum': ['YES', 'NO', 'UNCERTAIN'], 'type': 'string'}, 'maxItems': 4, 'minItems': 4, 'type': 'array'}, 'rationale': {'description': 'A rationale for each criteria evaluation', 'items': {'type': 'string'}, 'maxItems': 4, 'minItems': 4, 'type': 'array'}}, 'required': ['evaluations', 'rationale'], 'type': 'object'}}}]\n",
    "\n",
    "async_openai_client = AsyncOpenAI(\n",
    "        base_url=os.getenv(\"BASE_URL\"),\n",
    "        api_key=os.getenv(\"OPENAI_API_KEY\"),\n",
    "        http_client=httpx.AsyncClient(verify=False)\n",
    "    )\n",
    "response = await async_openai_client.chat.completions.create(\n",
    "    model=os.getenv(\"MODEL_NAME\"),\n",
    "    messages=messages[0],\n",
    "    tools=tools,\n",
    "    temperature=0\n",
    ")\n",
    "response.choices[0].message"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 52,
   "id": "6ecfac9c-3958-4c86-af6a-c7da0038f0dc",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'```json\\n{\\n  \"evaluations\": [\\n    \"YES\",\\n    \"YES\",\\n    \"UNCERTAIN\",\\n    \"YES\",\\n    \"YES\",\\n    \"UNCERTAIN\"\\n  ],\\n  \"rationale\": [\\n    \"The title mentions \\'metastatic colorectal cancer\\'\",\\n    \"The title mentions \\'Crizotinib\\'\",\\n    \"There is no comparison mentioned in the title\",\\n    \"Methods and results sections are briefly described but not detailed enough to confirm clarity\",\\n    \"The text indicates adenocarcinoma as the type of colorectal cancer\",\\n    \"No explicit statement about outcome duration is made\"\\n  ]\\n}\\n```  \\n\\n### Explanation of Decisions:\\n1. **Does the title mention \\'colorectal cancer\\'?**  \\n   *YES* — The title states “metastatic colorectal cancer.”\\n   \\n2. **Does the title mention \\'crizotinib\\'?**  \\n   *YES* — The term “Crizotinib” appears in the title.\\n\\n3. **Is there any indication in the title that the study compares crizotinib to another treatment?**  \\n   *UNCERTAIN* — There’s no direct comparison indicated in the title.\\n\\n4. **Are the methods section and results clearly described in the paper?**  \\n   *YES* — Methods and results are mentioned, though details are sparse.\\n\\n5. **Does the study specify the type of colorectal cancer (e.g., adenocarcinoma)?**  \\n   *YES* — The text specifies it as adenocarcinoma.\\n\\n6. **Were the outcomes measured over a sufficient duration to assess long-term effects?**  \\n   *UNCERTAIN* — No clear evidence of long-term follow-up is stated.'"
      ]
     },
     "execution_count": 52,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "response.choices[0].message.content"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 60,
   "id": "fa1b377c-97de-4216-95ef-57150b672ea3",
   "metadata": {
    "tags": []
   },
   "outputs": [],
   "source": [
    "from trialmind.api import extract_json,parse_json_outputs"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 62,
   "id": "f2c7b653-2bb6-4946-b79d-791ee3f4a1aa",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[{'evaluations': ['YES', 'YES', 'UNCERTAIN', 'YES', 'YES', 'UNCERTAIN'],\n",
       "  'rationale': [\"The title mentions 'metastatic colorectal cancer'\",\n",
       "   \"The title mentions 'Crizotinib'\",\n",
       "   'There is no comparison mentioned in the title',\n",
       "   'Methods and results sections are briefly described but not detailed enough to confirm clarity',\n",
       "   'The text indicates adenocarcinoma as the type of colorectal cancer',\n",
       "   'No explicit statement about outcome duration is made']}]"
      ]
     },
     "execution_count": 62,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "parse_json_outputs([response.choices[0].message.content])"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "0ef11792-9bc6-419a-9964-1c57f19ee864",
   "metadata": {},
   "source": [
    "### 5. paper screen\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "id": "6e510df2-8174-4105-bcaa-00767e4560ba",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1\n",
      "\n",
      "parsed_results in asynch ['```json\\n{\\n    \"evaluations\": [\"YES\", \"YES\", \"YES\", \"UNCERTAIN\"],\\n    \"rationale\": [\\n        \"Title mentions \\'Colorectal cancer\\'\",\\n        \"Title mentions \\'Crizotinib\\'\",\\n        \"Study population includes patients treated with Crizotinib\",\\n        \"No explicit reporting of outcomes like response rate, progression-free survival, overall survival, or adverse events\"\\n    ]\\n}\\n```']\n",
      "\n",
      "parsed_results in asynch ['```json\\n{\\n    \"evaluations\": [\"YES\", \"YES\", \"YES\", \"UNCERTAIN\"],\\n    \"rationale\": [\\n        \"The title mentions \\'Colorectal cancer\\'\",\\n        \"The title mentions \\'Crizotinib\\'\",\\n        \"There is evidence of Crizotinib administration in the study population\",\\n        \"No outcomes such as response rate, progression-free survival, overall survival, or adverse events are reported\"\\n    ]\\n}']\n",
      "\n",
      "parsed_results in asynch ['```json\\n{\\n    \"evaluations\": [\"YES\", \"YES\", \"YES\", \"UNCERTAIN\"],\\n    \"rationale\": [\\n        \"Title mentions \\'colorectal cancer\\'\",\\n        \"Title mentions \\'Crizotinib\\'\",\\n        \"Study population includes patients treated with Crizotinib\",\\n        \"No explicit reporting of response rate, progression-free survival, overall survival, or adverse events\"\\n    ]\\n}']\n",
      "\n",
      "parsed_results in asynch ['```json\\n{\\n    \"evaluations\": [\"YES\", \"YES\", \"YES\", \"NO\"],\\n    \"rationale\": [\\n        \"The title mentions \\'Colorectal cancer\\'\",\\n        \"The title mentions \\'Crizotinib\\'\",\\n        \"There is evidence of Crizotinib administration in the study population\",\\n        \"No outcomes such as response rate, progression-free survival, overall survival, or adverse events are reported\"\\n    ]\\n}\\n```']\n",
      "\n",
      "parsed_results in asynch ['```json\\n{\\n    \"evaluations\": [\"YES\", \"YES\", \"YES\", \"UNCERTAIN\"],\\n    \"rationale\": [\\n        \"Title mentions \\'metastatic colorectal cancer\\'\",\\n        \"Title mentions \\'Crizotinib\\'\",\\n        \"Study describes Crizotinib administration\",\\n        \"No explicit reporting of outcomes like response rate, progression-free survival, overall survival, or adverse events\"\\n    ]\\n}\\n```']\n",
      "\n",
      "parsed_results in asynch ['```json\\n{\\n    \"evaluations\": [\"YES\", \"YES\", \"YES\", \"UNCERTAIN\"],\\n    \"rationale\": [\\n        \"The title mentions \\'Colorectal cancer\\'\",\\n        \"The title mentions \\'Crizotinib\\'\",\\n        \"There is evidence of Crizotinib administration in the study population\",\\n        \"No explicit reporting of response rate, progression-free survival, overall survival, or adverse events\"\\n    ]\\n}']\n",
      "\n",
      "parsed_results in asynch ['```json\\n{\\n    \"evaluations\": [\"NO\", \"YES\", \"NO\", \"UNCERTAIN\"],\\n    \"rationale\": [\\n        \"Title does not mention colorectal cancer\",\\n        \"Title mentions Crizotinib\",\\n        \"No evidence of Crizotinib administration in the study population\",\\n        \"No outcomes such as response rate, progression-free survival, overall survival, or adverse events reported\"\\n    ]\\n}']\n",
      "\n",
      "OUTPUTS:  [{'evaluations': ['YES', 'YES', 'YES', 'UNCERTAIN'], 'rationale': [\"Title mentions 'Colorectal cancer'\", \"Title mentions 'Crizotinib'\", 'Study population includes patients treated with Crizotinib', 'No explicit reporting of outcomes like response rate, progression-free survival, overall survival, or adverse events']}, {'evaluations': ['YES', 'YES', 'YES', 'UNCERTAIN'], 'rationale': [\"The title mentions 'Colorectal cancer'\", \"The title mentions 'Crizotinib'\", 'There is evidence of Crizotinib administration in the study population', 'No outcomes such as response rate, progression-free survival, overall survival, or adverse events are reported']}, {'evaluations': ['YES', 'YES', 'YES', 'UNCERTAIN'], 'rationale': [\"Title mentions 'colorectal cancer'\", \"Title mentions 'Crizotinib'\", 'Study population includes patients treated with Crizotinib', 'No explicit reporting of response rate, progression-free survival, overall survival, or adverse events']}, {'evaluations': ['YES', 'YES', 'YES', 'NO'], 'rationale': [\"The title mentions 'Colorectal cancer'\", \"The title mentions 'Crizotinib'\", 'There is evidence of Crizotinib administration in the study population', 'No outcomes such as response rate, progression-free survival, overall survival, or adverse events are reported']}, {'evaluations': ['YES', 'YES', 'YES', 'UNCERTAIN'], 'rationale': [\"Title mentions 'metastatic colorectal cancer'\", \"Title mentions 'Crizotinib'\", 'Study describes Crizotinib administration', 'No explicit reporting of outcomes like response rate, progression-free survival, overall survival, or adverse events']}, {'evaluations': ['YES', 'YES', 'YES', 'UNCERTAIN'], 'rationale': [\"The title mentions 'Colorectal cancer'\", \"The title mentions 'Crizotinib'\", 'There is evidence of Crizotinib administration in the study population', 'No explicit reporting of response rate, progression-free survival, overall survival, or adverse events']}, {'evaluations': ['NO', 'YES', 'NO', 'UNCERTAIN'], 'rationale': ['Title does not mention colorectal cancer', 'Title mentions Crizotinib', 'No evidence of Crizotinib administration in the study population', 'No outcomes such as response rate, progression-free survival, overall survival, or adverse events reported']}]\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "[{'evaluations': ['YES', 'YES', 'YES', 'UNCERTAIN'],\n",
       "  'rationale': [\"Title mentions 'Colorectal cancer'\",\n",
       "   \"Title mentions 'Crizotinib'\",\n",
       "   'Study population includes patients treated with Crizotinib',\n",
       "   'No explicit reporting of outcomes like response rate, progression-free survival, overall survival, or adverse events']},\n",
       " {'evaluations': ['YES', 'YES', 'YES', 'UNCERTAIN'],\n",
       "  'rationale': [\"The title mentions 'Colorectal cancer'\",\n",
       "   \"The title mentions 'Crizotinib'\",\n",
       "   'There is evidence of Crizotinib administration in the study population',\n",
       "   'No outcomes such as response rate, progression-free survival, overall survival, or adverse events are reported']},\n",
       " {'evaluations': ['YES', 'YES', 'YES', 'UNCERTAIN'],\n",
       "  'rationale': [\"Title mentions 'colorectal cancer'\",\n",
       "   \"Title mentions 'Crizotinib'\",\n",
       "   'Study population includes patients treated with Crizotinib',\n",
       "   'No explicit reporting of response rate, progression-free survival, overall survival, or adverse events']},\n",
       " {'evaluations': ['YES', 'YES', 'YES', 'NO'],\n",
       "  'rationale': [\"The title mentions 'Colorectal cancer'\",\n",
       "   \"The title mentions 'Crizotinib'\",\n",
       "   'There is evidence of Crizotinib administration in the study population',\n",
       "   'No outcomes such as response rate, progression-free survival, overall survival, or adverse events are reported']},\n",
       " {'evaluations': ['YES', 'YES', 'YES', 'UNCERTAIN'],\n",
       "  'rationale': [\"Title mentions 'metastatic colorectal cancer'\",\n",
       "   \"Title mentions 'Crizotinib'\",\n",
       "   'Study describes Crizotinib administration',\n",
       "   'No explicit reporting of outcomes like response rate, progression-free survival, overall survival, or adverse events']},\n",
       " {'evaluations': ['YES', 'YES', 'YES', 'UNCERTAIN'],\n",
       "  'rationale': [\"The title mentions 'Colorectal cancer'\",\n",
       "   \"The title mentions 'Crizotinib'\",\n",
       "   'There is evidence of Crizotinib administration in the study population',\n",
       "   'No explicit reporting of response rate, progression-free survival, overall survival, or adverse events']},\n",
       " {'evaluations': ['NO', 'YES', 'NO', 'UNCERTAIN'],\n",
       "  'rationale': ['Title does not mention colorectal cancer',\n",
       "   'Title mentions Crizotinib',\n",
       "   'No evidence of Crizotinib administration in the study population',\n",
       "   'No outcomes such as response rate, progression-free survival, overall survival, or adverse events reported']}]"
      ]
     },
     "execution_count": 11,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "\n",
    "api = LiteratureScreening()\n",
    "ec_predP = api.run(\n",
    "    population = f\"Patients with {fin_condition} undergoing treatment with {treatements_eng[0]}\",\n",
    "    intervention = f\"{treatements_eng[0]}\",\n",
    "    comparator = \"\",\n",
    "    outcome = \"\",\n",
    "    llm = os.getenv(\"MODEL_NAME\"),\n",
    "    criteria = title_criteria + content_criteria,\n",
    "    papers = papers, # make for the top-100 for demo\n",
    ")\n",
    "ec_predP"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "id": "0e785c6e-737b-4f76-9cdf-d8dce4edf47a",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[[ 1  1  1  0]\n",
      " [ 1  1  1  0]\n",
      " [ 1  1  1  0]\n",
      " [ 1  1  1 -1]\n",
      " [ 1  1  1  0]\n",
      " [ 1  1  1  0]\n",
      " [-1  1 -1  0]]\n",
      "[ 3  3  3  2  3  3 -1]\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>PMID</th>\n",
       "      <th>Journal</th>\n",
       "      <th>Year</th>\n",
       "      <th>Month</th>\n",
       "      <th>Day</th>\n",
       "      <th>Title</th>\n",
       "      <th>Publication Type</th>\n",
       "      <th>Authors</th>\n",
       "      <th>Abstract</th>\n",
       "      <th>screen_eval</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>38711893</td>\n",
       "      <td>AME case reports</td>\n",
       "      <td>2024</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Partial response to crizotinib + regorafenib +...</td>\n",
       "      <td>Case Reports, Journal Article</td>\n",
       "      <td>Yingying Huang, Shuai Zhang, Xueqing Hu, Xiang...</td>\n",
       "      <td>Colorectal cancer (CRC) with the Raf murine sa...</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>40369167</td>\n",
       "      <td>Cell death and differentiation</td>\n",
       "      <td>2025</td>\n",
       "      <td>Nov</td>\n",
       "      <td></td>\n",
       "      <td>ARID1A loss enhances sensitivity to c-MET inhi...</td>\n",
       "      <td>Journal Article</td>\n",
       "      <td>Xu Zhang, Zihuan Wang, Yilin He, Kejin Wang, C...</td>\n",
       "      <td>ARID1A, a subunit of the SWI/SNF chromatin-rem...</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>41213063</td>\n",
       "      <td>Journal of environmental pathology, toxicology...</td>\n",
       "      <td>2025</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Radiotherapy-Related Autophagy Genes Predict P...</td>\n",
       "      <td>Journal Article</td>\n",
       "      <td>Mao Mao, Yichao Zhuang, Yan Chen</td>\n",
       "      <td>Numerous genes have been associated with color...</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>40211189</td>\n",
       "      <td>BMC cancer</td>\n",
       "      <td>2025</td>\n",
       "      <td>Apr</td>\n",
       "      <td>10</td>\n",
       "      <td>A Phase Ia/b study of MEK1/2 inhibitor binimet...</td>\n",
       "      <td>Journal Article, Clinical Trial, Phase I</td>\n",
       "      <td>Francesca Aroldi, Elena Elez, Thierry André, G...</td>\n",
       "      <td>Targeting RAS mutant (MT) colorectal cancer (C...</td>\n",
       "      <td>2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>40526090</td>\n",
       "      <td>Oncotarget</td>\n",
       "      <td>2025</td>\n",
       "      <td>Jun</td>\n",
       "      <td>17</td>\n",
       "      <td>Case Report WIN-MTB-2023001 WIN International ...</td>\n",
       "      <td>Journal Article, Case Reports</td>\n",
       "      <td>Alberto Hernando-Calvo, Razelle Kurzrock, Nadi...</td>\n",
       "      <td>Heavily pretreated metastatic colorectal cance...</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>40140597</td>\n",
       "      <td>BJC reports</td>\n",
       "      <td>2025</td>\n",
       "      <td>Mar</td>\n",
       "      <td>26</td>\n",
       "      <td>A phase Ia study of the MEK1/2 inhibitor PD-03...</td>\n",
       "      <td>Journal Article</td>\n",
       "      <td>Peter Gallagher, Christian Rolfo, Elena Elez, ...</td>\n",
       "      <td>Single-agent MEK1/2 inhibition has been disapp...</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>41268440</td>\n",
       "      <td>Frontiers in pharmacology</td>\n",
       "      <td>2025</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Case Report: HGF and NF1 mutations as putative...</td>\n",
       "      <td>Case Reports, Journal Article</td>\n",
       "      <td>Zhitao Chen, Shan Luo, Yangjun Gu, Qiyong Li</td>\n",
       "      <td>Hepatocellular carcinoma (HCC) is a highly agg...</td>\n",
       "      <td>-1</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "       PMID                                            Journal  Year Month  \\\n",
       "0  38711893                                   AME case reports  2024         \n",
       "1  40369167                     Cell death and differentiation  2025   Nov   \n",
       "2  41213063  Journal of environmental pathology, toxicology...  2025         \n",
       "3  40211189                                         BMC cancer  2025   Apr   \n",
       "4  40526090                                         Oncotarget  2025   Jun   \n",
       "5  40140597                                        BJC reports  2025   Mar   \n",
       "6  41268440                          Frontiers in pharmacology  2025         \n",
       "\n",
       "  Day                                              Title  \\\n",
       "0      Partial response to crizotinib + regorafenib +...   \n",
       "1      ARID1A loss enhances sensitivity to c-MET inhi...   \n",
       "2      Radiotherapy-Related Autophagy Genes Predict P...   \n",
       "3  10  A Phase Ia/b study of MEK1/2 inhibitor binimet...   \n",
       "4  17  Case Report WIN-MTB-2023001 WIN International ...   \n",
       "5  26  A phase Ia study of the MEK1/2 inhibitor PD-03...   \n",
       "6      Case Report: HGF and NF1 mutations as putative...   \n",
       "\n",
       "                           Publication Type  \\\n",
       "0             Case Reports, Journal Article   \n",
       "1                           Journal Article   \n",
       "2                           Journal Article   \n",
       "3  Journal Article, Clinical Trial, Phase I   \n",
       "4             Journal Article, Case Reports   \n",
       "5                           Journal Article   \n",
       "6             Case Reports, Journal Article   \n",
       "\n",
       "                                             Authors  \\\n",
       "0  Yingying Huang, Shuai Zhang, Xueqing Hu, Xiang...   \n",
       "1  Xu Zhang, Zihuan Wang, Yilin He, Kejin Wang, C...   \n",
       "2                   Mao Mao, Yichao Zhuang, Yan Chen   \n",
       "3  Francesca Aroldi, Elena Elez, Thierry André, G...   \n",
       "4  Alberto Hernando-Calvo, Razelle Kurzrock, Nadi...   \n",
       "5  Peter Gallagher, Christian Rolfo, Elena Elez, ...   \n",
       "6       Zhitao Chen, Shan Luo, Yangjun Gu, Qiyong Li   \n",
       "\n",
       "                                            Abstract  screen_eval  \n",
       "0  Colorectal cancer (CRC) with the Raf murine sa...            3  \n",
       "1  ARID1A, a subunit of the SWI/SNF chromatin-rem...            3  \n",
       "2  Numerous genes have been associated with color...            3  \n",
       "3  Targeting RAS mutant (MT) colorectal cancer (C...            2  \n",
       "4  Heavily pretreated metastatic colorectal cance...            3  \n",
       "5  Single-agent MEK1/2 inhibition has been disapp...            3  \n",
       "6  Hepatocellular carcinoma (HCC) is a highly agg...           -1  "
      ]
     },
     "execution_count": 12,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "evalsP = [i['evaluations'] for i in ec_predP]\n",
    "\n",
    "word2int = {\"YES\": 1, \n",
    "            \"UNCERTAIN\": 0,\n",
    "            \"NO\": -1\n",
    "           }\n",
    "#rev_subs = { v:k for k, v in word2int.items()} # subs.iteritems() In Python 3\n",
    "new_evalsP = []\n",
    "for one_e in evalsP:\n",
    "    new_evalsP.append([word2int.get(item, 0) for item in one_e ])\n",
    "new_evalsP = np.array(new_evalsP)    \n",
    "print(new_evalsP)\n",
    "print(new_evalsP.sum(axis=1))\n",
    "df_papers[0]['screen_eval'] = new_evalsP.sum(axis=1)\n",
    "df_papers[0]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "f4442059-f9e6-4373-a9f5-a1c9a9932a7d",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "markdown",
   "id": "e81ab35b-b66b-4258-8ebe-f79096db523c",
   "metadata": {},
   "source": [
    "### 6. papers results extraction\n",
    "Только для статей с оценкой выше 0 !! Чтобы не загружать полный текст у всех\n",
    "\n",
    "+ надо посмотреть: если фул текст недоступен, то загружается ли абстракт"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "id": "be05918b-367f-416e-a00d-dbf331c1ff2e",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/38711893/unicode?api_key=6892c4129cef143ff92d11533848d2e0d908\n",
      "https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/40369167/unicode?api_key=6892c4129cef143ff92d11533848d2e0d908\n",
      "https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/41213063/unicode?api_key=6892c4129cef143ff92d11533848d2e0d908\n",
      "https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/40211189/unicode?api_key=6892c4129cef143ff92d11533848d2e0d908\n",
      "https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/40526090/unicode?api_key=6892c4129cef143ff92d11533848d2e0d908\n",
      "https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/40140597/unicode?api_key=6892c4129cef143ff92d11533848d2e0d908\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>PMID</th>\n",
       "      <th>Journal</th>\n",
       "      <th>Year</th>\n",
       "      <th>Month</th>\n",
       "      <th>Day</th>\n",
       "      <th>Title</th>\n",
       "      <th>Publication Type</th>\n",
       "      <th>Authors</th>\n",
       "      <th>Abstract</th>\n",
       "      <th>screen_eval</th>\n",
       "      <th>FullText</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>38711893</td>\n",
       "      <td>AME case reports</td>\n",
       "      <td>2024</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Partial response to crizotinib + regorafenib +...</td>\n",
       "      <td>Case Reports, Journal Article</td>\n",
       "      <td>Yingying Huang, Shuai Zhang, Xueqing Hu, Xiang...</td>\n",
       "      <td>Colorectal cancer (CRC) with the Raf murine sa...</td>\n",
       "      <td>3</td>\n",
       "      <td>Partial response to crizotinib + regorafenib +...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>40369167</td>\n",
       "      <td>Cell death and differentiation</td>\n",
       "      <td>2025</td>\n",
       "      <td>Nov</td>\n",
       "      <td></td>\n",
       "      <td>ARID1A loss enhances sensitivity to c-MET inhi...</td>\n",
       "      <td>Journal Article</td>\n",
       "      <td>Xu Zhang, Zihuan Wang, Yilin He, Kejin Wang, C...</td>\n",
       "      <td>ARID1A, a subunit of the SWI/SNF chromatin-rem...</td>\n",
       "      <td>3</td>\n",
       "      <td>ARID1A loss enhances sensitivity to c-MET inhi...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>41213063</td>\n",
       "      <td>Journal of environmental pathology, toxicology...</td>\n",
       "      <td>2025</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Radiotherapy-Related Autophagy Genes Predict P...</td>\n",
       "      <td>Journal Article</td>\n",
       "      <td>Mao Mao, Yichao Zhuang, Yan Chen</td>\n",
       "      <td>Numerous genes have been associated with color...</td>\n",
       "      <td>3</td>\n",
       "      <td>Radiotherapy-Related Autophagy Genes Predict P...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>40211189</td>\n",
       "      <td>BMC cancer</td>\n",
       "      <td>2025</td>\n",
       "      <td>Apr</td>\n",
       "      <td>10</td>\n",
       "      <td>A Phase Ia/b study of MEK1/2 inhibitor binimet...</td>\n",
       "      <td>Journal Article, Clinical Trial, Phase I</td>\n",
       "      <td>Francesca Aroldi, Elena Elez, Thierry André, G...</td>\n",
       "      <td>Targeting RAS mutant (MT) colorectal cancer (C...</td>\n",
       "      <td>2</td>\n",
       "      <td>A Phase Ia/b study of MEK1/2 inhibitor binimet...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>40526090</td>\n",
       "      <td>Oncotarget</td>\n",
       "      <td>2025</td>\n",
       "      <td>Jun</td>\n",
       "      <td>17</td>\n",
       "      <td>Case Report WIN-MTB-2023001 WIN International ...</td>\n",
       "      <td>Journal Article, Case Reports</td>\n",
       "      <td>Alberto Hernando-Calvo, Razelle Kurzrock, Nadi...</td>\n",
       "      <td>Heavily pretreated metastatic colorectal cance...</td>\n",
       "      <td>3</td>\n",
       "      <td>Case Report WIN-MTB-2023001 WIN International ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>40140597</td>\n",
       "      <td>BJC reports</td>\n",
       "      <td>2025</td>\n",
       "      <td>Mar</td>\n",
       "      <td>26</td>\n",
       "      <td>A phase Ia study of the MEK1/2 inhibitor PD-03...</td>\n",
       "      <td>Journal Article</td>\n",
       "      <td>Peter Gallagher, Christian Rolfo, Elena Elez, ...</td>\n",
       "      <td>Single-agent MEK1/2 inhibition has been disapp...</td>\n",
       "      <td>3</td>\n",
       "      <td>A phase Ia study of the MEK1/2 inhibitor PD-03...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>41268440</td>\n",
       "      <td>Frontiers in pharmacology</td>\n",
       "      <td>2025</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Case Report: HGF and NF1 mutations as putative...</td>\n",
       "      <td>Case Reports, Journal Article</td>\n",
       "      <td>Zhitao Chen, Shan Luo, Yangjun Gu, Qiyong Li</td>\n",
       "      <td>Hepatocellular carcinoma (HCC) is a highly agg...</td>\n",
       "      <td>-1</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "       PMID                                            Journal  Year Month  \\\n",
       "0  38711893                                   AME case reports  2024         \n",
       "1  40369167                     Cell death and differentiation  2025   Nov   \n",
       "2  41213063  Journal of environmental pathology, toxicology...  2025         \n",
       "3  40211189                                         BMC cancer  2025   Apr   \n",
       "4  40526090                                         Oncotarget  2025   Jun   \n",
       "5  40140597                                        BJC reports  2025   Mar   \n",
       "6  41268440                          Frontiers in pharmacology  2025         \n",
       "\n",
       "  Day                                              Title  \\\n",
       "0      Partial response to crizotinib + regorafenib +...   \n",
       "1      ARID1A loss enhances sensitivity to c-MET inhi...   \n",
       "2      Radiotherapy-Related Autophagy Genes Predict P...   \n",
       "3  10  A Phase Ia/b study of MEK1/2 inhibitor binimet...   \n",
       "4  17  Case Report WIN-MTB-2023001 WIN International ...   \n",
       "5  26  A phase Ia study of the MEK1/2 inhibitor PD-03...   \n",
       "6      Case Report: HGF and NF1 mutations as putative...   \n",
       "\n",
       "                           Publication Type  \\\n",
       "0             Case Reports, Journal Article   \n",
       "1                           Journal Article   \n",
       "2                           Journal Article   \n",
       "3  Journal Article, Clinical Trial, Phase I   \n",
       "4             Journal Article, Case Reports   \n",
       "5                           Journal Article   \n",
       "6             Case Reports, Journal Article   \n",
       "\n",
       "                                             Authors  \\\n",
       "0  Yingying Huang, Shuai Zhang, Xueqing Hu, Xiang...   \n",
       "1  Xu Zhang, Zihuan Wang, Yilin He, Kejin Wang, C...   \n",
       "2                   Mao Mao, Yichao Zhuang, Yan Chen   \n",
       "3  Francesca Aroldi, Elena Elez, Thierry André, G...   \n",
       "4  Alberto Hernando-Calvo, Razelle Kurzrock, Nadi...   \n",
       "5  Peter Gallagher, Christian Rolfo, Elena Elez, ...   \n",
       "6       Zhitao Chen, Shan Luo, Yangjun Gu, Qiyong Li   \n",
       "\n",
       "                                            Abstract  screen_eval  \\\n",
       "0  Colorectal cancer (CRC) with the Raf murine sa...            3   \n",
       "1  ARID1A, a subunit of the SWI/SNF chromatin-rem...            3   \n",
       "2  Numerous genes have been associated with color...            3   \n",
       "3  Targeting RAS mutant (MT) colorectal cancer (C...            2   \n",
       "4  Heavily pretreated metastatic colorectal cance...            3   \n",
       "5  Single-agent MEK1/2 inhibition has been disapp...            3   \n",
       "6  Hepatocellular carcinoma (HCC) is a highly agg...           -1   \n",
       "\n",
       "                                            FullText  \n",
       "0  Partial response to crizotinib + regorafenib +...  \n",
       "1  ARID1A loss enhances sensitivity to c-MET inhi...  \n",
       "2  Radiotherapy-Related Autophagy Genes Predict P...  \n",
       "3  A Phase Ia/b study of MEK1/2 inhibitor binimet...  \n",
       "4  Case Report WIN-MTB-2023001 WIN International ...  \n",
       "5  A phase Ia study of the MEK1/2 inhibitor PD-03...  \n",
       "6                                                     "
      ]
     },
     "execution_count": 13,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "pmid_list = df_papers[0][df_papers[0].screen_eval>=0].PMID.values.tolist()\n",
    "#['41213063',#'26451310',]\n",
    "\n",
    "res = pmid2biocxml(pmid_list, api_key=pubmed_api_key)\n",
    "#print(res)\n",
    "res = [parse_bioc_xml(r) for r in res]\n",
    "# transform the parsed xml into paper content\n",
    "papers0 = []\n",
    "for parsed in res:\n",
    "    paper_content = []\n",
    "    for parsed_ in parsed[\"passage\"]:\n",
    "        paper_content.append(parsed_['content'])\n",
    "    paper_content = \"\\n\".join(paper_content)\n",
    "    papers0.append(paper_content)\n",
    "\n",
    "df_papers[0]['FullText'] = ''\n",
    "df_papers[0].loc[df_papers[0].screen_eval>=0, 'FullText'] = papers0\n",
    "df_papers[0]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "id": "d91fcf9c-674f-4925-8978-01e16fe26c1c",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['Partial response to crizotinib + regorafenib + PD-1 inhibitor in a metastatic: Colorectal cancer (CRC) with the Raf murine sarcoma viral oncogene homolog B (\\nA 49-year-old Chinese male was diagnosed with ascending colon adenocarcinoma (cT3N+?M1) with liver metastases. The patient performed next-generation sequencing (NGS) using tissue and circulating tumor DNA (ctDNA), and the results showed a\\nThis study reported a co-existence of a']"
      ]
     },
     "execution_count": 14,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "splited = split_text_into_chunks(papers[0], chunk_size=600,\n",
    "                                             chunk_overlap=300)\n",
    "splited"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "85e33385-e79a-4fcb-8194-7d8da7b13cb5",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "id": "54a0905b-be96-46ca-bdf6-afb466c2ef32",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'Radiotherapy-Related Autophagy Genes Predict Prognosis and Reveal Immunoscape Features and Immunotherapeutic Agents in Colorectal Cancer Patients.\\nNumerous genes have been associated with colorectal cancer (CRC) treatment in prior studies, but the impact of radiotherapy-related autophagy genes (RRAGs) on CRC remains largely unexplored. The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases were implemented to screen out RRAGs significantly associated with survival, and a prognostic model was constructed. Samples were categorized into high- and low-risk groups with median riskscore. Immunomicroenvironment analysis, immunotherapy response prediction, enrichment analysis, tumor mutation analysis and drug prediction were performed in risk groups. Expression of signature genes in CRC cells was examined using quantitative reverse transcription polymerase chain reaction (qRT-PCR). There were 10 CRC-related RRAGs found. Prognostic models were built with RRAGs. Based on immune infiltration analysis, low-risk populations showed significantly greater levels of immune infiltration (P P ARHGEF17 mutation rate was 6%. Medications such as CGP-082996, Dasatinib, Erlotinib, and Salubrinal were more sensitive to high-risk group, whereas drugs such as FTI-277, DMOG, and Crizotinib were more sensitive to low-risk group. UGT1A6 and IRGM were significantly upregulated in tumor group as revealed by qRT-PCR. This study constructed a new prognostic model for CRC patients based on RRAGs, and a series of analysis results is conducive to providing more theoretical references and new insights into precision treatment of CRC patients.'"
      ]
     },
     "execution_count": 15,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "papers0[2]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "5befc147-ca2f-44f2-886c-b0c613cf1ec7",
   "metadata": {},
   "outputs": [],
   "source": [
    "{\n",
    "     \"fieldresult\": [\n",
    "       {\n",
    "         \"name\": \"Title\",\n",
    "         \"value\": \"Основы программирования на Python\",\n",
    "         \"source_id\": [104]\n",
    "       },\n",
    "       {\n",
    "         \"name\": \"Pages\",\n",
    "         \"value\": \"300 страниц\",\n",
    "         \"source_id\": [105]\n",
    "       }\n",
    "     ]\n",
    "   }"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "89e15617-0b13-4cbf-b117-a1d6e4041597",
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "        Format:\n",
    "        ```json\n",
    "        [\n",
    "            {{\n",
    "                \"name\":  \\\\ str, length <= 25 tokens\n",
    "                \"value\":  \\\\ str, length <= 25 tokens\n",
    "                \"source_id\":  \\\\ list[int], length <= 3 ids\n",
    "            }},\n",
    "            {{\n",
    "                \"name\":, \\\\ str, length <= 25 tokens\n",
    "                \"value\":  \\\\ str, length <= 25 tokens\n",
    "                \"source_id\":  \\\\ list[int], length <= 3 ids\n",
    "            }},\n",
    "            ...\n",
    "        ]\n",
    "        ```\n",
    "    \\\"\\\"\\\"\n",
    "```\n",
    "    \n",
    "    \n",
    "new\n",
    "```json\n",
    "        [\n",
    "            {{\n",
    "                \"name\": \"fieldName1\",\n",
    "                \"value\": \"extractedInfo1\",\n",
    "                \"source_id\":[source1, source2, ...]\n",
    "            }},\n",
    "            {{\n",
    "                \"name\":[\"fieldName2\"],\n",
    "                \"value\":[\"extractedInfo2\"],\n",
    "                \"source_id\":[source1, source2, ...]\n",
    "            }},\n",
    "            ...\n",
    "        ]\n",
    "```"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "id": "cd09b9af-5299-40eb-a633-c5dc082895e6",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'$defs': {'FieldResult': {'properties': {'name': {'description': 'Field name that accurately represents the content of the field based on its description.',\n",
       "     'maxLength': 25,\n",
       "     'title': 'Name',\n",
       "     'type': 'string'},\n",
       "    'value': {'description': 'Extracted information from the text based on the field description.',\n",
       "     'maxLength': 50,\n",
       "     'title': 'Value',\n",
       "     'type': 'string'},\n",
       "    'source_id': {'description': 'Cited document IDs.',\n",
       "     'items': {'type': 'integer'},\n",
       "     'maxItems': 3,\n",
       "     'minItems': 1,\n",
       "     'title': 'Source Id',\n",
       "     'type': 'array'}},\n",
       "   'required': ['name', 'value', 'source_id'],\n",
       "   'title': 'FieldResult',\n",
       "   'type': 'object'}},\n",
       " 'properties': {'fieldresult': {'$ref': '#/$defs/FieldResult'}},\n",
       " 'required': ['fieldresult'],\n",
       " 'title': 'Results',\n",
       " 'type': 'object'}"
      ]
     },
     "execution_count": 26,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "from pydantic import BaseModel, validator, Field, conlist  # This is the new version\n",
    "from typing import Dict, Literal\n",
    "class FieldResult(BaseModel):\n",
    "    name: str = Field(description='Field name that accurately represents the content of the field based on its description.',\n",
    "                     max_length=25)\n",
    "    value: str = Field(description='Extracted information from the text based on the field description.',\n",
    "                      max_length=50)\n",
    "    source_id: conlist(int,min_length=1, max_length=3) = Field(description='Cited document IDs.')\n",
    "    \n",
    "class Results(BaseModel):\n",
    "    fieldresult: FieldResult\n",
    "    \n",
    "Results.model_json_schema()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 69,
   "id": "23b92842-78c9-4a6f-aef5-bc6c9bbae158",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "ename": "SyntaxError",
     "evalue": "trailing comma not allowed without surrounding parentheses (1178800490.py, line 1)",
     "output_type": "error",
     "traceback": [
      "  \u001b[36mCell\u001b[39m\u001b[36m \u001b[39m\u001b[32mIn[69]\u001b[39m\u001b[32m, line 1\u001b[39m\n\u001b[31m    \u001b[39m\u001b[31mfrom pydantic import BaseModel, validator, Field, conlist,   # This is the new version\u001b[39m\n                                                                 ^\n\u001b[31mSyntaxError\u001b[39m\u001b[31m:\u001b[39m trailing comma not allowed without surrounding parentheses\n"
     ]
    }
   ],
   "source": [
    "from pydantic import BaseModel, validator, Field, conlist,   # This is the new version\n",
    "from typing import Dict, Literal\n",
    "import pydantic\n",
    "import random\n",
    "class Nested(pydantic.BaseModel):\n",
    "    a: str = pydantic.Field(examples=[\"hello\"])\n",
    "\n",
    "\n",
    "class ExampleData(pydantic.BaseModel):\n",
    "    a: int = pydantic.Field(examples=[1])\n",
    "    b: str = pydantic.Field(min_length=10, max_length=10, examples=[\"abc-123-45\"])\n",
    "    c: int = pydantic.Field(default=100)\n",
    "    # Note: Example will be populated by child, so no explicit example needs\n",
    "    # to be provided for nested models\n",
    "    n: Nested\n",
    "    \n",
    "nn = 1    \n",
    "class FieldResult(BaseModel):\n",
    "    name: str = Field(description='Field name that accurately represents the content of the field based on its description.',\n",
    "                     max_length=25, default='effectiveness')\n",
    "    value: str = Field(description='Extracted information from the text based on the field description.',\n",
    "                      max_length=50, default='total of 5% died')\n",
    "    #source_id: conlist(int,min_length=1, max_length=3) = Field(description='Cited document IDs.', examples=[1,3])\n",
    "    \n",
    "class Results(BaseModel):\n",
    "    fieldresult: list[FieldResult]\n",
    "\n",
    "    \n",
    "def populate_with_examples_recursive(model: pydantic.BaseModel) -> dict:\n",
    "    \"\"\"Populate fields with example values\"\"\"\n",
    "\n",
    "    result = {}\n",
    "    \n",
    "    for name, field_info in model.model_fields.items():\n",
    "        if issubclass(field_info.annotation, pydantic.BaseModel):\n",
    "            result[name] = populate_with_examples_recursive(field_info.annotation)\n",
    "        elif field_info.examples:\n",
    "            result[name] = random.choice(field_info.examples)\n",
    "        elif field_info.default:\n",
    "            result[name] = field_info.default\n",
    "\n",
    "    return dict(result)\n",
    "\n",
    "\n",
    "# Execute it:\n",
    "#json.loads(f'''{populate_with_examples_recursive(ExampleData)}''')\n",
    "\n",
    "(populate_with_examples_recursive(Results))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 83,
   "id": "e47f8ef2-74f7-4614-8c2c-f461044b4c6c",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "ename": "ValidationError",
     "evalue": "1 validation error for FieldResult\nsource_id\n  Field required [type=missing, input_value={}, input_type=dict]\n    For further information visit https://errors.pydantic.dev/2.12/v/missing",
     "output_type": "error",
     "traceback": [
      "\u001b[31m---------------------------------------------------------------------------\u001b[39m",
      "\u001b[31mValidationError\u001b[39m                           Traceback (most recent call last)",
      "\u001b[36mCell\u001b[39m\u001b[36m \u001b[39m\u001b[32mIn[83]\u001b[39m\u001b[32m, line 11\u001b[39m\n\u001b[32m      8\u001b[39m \u001b[38;5;28;01mclass\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[34;01mResults\u001b[39;00m(BaseModel):\n\u001b[32m      9\u001b[39m     fieldresult: \u001b[38;5;28mlist\u001b[39m[FieldResult]\n\u001b[32m---> \u001b[39m\u001b[32m11\u001b[39m a1 = \u001b[43mFieldResult\u001b[49m\u001b[43m(\u001b[49m\u001b[43m)\u001b[49m\n\u001b[32m     12\u001b[39m a = Results(fieldresult=[a1,a1])\n\u001b[32m     14\u001b[39m \u001b[38;5;28mprint\u001b[39m(a.model_dump_json(indent=\u001b[32m4\u001b[39m))\n",
      "\u001b[36mFile \u001b[39m\u001b[32m~\\anaconda3\\envs\\llms\\Lib\\site-packages\\pydantic\\main.py:250\u001b[39m, in \u001b[36mBaseModel.__init__\u001b[39m\u001b[34m(self, **data)\u001b[39m\n\u001b[32m    248\u001b[39m \u001b[38;5;66;03m# `__tracebackhide__` tells pytest and some other tools to omit this function from tracebacks\u001b[39;00m\n\u001b[32m    249\u001b[39m __tracebackhide__ = \u001b[38;5;28;01mTrue\u001b[39;00m\n\u001b[32m--> \u001b[39m\u001b[32m250\u001b[39m validated_self = \u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43m__pydantic_validator__\u001b[49m\u001b[43m.\u001b[49m\u001b[43mvalidate_python\u001b[49m\u001b[43m(\u001b[49m\u001b[43mdata\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mself_instance\u001b[49m\u001b[43m=\u001b[49m\u001b[38;5;28;43mself\u001b[39;49m\u001b[43m)\u001b[49m\n\u001b[32m    251\u001b[39m \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;28mself\u001b[39m \u001b[38;5;129;01mis\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m validated_self:\n\u001b[32m    252\u001b[39m     warnings.warn(\n\u001b[32m    253\u001b[39m         \u001b[33m'\u001b[39m\u001b[33mA custom validator is returning a value other than `self`.\u001b[39m\u001b[38;5;130;01m\\n\u001b[39;00m\u001b[33m'\u001b[39m\n\u001b[32m    254\u001b[39m         \u001b[33m\"\u001b[39m\u001b[33mReturning anything other than `self` from a top level model validator isn\u001b[39m\u001b[33m'\u001b[39m\u001b[33mt supported when validating via `__init__`.\u001b[39m\u001b[38;5;130;01m\\n\u001b[39;00m\u001b[33m\"\u001b[39m\n\u001b[32m    255\u001b[39m         \u001b[33m'\u001b[39m\u001b[33mSee the `model_validator` docs (https://docs.pydantic.dev/latest/concepts/validators/#model-validators) for more details.\u001b[39m\u001b[33m'\u001b[39m,\n\u001b[32m    256\u001b[39m         stacklevel=\u001b[32m2\u001b[39m,\n\u001b[32m    257\u001b[39m     )\n",
      "\u001b[31mValidationError\u001b[39m: 1 validation error for FieldResult\nsource_id\n  Field required [type=missing, input_value={}, input_type=dict]\n    For further information visit https://errors.pydantic.dev/2.12/v/missing"
     ]
    }
   ],
   "source": [
    "class FieldResult(BaseModel):\n",
    "    name: str = Field(description='Field name that accurately represents the content of the field based on its description.',\n",
    "                     max_length=25, default='effectiveness')\n",
    "    value: str = Field(description='Extracted information from the text based on the field description.',\n",
    "                      max_length=50, default='total of 5% died')\n",
    "    source_id: list[int] = Field(description='Cited document IDs.', examples=[1,3])\n",
    "    #conlist ,min_length=1, max_length=3\n",
    "class Results(BaseModel):\n",
    "    fieldresult: list[FieldResult]\n",
    "\n",
    "a1 = FieldResult()\n",
    "a = Results(fieldresult=[a1,a1])\n",
    "\n",
    "print(a.model_dump_json(indent=4))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "id": "00bbfbcd-bfb7-4126-900e-65b92a036230",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['Partial response to crizotinib + regorafenib + PD-1 inhibitor in a metastatic: Colorectal cancer (CRC) with the Raf murine sarcoma viral oncogene homolog B (\\nA 49-year-old Chinese male was diagnosed with ascending colon adenocarcinoma (cT3N+?M1) with liver metastases. The patient performed next-generation sequencing (NGS) using tissue and circulating tumor DNA (ctDNA), and the results showed a\\nThis study reported a co-existence of a',\n",
       " 'ARID1A loss enhances sensitivity to c-MET inhibition by dual targeting of GPX4 and iron homeostasis, inducing ferroptosis.: ARID1A, a subunit of the SWI/SNF chromatin-remodeling complex, functions as a tumor suppressor in various cancer types. Owing to its high frequency of inactivating mutations, ARID1A has emerged as a promising target for the development of anticancer drugs. In this study, we report that ARID1A-deficient colorectal cancer (CRC) cells induce synthetic lethality when treated with inhibitors of c-MET receptor tyrosine kinase. c-MET specific inhibitor PHA-665752 as well as two other FDA-approved drugs, crizotinib and cabozantinib, selectively inhibited the growth of ARID1A-deficient CRC cells in vitro and in xenograft tumor models. Mechanistically, we identified a tripartite functional association among ARID1A, c-MET, and NRF2, where ARID1A and c-MET pathways converge on the NRF2 transcription factor, which regulates the transcription of GPX4, a key regulator of ferroptosis. ARID1A inactivation reduces c-MET expression, decreasing NRF2 nuclear localization and its binding to the GPX4 promoter, resulting in reduced GPX4 transcription. This creates a cellular dependency on the residual c-MET for minimal GPX4 expression to survive the ferroptotic cell death. Additionally, we demonstrate that ARID1A loss leads to increased intracellular labile iron accumulation by downregulating the iron-exporting protein SLC40A1, thereby increasing cellular susceptibility to ferroptosis. Inhibition of c-MET in ARID1A-deficient CRC cells diminishes GPX4 expression, resulting in elevated lipid peroxidation and glutathione depletion, ultimately inducing ferroptosis. This study reveals a novel synthetic lethal relationship between ARID1A and c-MET signaling in promoting ferroptosis and proposes c-MET inhibitors as a potential therapeutic strategy for ARID1A-deficient CRC.']"
      ]
     },
     "execution_count": 27,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "papers[:2]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 53,
   "id": "9b1d2861-abc0-45d6-b7c6-874dfd60514e",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['',\n",
       " 'Partial response to crizotinib + regorafenib + PD-1 inhibitor in a metastatic: Colorectal cancer (CRC) with the Raf murine sarcoma viral oncogene homolog B (\\nA 49-year-old Chinese male was diagnosed with ascending colon adenocarcinoma (cT3N+?M1) with liver metastases. The patient performed next-generation sequencing (NGS) using tissue and circulating tumor DNA (ctDNA), and the results showed a\\nThis study reported a co-existence of a',\n",
       " 'ARID1A loss enhances sensitivity to c-MET inhibition by dual targeting of GPX4 and iron homeostasis, inducing ferroptosis.: ARID1A, a subunit of the SWI/SNF chromatin-remodeling complex, functions as a tumor suppressor in various cancer types. Owing to its high frequency of inactivating mutations, ARID1A has emerged as a promising target for the development of anticancer drugs. In this study, we report that ARID1A-deficient colorectal cancer (CRC) cells induce synthetic lethality when treated with inhibitors of c-MET receptor tyrosine kinase. c-MET specific inhibitor PHA-665752 as well as two other FDA-approved drugs, crizotinib and cabozantinib, selectively inhibited the growth of ARID1A-deficient CRC cells in vitro and in xenograft tumor models. Mechanistically, we identified a tripartite functional association among ARID1A, c-MET, and NRF2, where ARID1A and c-MET pathways converge on the NRF2 transcription factor, which regulates the transcription of GPX4, a key regulator of ferroptosis. ARID1A inactivation reduces c-MET expression, decreasing NRF2 nuclear localization and its binding to the GPX4 promoter, resulting in reduced GPX4 transcription. This creates a cellular dependency on the residual c-MET for minimal GPX4 expression to survive the ferroptotic cell death. Additionally, we demonstrate that ARID1A loss leads to increased intracellular labile iron accumulation by downregulating the iron-exporting protein SLC40A1, thereby increasing cellular susceptibility to ferroptosis. Inhibition of c-MET in ARID1A-deficient CRC cells diminishes GPX4 expression, resulting in elevated lipid peroxidation and glutathione depletion, ultimately inducing ferroptosis. This study reveals a novel synthetic lethal relationship between ARID1A and c-MET signaling in promoting ferroptosis and proposes c-MET inhibitors as a potential therapeutic strategy for ARID1A-deficient CRC.']"
      ]
     },
     "execution_count": 53,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 54,
   "id": "d71c255e-1f6c-429c-8e14-3c03f724a1bd",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "You are now the following python function: ```\n",
      "def extract_fields_from_input_study(inputs: Dict[str, Any]) -> str:\n",
      "    \"\"\"\n",
      "    This function is tasked with analyzing clinical trial study reports or papers to extract specific information as structured data and provide citations for the extracted information.\n",
      "    The user will provide a list of fields they are interested in, along with a natural language description for each field to guide you on what content to look for and from which parts of the report to extract it.\n",
      "\n",
      "    IMPORTANT:\n",
      "    For each field described by the user, you need to:\n",
      "    1. Identify and extract the relevant information from the report, based on the provided description.\n",
      "    2. Generate a field name that accurately represents the content of the field based on its description.\n",
      "    3. Structure the extracted information into a standard format whenever possible (e.g., integer, numerical values, dates, keywords, list of terms). \n",
      "        If standardization is not possible, the information should be presented in text format.\n",
      "        If the field is not found in the report, the extracted value should be \"NP\".\n",
      "    4. Provide a reference to the document ID from which this information was extracted.\n",
      "        This citation id should be restricted to be integers only.\n",
      "        You should NOT cite more than three sources for a single field.\n",
      "        You should try your best to provide the most relevant and specific citation for each field.\n",
      "        If two or more sources are equally relevant, you can just cite one of them.\n",
      "\n",
      "    The function returns a string representing a dictionary with each key representing a field and its extracted value.\n",
      "\n",
      "# User provided inputs\n",
      "paper_content = \"\"\"{paper_content}\"\"\"\n",
      "fields = \"\"\"{fields}\"\"\"\n",
      "\n",
      "inputs = {{\n",
      "    \"paper_content\": paper_content,\n",
      "    \"fields\": fields\n",
      "}}\n",
      "\n",
      "# Reply Format: \n",
      "Return the information in the following JSON-format.\n",
      "```json\n",
      "{{        \n",
      "    [\n",
      "        {{\n",
      "            \"name\": \"fieldName1\",\n",
      "            \"value\": \"extractedInfo1\",\n",
      "            \"source_id\":[source1, source2, ...]\n",
      "        }},\n",
      "        {{\n",
      "            \"name\":\"fieldName2\",\n",
      "            \"value\":\"extractedInfo2\",\n",
      "            \"source_id\":[source1, source2, ...]\n",
      "        }},\n",
      "        ...\n",
      "    ]\n",
      "}}\n",
      "```\n",
      "You MUST return ONLY valid JSON, Do NOT include any explanations, comments, or extra text.\n",
      "\n",
      "1\n",
      "\n",
      "parsed_results in asynch ['```json\\n[\\n  {\\n    \"name\": \"Crizotinib_Results\",\\n    \"value\": \"NP\",\\n    \"source_id\": []\\n  },\\n  {\\n    \"name\": \"Participants\",\\n    \"value\": \"NP\",\\n    \"source_id\": []\\n  }\\n]\\n```']\n",
      "\n",
      "parsed_results in asynch ['```json\\n[\\n  {\\n    \"name\": \"Crizotinib Results\",\\n    \"value\": \"main results of the study regarding Crizotinib about treatment effectiveness\",\\n    \"source_id\": [\"0\"]\\n  },\\n  {\\n    \"name\": \"Participants\",\\n    \"value\": \"number of participants\",\\n    \"source_id\": [\"0\"]\\n  }\\n]\\n```']\n",
      "\n",
      "parsed_results in asynch ['```json\\n[\\n  {\\n    \"name\": \"Crizotinib Results\",\\n    \"value\": \"selectively inhibited the growth of ARID1A-deficient CRC cells in vitro and in xenograft tumor models.\",\\n    \"source_id\": [\"3\", \"4\"]\\n  },\\n  {\\n    \"name\": \"Participants\",\\n    \"value\": \"NP\",\\n    \"source_id\": []\\n  }\\n]\\n```']\n",
      "\n",
      "outputs: ['```json\\n[\\n  {\\n    \"name\": \"Crizotinib_Results\",\\n    \"value\": \"NP\",\\n    \"source_id\": []\\n  },\\n  {\\n    \"name\": \"Participants\",\\n    \"value\": \"NP\",\\n    \"source_id\": []\\n  }\\n]\\n```', '```json\\n[\\n  {\\n    \"name\": \"Crizotinib Results\",\\n    \"value\": \"main results of the study regarding Crizotinib about treatment effectiveness\",\\n    \"source_id\": [\"0\"]\\n  },\\n  {\\n    \"name\": \"Participants\",\\n    \"value\": \"number of participants\",\\n    \"source_id\": [\"0\"]\\n  }\\n]\\n```', '```json\\n[\\n  {\\n    \"name\": \"Crizotinib Results\",\\n    \"value\": \"selectively inhibited the growth of ARID1A-deficient CRC cells in vitro and in xenograft tumor models.\",\\n    \"source_id\": [\"3\", \"4\"]\\n  },\\n  {\\n    \"name\": \"Participants\",\\n    \"value\": \"NP\",\\n    \"source_id\": []\\n  }\\n]\\n```']\n",
      "\n",
      "parsed_outputs: [[{'name': 'Crizotinib_Results', 'value': 'NP', 'source_id': []}, {'name': 'Participants', 'value': 'NP', 'source_id': []}], [{'name': 'Crizotinib Results', 'value': 'main results of the study regarding Crizotinib about treatment effectiveness', 'source_id': ['0']}, {'name': 'Participants', 'value': 'number of participants', 'source_id': ['0']}], [{'name': 'Crizotinib Results', 'value': 'selectively inhibited the growth of ARID1A-deficient CRC cells in vitro and in xenograft tumor models.', 'source_id': ['3', '4']}, {'name': 'Participants', 'value': 'NP', 'source_id': []}]]\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "[[{'name': 'Crizotinib_Results',\n",
       "   'value': 'NP',\n",
       "   'source_id': [],\n",
       "   'cited_blocks': []},\n",
       "  {'name': 'Participants',\n",
       "   'value': 'NP',\n",
       "   'source_id': [],\n",
       "   'cited_blocks': []}],\n",
       " [{'name': 'Crizotinib Results',\n",
       "   'value': 'main results of the study regarding Crizotinib about treatment effectiveness',\n",
       "   'source_id': ['0'],\n",
       "   'cited_blocks': ['Partial response to crizotinib + regorafenib + PD-1 inhibitor in a metastatic: Colorectal cancer (CRC) with the Raf murine sarcoma viral oncogene homolog B (\\nA 49-year-old Chinese male was diagnosed with ascending colon adenocarcinoma (cT3N+?M1) with liver metastases. The patient performed next-generation sequencing (NGS) using tissue and circulating tumor DNA (ctDNA), and the results showed a\\nThis study reported a co-existence of a']},\n",
       "  {'name': 'Participants',\n",
       "   'value': 'number of participants',\n",
       "   'source_id': ['0'],\n",
       "   'cited_blocks': ['Partial response to crizotinib + regorafenib + PD-1 inhibitor in a metastatic: Colorectal cancer (CRC) with the Raf murine sarcoma viral oncogene homolog B (\\nA 49-year-old Chinese male was diagnosed with ascending colon adenocarcinoma (cT3N+?M1) with liver metastases. The patient performed next-generation sequencing (NGS) using tissue and circulating tumor DNA (ctDNA), and the results showed a\\nThis study reported a co-existence of a']}],\n",
       " [{'name': 'Crizotinib Results',\n",
       "   'value': 'selectively inhibited the growth of ARID1A-deficient CRC cells in vitro and in xenograft tumor models.',\n",
       "   'source_id': ['3', '4'],\n",
       "   'cited_blocks': ['FDA-approved drugs, crizotinib and cabozantinib, selectively inhibited the growth of ARID1A-deficient CRC cells in vitro and in xenograft tumor models. Mechanistically, we identified a tripartite functional association among ARID1A, c-MET, and NRF2, where ARID1A and c-MET pathways converge on the NRF2 transcription factor, which regulates the transcription of GPX4, a key regulator of ferroptosis. ARID1A inactivation reduces c-MET expression, decreasing NRF2 nuclear localization and its binding to the GPX4 promoter, resulting in reduced GPX4 transcription. This creates a cellular dependency on',\n",
       "    'residual c-MET for minimal GPX4 expression to survive the ferroptotic cell death. Additionally, we demonstrate that ARID1A loss leads to increased intracellular labile iron accumulation by downregulating the iron-exporting protein SLC40A1, thereby increasing cellular susceptibility to ferroptosis. Inhibition of c-MET in ARID1A-deficient CRC cells diminishes GPX4 expression, resulting in elevated lipid peroxidation and glutathione depletion, ultimately inducing ferroptosis. This study reveals a novel synthetic lethal relationship between ARID1A and c-MET signaling in promoting ferroptosis and']},\n",
       "  {'name': 'Participants',\n",
       "   'value': 'NP',\n",
       "   'source_id': [],\n",
       "   'cited_blocks': []}]]"
      ]
     },
     "execution_count": 54,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "\n",
    "api = StudyCharacteristicsExtraction()\n",
    "extracted = api.run(\n",
    "    papers=['',*papers[:2]],\n",
    "    fields=['Crizotinib Results, string, main results of the study regarding Crizotinib about treatment effectiveness',\n",
    "           'Participants, string, number of participants'],#api.DEFAULT_FIELDS,\n",
    "    llm=os.getenv(\"MODEL_NAME\"),\n",
    "    chunk_size=600,\n",
    "    chunk_overlap=300,\n",
    "    thinking=False,\n",
    ")\n",
    "extracted"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "3bf57af4-12ea-467f-a9fe-626409d99cd3",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 56,
   "id": "6c56a5d4-cb26-4961-8f94-dd99ca18b60f",
   "metadata": {
    "tags": []
   },
   "outputs": [],
   "source": [
    "os.environ[\"BASE_URL\"] = \"https://router.huggingface.co/v1\"\n",
    "os.environ[\"MODEL_NAME\"] ='Qwen/Qwen3-32B'\n",
    "os.environ[\"OPENAI_API_KEY\"] = os.getenv(\"HUGGINGFACE_HUB_TOKEN\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 59,
   "id": "c0ac0fe2-424f-4c3b-afb6-a2e48916737a",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "You are now the following python function: ```\n",
      "def extract_fields_from_input_study(inputs: Dict[str, Any]) -> str:\n",
      "    \"\"\"\n",
      "    This function is tasked with analyzing clinical trial study reports or papers to extract specific information as structured data and provide citations for the extracted information.\n",
      "    The user will provide a list of fields they are interested in, along with a natural language description for each field to guide you on what content to look for and from which parts of the report to extract it.\n",
      "\n",
      "    IMPORTANT:\n",
      "    For each field described by the user, you need to:\n",
      "    1. Identify and extract the relevant information from the report, based on the provided description.\n",
      "    2. Generate a field name that accurately represents the content of the field based on its description.\n",
      "    3. Structure the extracted information into a standard format whenever possible (e.g., integer, numerical values, dates, keywords, list of terms). \n",
      "        If standardization is not possible, the information should be presented in text format.\n",
      "        If the field is not found in the report, the extracted value should be \"NP\".\n",
      "    4. Provide a reference to the document ID from which this information was extracted.\n",
      "        This citation id should be restricted to be integers only.\n",
      "        You should NOT cite more than three sources for a single field.\n",
      "        You should try your best to provide the most relevant and specific citation for each field.\n",
      "        If two or more sources are equally relevant, you can just cite one of them.\n",
      "\n",
      "    The function returns a string representing a dictionary with each key representing a field and its extracted value.\n",
      "\n",
      "# User provided inputs\n",
      "paper_content = \"\"\"{paper_content}\"\"\"\n",
      "fields = \"\"\"{fields}\"\"\"\n",
      "\n",
      "inputs = {{\n",
      "    \"paper_content\": paper_content,\n",
      "    \"fields\": fields\n",
      "}}\n",
      "\n",
      "# Reply Format: \n",
      "Return the information in the following JSON-format.\n",
      "```json\n",
      "{{        \n",
      "    [\n",
      "        {{\n",
      "            \"name\": \"fieldName1\",\n",
      "            \"value\": \"extractedInfo1\",\n",
      "            \"source_id\":[source1, source2, ...]\n",
      "        }},\n",
      "        {{\n",
      "            \"name\":\"fieldName2\",\n",
      "            \"value\":\"extractedInfo2\",\n",
      "            \"source_id\":[source1, source2, ...]\n",
      "        }},\n",
      "        ...\n",
      "    ]\n",
      "}}\n",
      "```\n",
      "You MUST return ONLY valid JSON, Do NOT include any explanations, comments, or extra text.\n",
      "\n",
      "1\n",
      "\n",
      "parsed_results in asynch ['{\"name\": \"Crizotinib Results\", \"value\": \"NP\", \"source_id\": []}']\n",
      "\n",
      "parsed_results in asynch ['{\"name\": \"Crizotinib Results\", \"value\": \"Partial response to crizotinib + regorafenib + PD-1 inhibitor in a metastatic: Colorectal cancer (CRC) with the Raf murine sarcoma viral oncogene homolog B\", \"source_id\": [0], \"id\": 1, \"type\": \"string\", \"description\": \"main results of the study regarding Crizotinib about treatment effectiveness\"}']\n",
      "\n",
      "parsed_results in asynch ['{\"Crizotinib Results, string, main results of the study regarding Crizotinib about treatment effectiveness\": \"FDA-approved drugs, crizotinib and cabozantinib, selectively inhibited the growth of ARID1A-deficient CRC cells in vitro and in xenograft tumor models.\", \"source_id\": [0, 3], \"Participants, string, number of participants\": \"NP\", \"source_id\": []}']\n",
      "\n",
      "outputs: ['{\"name\": \"Crizotinib Results\", \"value\": \"NP\", \"source_id\": []}', '{\"name\": \"Crizotinib Results\", \"value\": \"Partial response to crizotinib + regorafenib + PD-1 inhibitor in a metastatic: Colorectal cancer (CRC) with the Raf murine sarcoma viral oncogene homolog B\", \"source_id\": [0], \"id\": 1, \"type\": \"string\", \"description\": \"main results of the study regarding Crizotinib about treatment effectiveness\"}', '{\"Crizotinib Results, string, main results of the study regarding Crizotinib about treatment effectiveness\": \"FDA-approved drugs, crizotinib and cabozantinib, selectively inhibited the growth of ARID1A-deficient CRC cells in vitro and in xenograft tumor models.\", \"source_id\": [0, 3], \"Participants, string, number of participants\": \"NP\", \"source_id\": []}']\n",
      "\n",
      "parsed_outputs: [{'name': 'Crizotinib Results', 'value': 'NP', 'source_id': []}, {'name': 'Crizotinib Results', 'value': 'Partial response to crizotinib + regorafenib + PD-1 inhibitor in a metastatic: Colorectal cancer (CRC) with the Raf murine sarcoma viral oncogene homolog B', 'source_id': [0], 'id': 1, 'type': 'string', 'description': 'main results of the study regarding Crizotinib about treatment effectiveness'}, {'Crizotinib Results, string, main results of the study regarding Crizotinib about treatment effectiveness': 'FDA-approved drugs, crizotinib and cabozantinib, selectively inhibited the growth of ARID1A-deficient CRC cells in vitro and in xenograft tumor models.', 'source_id': [], 'Participants, string, number of participants': 'NP'}]\n"
     ]
    },
    {
     "ename": "AttributeError",
     "evalue": "'str' object has no attribute 'get'",
     "output_type": "error",
     "traceback": [
      "\u001b[31m---------------------------------------------------------------------------\u001b[39m",
      "\u001b[31mAttributeError\u001b[39m                            Traceback (most recent call last)",
      "\u001b[36mCell\u001b[39m\u001b[36m \u001b[39m\u001b[32mIn[59]\u001b[39m\u001b[32m, line 2\u001b[39m\n\u001b[32m      1\u001b[39m api = StudyCharacteristicsExtraction()\n\u001b[32m----> \u001b[39m\u001b[32m2\u001b[39m extracted = \u001b[43mapi\u001b[49m\u001b[43m.\u001b[49m\u001b[43mrun\u001b[49m\u001b[43m(\u001b[49m\n\u001b[32m      3\u001b[39m \u001b[43m    \u001b[49m\u001b[43mpapers\u001b[49m\u001b[43m=\u001b[49m\u001b[43m[\u001b[49m\u001b[33;43m'\u001b[39;49m\u001b[33;43m'\u001b[39;49m\u001b[43m,\u001b[49m\u001b[43m*\u001b[49m\u001b[43mpapers\u001b[49m\u001b[43m[\u001b[49m\u001b[43m:\u001b[49m\u001b[32;43m2\u001b[39;49m\u001b[43m]\u001b[49m\u001b[43m]\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m      4\u001b[39m \u001b[43m    \u001b[49m\u001b[43mfields\u001b[49m\u001b[43m=\u001b[49m\u001b[43m[\u001b[49m\u001b[33;43m'\u001b[39;49m\u001b[33;43mCrizotinib Results, string, main results of the study regarding Crizotinib about treatment effectiveness\u001b[39;49m\u001b[33;43m'\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[32m      5\u001b[39m \u001b[43m           \u001b[49m\u001b[33;43m'\u001b[39;49m\u001b[33;43mParticipants, string, number of participants\u001b[39;49m\u001b[33;43m'\u001b[39;49m\u001b[43m]\u001b[49m\u001b[43m,\u001b[49m\u001b[38;5;66;43;03m#api.DEFAULT_FIELDS,\u001b[39;49;00m\n\u001b[32m      6\u001b[39m \u001b[43m    \u001b[49m\u001b[43mllm\u001b[49m\u001b[43m=\u001b[49m\u001b[43mos\u001b[49m\u001b[43m.\u001b[49m\u001b[43mgetenv\u001b[49m\u001b[43m(\u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mMODEL_NAME\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m)\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m      7\u001b[39m \u001b[43m    \u001b[49m\u001b[43mchunk_size\u001b[49m\u001b[43m=\u001b[49m\u001b[32;43m600\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[32m      8\u001b[39m \u001b[43m    \u001b[49m\u001b[43mchunk_overlap\u001b[49m\u001b[43m=\u001b[49m\u001b[32;43m300\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[32m      9\u001b[39m \u001b[43m    \u001b[49m\u001b[43mthinking\u001b[49m\u001b[43m=\u001b[49m\u001b[38;5;28;43;01mTrue\u001b[39;49;00m\u001b[43m,\u001b[49m\n\u001b[32m     10\u001b[39m \u001b[43m)\u001b[49m\n\u001b[32m     11\u001b[39m extracted\n",
      "\u001b[36mFile \u001b[39m\u001b[32m~\\Documents\\GitHub\\TrialMind-SLR\\trialmind\\api.py:41\u001b[39m, in \u001b[36mrun\u001b[39m\u001b[34m(self, papers, fields, llm, batch_size, semantic_filtering, semantic_filtering_top_k, chunk_size, chunk_overlap, thinking)\u001b[39m\n\u001b[32m      0\u001b[39m <Error retrieving source code with stack_data see ipython/ipython#13598>\n",
      "\u001b[31mAttributeError\u001b[39m: 'str' object has no attribute 'get'"
     ]
    }
   ],
   "source": [
    "\n",
    "api = StudyCharacteristicsExtraction()\n",
    "extracted = api.run(\n",
    "    papers=['',*papers[:2]],\n",
    "    fields=['Crizotinib Results, string, main results of the study regarding Crizotinib about treatment effectiveness',\n",
    "           'Participants, string, number of participants'],#api.DEFAULT_FIELDS,\n",
    "    llm=os.getenv(\"MODEL_NAME\"),\n",
    "    chunk_size=600,\n",
    "    chunk_overlap=300,\n",
    "    thinking=True,\n",
    ")\n",
    "extracted"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "e6851581-7194-4798-a091-468786a6734a",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "markdown",
   "id": "fcc2864f-dc61-4eb8-a720-c4f9040724b5",
   "metadata": {
    "jp-MarkdownHeadingCollapsed": true,
    "tags": []
   },
   "source": [
    "# d"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 81,
   "id": "c69ff7c4-4e91-4afc-bdae-ec1fbf094012",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/40140597/unicode?api_key=6892c4129cef143ff92d11533848d2e0d908\n",
      "https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/40211189/unicode?api_key=6892c4129cef143ff92d11533848d2e0d908\n",
      "https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/40526090/unicode?api_key=6892c4129cef143ff92d11533848d2e0d908\n",
      "https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/41213063/unicode?api_key=6892c4129cef143ff92d11533848d2e0d908\n",
      "https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/41268440/unicode?api_key=6892c4129cef143ff92d11533848d2e0d908\n",
      "https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/38711893/unicode?api_key=6892c4129cef143ff92d11533848d2e0d908\n",
      "https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/40369167/unicode?api_key=6892c4129cef143ff92d11533848d2e0d908\n"
     ]
    }
   ],
   "source": [
    "pmid_list = df_papers[0].PMID.values.tolist()\n",
    "#['41213063',#'26451310',]\n",
    "\n",
    "res = pmid2biocxml(pmid_list, api_key=pubmed_api_key)\n",
    "#print(res)\n",
    "res = [parse_bioc_xml(r) for r in res]\n",
    "# transform the parsed xml into paper content\n",
    "papers0 = []\n",
    "for parsed in res:\n",
    "    paper_content = []\n",
    "    for parsed_ in parsed[\"passage\"]:\n",
    "        paper_content.append(parsed_['content'])\n",
    "    paper_content = \"\\n\".join(paper_content)\n",
    "    papers0.append(paper_content)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "8da18fc3-9928-4516-b83c-23f117b51f41",
   "metadata": {},
   "outputs": [],
   "source": [
    "df_papers[0]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 85,
   "id": "a5439e3b-a23a-4460-ae0c-3f07723f3374",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'Case Report WIN-MTB-2023001 WIN International Molecular Tumor Board A 62-year-old male with metastatic colorectal cancer with 5 prior lines of treatment\\nHeavily pretreated metastatic colorectal cancer (mCRC) poses significant therapeutic challenges. Advances in molecular profiling enables personalized strategies. We present a 62-year-old male with mCRC harboring BRAF, MET, APC, TP53 and NRAS alterations, following FOLFOX and FOLFIRI, dabrafenib plus panitumumab, and a BRAF inhibitor clinical trial, each leading to initial responses followed by disease progression.\\nWIN Consortium International Molecular Tumor Board (MTB), included experts from institutions across 13 countries. Enrollment in suitable clinical trials was explored but limited by availability. Personalized combinations suggested included amivantamab-vmjw (anti-MET/EGFR antibody) (one-third standard dose) (for MET amplification and due to prior response to anti-EGFR antibody), trametinib, 1 mg po daily (MEK inhibitor for BRAF V600E mutation), and regorafenib (may have WNT inhibitor activity relevant to APC mutation; VEGFR activity relevant since TP53 alterations upregulate VEGF/VEGFR axis) starting at 40 mg po daily three weeks on, one week off. Another option was trametinib at 1 mg daily, cetuximab (EGFR antibody), 250 mg/mÂ² IV every two-weeks, and cabozantinib (MET and VEGFR inhibitor), 40 mg po daily. FOLFOXFIRI combined with bevacizumab, or liver-directed therapies for hepatic metastases, or regorafenib with 5FU, or crizotinib (MET inhibitor) combined with regorafenib or dabrafenib, was also suggested.\\nThis case emphasizes the critical role of comprehensive molecular profiling and personalized therapeutic approaches in managing complex mCRC. The WIN International MTB aims to provide treatment and biomarker analysis discussion with the ultimate goal of optimizing treatment efficacy by targeting specific molecular alterations, though final treatment decisions remain at the discretion of the treating physician.\\nINTRODUCTION\\nColorectal cancer (CRC) ranks among the most prevalent and lethal cancers globally. The metastatic form of CRC presents significant challenges due to its complexity and the variability in treatment responses. Advances in molecular genetics have markedly improved cancer management, facilitating more personalized treatment strategies based on individual tumor molecular profiles.\\nHere, we present the case of a 62-years-old male patient with metastatic CRC (mCRC) who underwent a comprehensive multimodal treatment regimen. This patientâ\\x80\\x99s tumor genomic analysis revealed aberrations in BRAF, MET, APC, TP53 and NRAS.\\n BRAF V600E mutations in mCRC represent a distinct subset with unique prognostic and therapeutic implications. This mutation is a class I mutation that activates the MAPK pathway, leading to uncontrolled cell proliferation and tumor growth. Specifically, the BRAF V600E mutation is associated with a more aggressive disease course, poorer overall survival, and a higher likelihood of resistance to standard therapies. Multiple studies have also suggested that the BRAF V600E mutation serves as a predictor of reduced efficacy of EGFR monoclonal antibodies, such as cetuximab and panitumumab, either as monotherapy or in combination with chemotherapy. The MET receptor tyrosine kinase, when mutated or amplified, activates the MET signaling pathway, promoting cellular proliferation and metastasis. In mCRC, MET mutations and alterations, though less common than other mutations, can lead to resistance to standard treatments and contribute to more aggressive tumor behavior, significantly impacting disease progression and therapeutic response. APC mutations are highly prevalent in mCRC, occurring in approximately 80% of cases. These mutations are critical drivers of tumor development and progression, primarily through their impact on the WNT signaling pathway. The APC protein normally functions as a negative regulator of the WNT signaling pathway, which controls cell proliferation and differentiation. When APC is mutated, it results in uncontrolled activation of WNT signaling, leading to increased cell growth and tumorigenesis. TP53 is a pivotal tumor suppressor gene frequently mutated in CRC. Mutations in TP53 often result in the loss of its tumor-suppressive functions, leading to increased genomic instability and resistance to apoptosis, which promotes tumor growth and metastasis. The presence of TP53 mutations is generally associated with more aggressive tumor characteristics and may impact the effectiveness of certain therapies. NRAS, a member of the RAS family of oncogenes, plays a crucial role in regulating cell signaling pathways involved in growth and survival. NRAS mutations can lead to continuous activation of the MAPK pathway, which promotes cell proliferation and tumor growth. When mutated, NRAS can drive resistance to anti-EGFR therapies by bypassing the effects of these drugs. While anti-EGFR treatments target the EGFR pathway to inhibit tumor growth, NRAS mutations can activate downstream signaling pathways independently of EGFR, allowing tumor cells to evade EGFR blockade and continue proliferating. \\nThe case presented here was reviewed by an international Molecular Tumor Board (MTB) convened by the WIN consortium, a French-based non-profit association comprising academic oncological centers, industry groups, research organizations, and patients advocates from multiple countries across several continents. The MTB is an international committee of expert physicians and scientists specialized in personalized cancer medicine from 18 centers across 13 countries, as shown in Figure 1. The MTB is unique in bringing together experts from multiple countries which practice in very different healthcare systems with a wide variety of drug access. The purpose of this committee is to improve the knowledge about personalized cancer therapies. As such, discussions that occurred during the MTB are for educational purposes and considered advisory only. The choice of therapy is up to the treating physician and geographic treatment availability. The board of experts evaluated the patientâ\\x80\\x99s medical history and genetic profile, suggesting a variety of treatment options, including customized combination therapies, targeted treatments, standard-of-care approaches and clinical trials. The goal was to discuss treatment strategies tailored to the patientâ\\x80\\x99s unique genetic molecular profile.\\nCASE REPORT DESCRIPTION\\nDiagnosis\\nThe patient, a 62-year-old male, was diagnosed in May 2021 with stage IV CRC presenting with two potentially resectable liver metastases and no evidence of disease elsewhere. His medical history included high blood pressure, hyperuricemia, and kidney stones. Immunohistochemistry (IHC) performed at time of diagnosis showed that the patient was mismatch repair proficient and HER2 negative. Testing for RAS and BRAF mutations, as mandated by local clinical guidelines, identified a BRAF V600E mutation revealed by real-time polymerase chain reaction (RT-PCR) at the time of diagnosis.\\nFirst line of treatment\\nIn May 2021, shortly after his diagnosis, the patient began perioperative chemotherapy with FOLFOX (folinic acid, fluorouracil, and oxaliplatin), which resulted in a partial response. Following this response, the patient underwent surgical resection of the liver metastases. Post-surgery, the patient resumed FOLFOX chemotherapy until the primary colorectal tumor, located in the transverse colon, was also resected. The patient continued with the FOLFOX regimen for an additional two months, completing a total of 12 cycles. A subsequent CT scan confirmed the absence of recurrence. The progression-free survival (PFS) under the first line treatment of FOLFOX lasted for 10 months. However, in June 2022, a potentially resectable recurrence was identified, with two liver metastases and with no evidence of other disease sites.\\nSecond line of treatment\\nIn October 2022, the patient commenced a second line of treatment of FOLFIRI (folinic acid, fluorouracil, and irinotecan hydrochloride). Given the possibility of resectable liver disease recurrence, FOLFIRI was administered without biological agents such as aflibercept or bevacizumab. Unfortunately, this treatment was discontinued after less than two months, in December 2022, due to disease progression which was confirmed by a CT scan revealing a total of 10 liver metastases. The scan also revealed a pulmonary embolism. It is important to note that the primary goal of both the first and second lines of treatment was to facilitate liver disease resection.\\nThird line of treatment\\nIn January 2023 the patient was enrolled in an early phase clinical trial involving an efflux pump inhibitor (EPI) and cancer stem-cell marker ABCG2. It is worth noting that on January 2023, the combination of encorafenib and cetuximab was not a reimbursed treatment in Spain, where the patientâ\\x80\\x99s treatment center is located. Additionally, no clinical trials specifically for BRAFV600-mutated mCRC were available at the center or in nearby institutions. The clinical trialâ\\x80\\x99s treatment was eventually discontinued due to disease progression.\\nAt this time, results from a custom 432-gene hybrid capture-based panel (VHIO-300) of a tissue sample confirmed the presence of a BRAF V600E mutation (Table 1), which had already been identified at the time of diagnosis. Table 1 and Supplementary Table 1 provide a list of additional detected mutations including both pathogenic/likely pathogenic variants and variant of unknown significance (VUS).\\nAdditionally, the tumor mutational burden (TMB) was measured at 11.19 mutations/megabase, which is below the high TMB cutoff of 13 mutations/megabase. This cutoff, defined through cross-validation with FoundationOne, is equivalent to 10 mutations/megabase as used typically in FoundationOne assays. Therefore, the patient did not have a high TMB.\\nFourth line of treatment\\nIn February 2023, the patient began a compassionate use treatment with a combination of dabrafenib and panitumumab, targeting BRAF and EGFR respectively. Initially, the patient showed a partial response. By the time of the documented radiological response, a liquid biopsy was performed by means of the VHIO360 ISO-certified panel using Guardant360Â® technology.\\nctDNA profiling showed a BRAF allele frequency (2.09%) (Table 1 May 2023). However, the disease eventually progressed, accompanied by an increase in BRAF allele frequency (41.58%) (Table 1 August 2023). This line of treatment lasted for five months. ctDNA molecular profiling detected NRAS Q61K at a low allele frequency (0.38%).\\nFifth line of treatment\\nIn August 2023, the patient started treatment with a novel BRAF V600 inhibitor as part of a phase I clinical trial. At the time of screening a CT scan confirmed the presence of liver metastases and, for the first time, identified lung metastases. The patient achieved stable disease as best response in September 2023 with a 13% reduction in the sum of target lesions. However, the disease eventually progressed again after two months. A new VHIO360 test after disease progression showed a BRAF allele frequency of 20.93% and also revealed emerging mutations and amplifications (Table 1 October 2023). Also, the number of copies of MET increased to 10.1, up from 3.2 in the previous test.\\nThroughout his treatment as shown in Figure 2, the patient continued to maintain an ECOG performance status of 0, remaining asymptomatic and physically active. At the time of the MTB, no new treatment had been administered while exploring further therapeutic options after MTB case discussion.\\nDISCUSSION\\nThe case presented here is clinically unique due to the complexity of the tumorâ\\x80\\x99s genetic profile. At disease progression, repeat testing with both circulating tumor DNA (ctDNA) and tissue next-generation sequencing (NGS) proves valuable in identifying new genomic alterations and tracking changes in variant allele frequency (VAF). These tools not only detect emerging resistance mutations but also provide insights into tumor evolution, guiding more informed treatment decisions. While ctDNA offers a non-invasive approach to monitor tumor dynamics in real time, tissue NGS delivers a more comprehensive view of the genomic landscape. When used together, they enhance the detection of actionable targets and support a more personalized approach to cancer therapy.\\nThe multidisciplinary discussion by the experts of the MTB aimed to discuss tailored therapeutic approaches based on the patientâ\\x80\\x99s specific molecular alterations while considering its previous multimodal treatments. The discussion presents a list of therapeutic strategies prioritized by their expected efficacy. While standard-of-care options are considered, they may not appear first if they are not deemed the most suitable match for the patient. Matched therapy, where treatments are tailored to specific molecular alterations in a patientâ\\x80\\x99s tumor, has shown significant benefits in improving clinical outcomes compared to non-matched therapies, especially in heavily pretreated cancer patients. Two landmark studies, I-PREDICT and WINTHER, provide key evidence for this approach. In the prospective I-PREDICT trial, patients received therapies matched to their tumorâ\\x80\\x99s molecular alterations, resulting in improved clinical outcomes, including higher response rates and longer survival. Notably, patients who received a tailored therapy with a higher degree of matching, experienced significantly better progression-free survival than those with fewer matched alterations. The WINTHER trial, which utilized both genomic and transcriptomics data to guide personalized therapies, further demonstrated the feasibility of implementing matched therapy and improving clinical outcomes in patients with advanced cancers.\\nAlso, it is important to mention that as patients with mCRC progress through multiple lines of therapy, the probability of achieving meaningful tumor responses declines significantly. Numerous studies have shown that in heavily pretreated patients - such as the patient described in this case â\\x80\\x93 response rates tend to be low, and OS remains poor. For instance, the pivotal RECOURSE trial, a Phase III study evaluating TAS-102 (trifluridine/tipiracil) in mCRC patients previously treated with at least two chemotherapy regimens, demonstrated a median OS of 7.1 months with TAS-102 versus 5.3 months with placebo. The median progression-free survival (PFS) was 2.0 months vs. 1.7 months, respectively, and the disease control rate reached 44% in the treatment arm. Similarly, the CORRECT trial, a phase III study assessing regorafenib in mCRC patients who had progressed on standard therapies, reported median OS of 6.4 months with regorafenib compared to 5.0 months with placebo, and a median PFS of 1.9 vs. 1.7 months, respectively. More recently, the CAROSELL trial, a phase II study evaluating the combination of zabadinostat and nivolumab in patients with MSS mCRC after at least two prior lines of therapy, showed a median OS of 7 months. Collectively, these findings highlight the critical need for novel, more effective treatment strategies for patients with refractory mCRCâ\\x80\\x94especially in the context of later-line therapies where clinical benefit remains modest.\\nPrior to inclusion in the BRAF inhibitor phase 1 clinical trial, the patient had two MET mutations classified as VUS. The most recent liquid biopsy test at the time of the MTB discussion had identified three MET mutations still classified as VUS. These MET mutations, along with the increase in the number of copies, might have contributed to the resistance mechanism observed in the patient.\\nAdditionally, an NRAS variant was detected at a very low allele fraction, raising the possibility of it being a clonal hematopoiesis of indeterminate potential (CHIP) rather than a true tumor mutation. Since the tests were performed on blood samples (liquid biopsies), without tissue confirmation, the NRAS Q61K mutation could either have represented a minor clone or a CHIP alteration. A tissue biopsy, if feasible, could provide crucial missing information, and particularly confirm whether the NRAS mutation is genuine.\\nThe MTB experts discussed the possibility of enrolling the patient in a clinical trial, but no suitable trials were currently available at the treating cancer center. A clinical study involving an anti-carcinoembryonic antigen (anti-CEA) antibody-drug conjugate (ADC) was considered, but no slots were available at the time. The MTB agreed that an ADC targeting CEA with a topotecan payload could be an interesting approach if the patient is a CEA producer. Although this represents a different direction, it could be highly beneficial if the patient could participate in such a study.\\nAlso, the question arose whether it should be worthwhile to include the patient in a new single-agent BRAF inhibitor trial, given the complex genetic landscape observed in recent tests and the patientâ\\x80\\x99s previous treatments with two BRAF inhibitors, including a novel BRAF inhibitor that was unsuccessful. The consensus was that it might not be prudent to prioritize another BRAF inhibitor trial due to the poor response observed with previous BRAF inhibitors and the patientâ\\x80\\x99s complex genetic profile.\\nDuring the MTB discussion, it was highlighted that prioritizing secondary clinical trials may present challenges, including limited available slots and patient ineligibility. Moreover, if clinical trial opportunities are considered, it is crucial to assess whether the use of local therapies such as hepatic arterial infusion (HAI) or palliative radiotherapy might affect the eligibility of the patient to future clinical trials.\\nExperts in the MTB are favoring a customized combination therapies approach when considering treatment options. This methodology has been in use since 2015 under the I-PREDICT protocol at the University of California, San Diego. This approach involves combining therapies that are often used off-label and may not be accessible in some countries.\\nThe patient presented with significant genetic alterations, including a challenging-to-target APC mutation, a previously targeted BRAF mutation with limited response, an NRAS mutation that could be crucial but might also be a minor clone or CHIP alteration, a notable TP53 mutation, and MET amplifications. Given the patientâ\\x80\\x99s treatment history with BRAF inhibitors, one proposed approach was to consider trametinib, a MEK inhibitor that could target both BRAF and NRAS. Even if the NRAS mutation is a CHIP alteration, trametinib could still be effective against both targets. The EGFR pathway is also of interest, as targeted with the previous combination of panitumumab and dabrafenib (BRAF inhibitor) that was administered to the patient (Line 4 â\\x80\\x93 5 months â\\x80\\x93 PR). Another discussed option was to target the EGFR pathway and the MET alteration, for which amivantamab-vmjw, a bi-specific antibody for MET and EGFR approved in the U.S., was suggested. However, the availability of this drug outside the U.S. is uncertain. The rationale behind this treatment strategy lies in the observation that MET amplification frequently emerges following anti-EGFR therapies, such as the panitumumab, which was used in the patient presented here. While MET amplification confers resistance to anti-EGFR therapies in CRC, this resistance can be overcome by MET kinase inhibitors, which restore sensitivity to EGFR blockade and significantly inhibit tumor growth. Therefore, incorporating a MET inhibitor, such as amivantamab, which targets both EGFR and MET, was considered a potential therapeutic approach.\\nRegorafenib, a VEGF inhibitor, also has potential efficacy, particularly given its ability to down-regulate the WNT pathway activated by APC mutations, and its potential effectiveness in the context of the TP53 alteration, which is associated with an upregulation of the VEGF-VEGFR pathway. Based on these considerations, a customized combination therapy involving amivantamab-vmjw, trametinib, and regorafenib was suggested. While regorafenib is approved in this indication, the other two drugs are not, raising questions about the practicality of this combination. In some regions of the U.S., these drugs may be accessible, but this might not be the case elsewhere. The strategy for administering customized combination therapies involves starting with reduced doses of all drugs, a practice that has been shown to be safe with close monitoring. Indeed, generally, combining multiple anticancer agents often leads to overlapping toxicities, which can be more severe than those observed with single agents. Consequently, it is rare to administer the full recommended doses of each agent in combination therapies to avoid supra-additive toxicities that are frequently observed otherwise. For amivantamab-vmjw, a starting dose of about one-third of the standard dose was suggested due to its challenging tolerability. Trametinib could be started at 1 mg daily, about half of the standard dose, and regorafenib at a starting dose of 40 mg daily for three weeks, followed by one week off. Close monitoring of the patient throughout the treatment would be essential.\\nAnother potential customized combination discussed was trametinib combined with cetuximab and an additional drug such as cabozantinib. Cetuximab was considered for its role in targeting the EGFR feedback loop, while cabozantinib was chosen for its dual inhibition of MET and VEGFR. For this combination, it was suggested to start trametinib at 1 mg daily, cetuximab at half the usual dose (250 mg/m2 intravenously every two weeks in the U.S.), and cabozantinib at an initial lower dose of 40 mg daily, as the approved dose is often too high.\\nA different direction was to explore more standard treatment regimens. Given the patientâ\\x80\\x99s good performance status and the presence of metastases beyond the liver, such treatments could be considered. Since the patient has not previously received antiangiogenic therapy, a regimen like FOLFOXFIRI combined with bevacizumab could be an option, as it is generally well-tolerated. Additionally, depending on the extent of the liver disease, consulting with specialists in liver-directed therapies might be beneficial. If the metastases were confined to the liver, some clinicians might consider hepatic arterial infusion (HAI) pumps or alternating systemic chemotherapy with intrahepatic therapy. Although HAI therapy has become less popular in recent years, it remains effective and could be useful. However, its effectiveness is limited by the need for specialized expertise that may not be available at all treatment centers. Other liver-directed therapies, such as radiofrequency ablation and chemoembolization, could also be considered later, although some practitioners might use these methods earlier in the course of the disease. While these approaches are less relevant for tumors outside the liver, if systemic chemotherapy was being administered and there was a significant TMB in the liver with progression, HAI and other liver-directed therapies could be considered and carefully discussed with liver experts to make sure that such therapy would not be an exclusion criterion for future potential clinical trial options. Indeed, it was highlighted that many clinical trials exclude patients based on the number or type of prior therapies received. This can limit access to potentially beneficial trials for patients who have undergone multiple treatments. Also, certain therapies can impair organ functions, making patients ineligible for enrolling later on trials that require specific organ function benchmarks. In addition, treatments may deteriorate a patientâ\\x80\\x99s performance status, disqualifying them from trials that require better ECOG. These challenges often require adopting strategies to mitigate these hurdles. For example, oncologists should consider potential future trialsâ\\x80\\x99 eligibility when determining full treatment plans for the course of the disease.\\nAnother option discussed was to combine crizotinib, which targets both MET and ALK with other drugs, such as regorafenib or dabrafenib. The question remains whether focusing on targeting MET should be a priority at this stage. Regarding regorafenib, a dose of 40 mg, as previously suggested, may be effective for some patients, but in combination strategies, dose escalation to 80 mg could be explored if tolerated by the patient. The ReDOS study demonstrated that starting with lower doses and escalating if tolerated can be effective.\\nDabrafenib, a BRAF inhibitor could also be considered in combination with trametinib (MEK inhibitor), as the combination has already been used in BRAF-mutated colorectal cancer patients, particularly when these drugs were first introduced.\\nIn general, regorafenib as a monotherapy is not favored due to its limited duration of effectiveness. However, there is experience using regorafenib both as a monotherapy and in combination with 5-fluorouracil (5FU), although this combination has not been fully tested. For patients who progress after regorafenib, adding 5FU has been shown to be an effective regimen. Therefore, regorafenib with 5FU could be also an option.\\nOther potential treatment directions discussed included combining FOLFOX with immunotherapy.\\nIt is important to note that discussions held during the MTB were for educational purposes only. The ultimate decision regarding the patientâ\\x80\\x99s treatment is made exclusively by the treating physician of the patient.\\nWhile the MTB is primarily for educational purposes, there is no obligation/or in some cases ability for the treating physician to follow the treatment options discussed at the MTB. However, specifically for the case presented here, follow up was available. The patient received regorafenib at from December 2023 to February 2024, with the best response being progression in the lungs and liver. Following this progression, the patientâ\\x80\\x99s ECOG performance status deteriorated, and passed away in April 2024.\\nOne limitation was that the trajectory of tumor markers was not included, as the patient received multiple treatments across multiple institutions with varying units and reference ranges, making data availability and consistent interoperations challenging. Another limitation is the lack of ctDNA tumor fraction data at different time points. In the VHIO360 liquid biopsy panel, tumor fraction information is unavailable. However, current guidelines also recommend the use of the mean or maximum VAF of detected somatic mutations at each timepoint to monitor ctDNA kinetics. However, Guardant360 tests do not provide an estimate of tumor fraction. Since the VHIO360 liquid biopsy panel is based on Guardant360 technology, tumor fraction information is similarly unavailable.\\nIn conclusion, the WIN consortiumâ\\x80\\x99s MTB encompassing stakeholders from all over the world discussed several treatment options and emphasized the importance of tailoring treatment strategies and using combinations to limit escape mechanism.'"
      ]
     },
     "execution_count": 85,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "papers0[2]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "id": "3ac1dabb-884d-4bd7-9ce3-edd08f6c9e35",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[1672, 1652, 27171, 2627, 46819]"
      ]
     },
     "execution_count": 11,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "[len(i) for i in papers]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "id": "6a9ab051-ac79-4050-93d9-7008b5074ed6",
   "metadata": {
    "collapsed": true,
    "jupyter": {
     "outputs_hidden": true
    },
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['Case Report: HGF and NF1 mutations as putative bypass mechanisms of MET inhibitor resistance in hepatocellular carcinoma: a case study.',\n",
       " 'Background: Hepatocellular carcinoma (HCC) is a highly aggressive liver cancer with poor prognosis, often associated with resistance to treatment. MET amplification has been identified as a potential therapeutic target, but resistance to MET inhibitors, such as crizotinib, remains a significant challenge. This study aims to explore the molecular mechanisms underlying resistance to MET inhibitors in MET-amplified HCC. Methods: We present a case of advanced HCC in a patient with MET amplification treated with crizotinib. After initial tumor regression, disease progression occurred. Genetic',\n",
       " 'challenge. This study aims to explore the molecular mechanisms underlying resistance to MET inhibitors in MET-amplified HCC. Methods: We present a case of advanced HCC in a patient with MET amplification treated with crizotinib. After initial tumor regression, disease progression occurred. Genetic analysis using next-generation sequencing (NGS) was performed on biopsy samples taken before and after progression to identify mutations associated with resistance. Results: NGS revealed the loss of MET amplification and identified HGF and NF1 mutations as potential bypass mechanisms. Specifically,',\n",
       " 'analysis using next-generation sequencing (NGS) was performed on biopsy samples taken before and after progression to identify mutations associated with resistance. Results: NGS revealed the loss of MET amplification and identified HGF and NF1 mutations as potential bypass mechanisms. Specifically, a missense mutation in HGF (p.G401A) was observed, which may enhance ligand-receptor binding, while an NF1 mutation (p.M546L) may permit sustained MAPK and PI3K activation despite MET inhibition. These observations are preliminary and require validation in larger patient cohorts. Conclusion: Our',\n",
       " 'a missense mutation in HGF (p.G401A) was observed, which may enhance ligand-receptor binding, while an NF1 mutation (p.M546L) may permit sustained MAPK and PI3K activation despite MET inhibition. These observations are preliminary and require validation in larger patient cohorts. Conclusion: Our findings suggest that acquired resistance to MET inhibitors in MET-amplified HCC may involve clonal evolution and activation of compensatory signaling pathways. These insights highlight the need for dynamic molecular surveillance and the development of strategies targeting multiple pathways to',\n",
       " 'Our findings suggest that acquired resistance to MET inhibitors in MET-amplified HCC may involve clonal evolution and activation of compensatory signaling pathways. These insights highlight the need for dynamic molecular surveillance and the development of strategies targeting multiple pathways to overcome resistance and improve patient outcomes.']"
      ]
     },
     "execution_count": 15,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "splited = split_text_into_chunks(papers[1], chunk_size=600,\n",
    "                                             chunk_overlap=300)\n",
    "splited"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "id": "ac23d300-fc62-407f-8265-409a50f8a216",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "False\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "[[{'name': 'Crizotinib treatment effectiveness',\n",
       "   'value': 'initial tumor regression followed by disease progression',\n",
       "   'source_id': [2],\n",
       "   'cited_blocks': ['challenge. This study aims to explore the molecular mechanisms underlying resistance to MET inhibitors in MET-amplified HCC. Methods: We present a case of advanced HCC in a patient with MET amplification treated with crizotinib. After initial tumor regression, disease progression occurred. Genetic analysis using next-generation sequencing (NGS) was performed on biopsy samples taken before and after progression to identify mutations associated with resistance. Results: NGS revealed the loss of MET amplification and identified HGF and NF1 mutations as potential bypass mechanisms. Specifically,']}],\n",
       " [{'name': 'Crizotinib effectiveness',\n",
       "   'value': 'More sensitive to low-risk group',\n",
       "   'source_id': [5],\n",
       "   'cited_blocks': ['performed in risk groups. Expression of signature genes in CRC cells was examined using quantitative reverse transcription polymerase chain reaction (qRT-PCR). There were 10 CRC-related RRAGs found. Prognostic models were built with RRAGs. Based on immune infiltration analysis, low-risk populations showed significantly greater levels of immune infiltration (P P ARHGEF17 mutation rate was 6%. Medications such as CGP-082996, Dasatinib, Erlotinib, and Salubrinal were more sensitive to high-risk group, whereas drugs such as FTI-277, DMOG, and Crizotinib were more sensitive to low-risk group.']}],\n",
       " [{'name': 'Crizotinib effectiveness',\n",
       "   'value': 'NP',\n",
       "   'source_id': [],\n",
       "   'cited_blocks': []}],\n",
       " [{'name': 'main_results_crizotinib',\n",
       "   'value': 'no objective responses observed in RASMT advanced CRC patients',\n",
       "   'source_id': [7],\n",
       "   'cited_blocks': ['with low baselineÂ\\xa0KRASMT allele frequency. CONCLUSIONS: Combination binimetinib/crizotinib showed a poor tolerability with no objective responses observed in RASMT advanced CRC patients. EudraCT-Number: 2014-000463 -â\\x80\\x8940 (20/06/2014: A Sequential Phase I study of MEK1/2 inhibitors PD- 0325901 or Binimetinib combined with cMET inhibitor Crizotinib in RAS Mutant and RAS Wild Type with aberrant c-MET).']}],\n",
       " [{'name': 'Crizotinib_effectiveness',\n",
       "   'value': 'selectively inhibited the growth of ARID1A-deficient CRC cells',\n",
       "   'source_id': [80, 142],\n",
       "   'cited_blocks': ['validated the synthetic lethal effect of the c-MET inhibitor PHA-665752 (PHA) in two ARID1A knockout (ARID1A-KO) clones, where PHA selectively inhibited the growth of ARID1A-KO HCT116 cells (Fig.Â\\xa01D). Moreover, two FDA-approved c-MET inhibitors, crizotinib, and cabozantinib, also showed synthetic lethality in ARID1A-KO HCT116 clones (Fig.Â\\xa01E, F). These results suggest that c-MET is a potential synthetic lethal target for ARID1A in CRC cells.',\n",
       "    'synthetic lethality in ARID1A-deficient CRC. Notably, FDA-approved c-MET inhibitors, such as crizotinib and cabozantinib, have demonstrated enhanced cytotoxicity in ARID1A-deficient cancers, facilitating the translation of these approved drugs for repurposing in ARID1A-targeted precision cancer medicine.']}]]"
      ]
     },
     "execution_count": 12,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "\n",
    "api = StudyCharacteristicsExtraction()\n",
    "extracted = api.run(\n",
    "    papers=papers,\n",
    "    fields=['Results, string, main results of the study regarding Crizotinib, usually about treatment effectiveness'],#api.DEFAULT_FIELDS,\n",
    "    llm='Qwen/Qwen3-32B',#\"openai-gpt-4o\",\n",
    "    chunk_size=600,\n",
    "    chunk_overlap=300,\n",
    "    thinking=False,\n",
    ")\n",
    "extracted"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 77,
   "id": "dc85b6da-8fe9-4484-8430-e55e239b2525",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[[{'name': 'Crizotinib effectiveness',\n",
       "   'value': 'More sensitive to low-risk group',\n",
       "   'source_id': [4],\n",
       "   'cited_blocks': ['performed in risk groups. Expression of signature genes in CRC cells was examined using quantitative reverse transcription polymerase chain reaction (qRT-PCR). There were 10 CRC-related RRAGs found. Prognostic models were built with RRAGs. Based on immune infiltration analysis, low-risk populations showed significantly greater levels of immune infiltration (P P ARHGEF17 mutation rate was 6%. Medications such as CGP-082996, Dasatinib, Erlotinib, and Salubrinal were more sensitive to high-risk group, whereas drugs such as FTI-277, DMOG, and Crizotinib were more sensitive to low-risk group.']}],\n",
       " [{'name': 'Crizotinib treatment effectiveness',\n",
       "   'value': 'initial tumor regression followed by disease progression',\n",
       "   'source_id': [1],\n",
       "   'cited_blocks': ['challenge. This study aims to explore the molecular mechanisms underlying resistance to MET inhibitors in MET-amplified HCC. Methods: We present a case of advanced HCC in a patient with MET amplification treated with crizotinib. After initial tumor regression, disease progression occurred. Genetic analysis using next-generation sequencing (NGS) was performed on biopsy samples taken before and after progression to identify mutations associated with resistance. Results: NGS revealed the loss of MET amplification and identified HGF and NF1 mutations as potential bypass mechanisms. Specifically,']}]]"
      ]
     },
     "execution_count": 77,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 38,
   "id": "80601546-e32e-4b65-b837-b5dec0abdfc4",
   "metadata": {},
   "outputs": [],
   "source": [
    "llm_reasoning = ChatOpenAI(\n",
    "    base_url=BASE_URL,\n",
    "    api_key=HUGGINGFACE_HUB_TOKEN,\n",
    "    model=MODEL_NAME_HF,\n",
    "    streaming=True,\n",
    "    temperature=0,\n",
    "    #http_client=httpx_client\n",
    "    http_async_client=httpx.AsyncClient(verify=False)\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 47,
   "id": "87efd589-f082-4326-bc29-42ab4cd01c9a",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "<think>\n",
      "\n",
      "</think>\n",
      "\n",
      "```json\n",
      "[\n",
      "    {\n",
      "        \"name\": \"Crizotinib effectiveness\",\n",
      "        \"value\": \"More sensitive to low-risk group\",\n",
      "        \"source_id\": [3]\n",
      "    }\n",
      "]\n",
      "```\n"
     ]
    }
   ],
   "source": [
    "prompt = ChatPromptTemplate.from_messages([\n",
    "    (\"user\", '/no_think {text}'),\n",
    "    # (\"ai\", \"Good.\")\n",
    "])\n",
    "\n",
    "chain = prompt | llm_reasoning\n",
    "response = await chain.ainvoke({\"text\": ff})\n",
    "\n",
    "#fin_condition = response.content.strip('<think>\\n\\n</think>\\n\\n')\n",
    "print(response.content)"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python [conda env:llms]",
   "language": "python",
   "name": "conda-env-llms-py"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.14.2"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
